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Abstract
Component enzyme purification and reconstitution studies have been 
conducted on the dihydrolipoamide acetyltransferase-protein X core subcomplex 
(E2/X) of bovine heart pyruvate dehydrogenase complex (PDC). Gel permeation 
chromatography, in the presence of IM NaCl, produced an E2/X core and E1/E3 
fraction. Subsequent, anion exchange chromatography successfully separated the El 
and E3 components into homogeneous fractions. Electrospray mass spectrometry 
(ES/MS) determined the Mj- of bovine E2 and protein X.
GdnHCl induced dissociation of the E2/X core disclosed that it was an ordered 
co-operative event involving formation of specific lower Mr intermediates 
corresponding to dihydrolipoamide acetyltransferase trimers and monomers. 
Modulation of refolding conditions allowed for the reassembly of native E2 cores 
devoid or partially depleted of the protein X component, as determined by 
immunological analysis.
Reconstitution studies, with stoichiometric levels of the E1/E3 components, 
were unable to sustain overall complex activity with the E2 core devoid of protein X. 
In contrast 30-35% recovery of PDC activity could be obtained, under the same 
conditions, with the E2 core depleted of protein X, as compared to the native E2/X 
core assembly. Further reconstitution studies with excess (up to 100 fold) E3 were 
able, in both instances, to promote significant additional stimulation of PDC activity 
(25-30%). This effect was dependent on the source of E3 used and was optimal with 
parent bovine E3. These studies, using the refolded E2 cores, demonstrated the low 
affinity, but specific, binding of the dihydrolipoamide dehydrogenase (E3) component 
to sites on E2. This provided in vitro evidence to support the low levels of PDC 
activity observed in cell lines derived from patients who do not express protein X.
iv
A protocol has been devised which facilitated the dissociation of the 2- 
oxoglutarate decarboxylase (El) and E3 components from the 24meric 
dihydrolipoamide succinyltransferase (E2) core of the mammalian 2-oxoglutarate 
dehydrogenase complex (OGDC). By mixing the components in stoichiometric 
quantities, it was possible to reconstitute significant levels of OGDC activity. Gel 
permeation analysis of the E1/E3 fraction, performed under associative conditions, 
indicated the ability of the two homodimeric components to interact and form a stable 
subcomplex, comprising single copies of the two components.
N-terminal sequence analysis identified SP-22, a thiol specific antioxidant 
protein, which appears to associate with the E3 component of mammalian PDC. Using 
specific primers, the polymerase chain reaction (PCR) was employed to obtain double 
stranded SP-22 DNA from bovine brain cDNA. Following purification, the DNA was 
cloned, in a blunt ended fashion, into the pCR-script vector. Both single and double 
restriction enzyme analyses were performed to screen the clones obtained for the 
presence of the appropriate inset. Subsequent in vitro transcription /translation 
analysis of the clones succeeded in identifying one capable of synthesising a protein 
product of the predicted Mr.
:i::
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Chapter 1
Introduction
The 2-Oxoacid Dehydrogenase Multienzyme
Complexes
:1 Introduction
1.1 The 2-oxoacid dehydrogenase family of multienzyme 
com plexes
The faiTiily of 2-oxoacid dehydrogenase multienzyme complexes, found
both in prokaryotic and eukaiyotic organisms, consists of three members: the 
pyruvate dehydrogenase complex (PDC); the 2-oxoglutarate dehydrogenase 
complex (OGDC) and the branched chain 2-oxoacid dehydrogenase complex 
(B CO ADC). These three multienzyme complexes occupy important roles in the 
inteiTnediary metabolism of carbohydrates and branched chain amino acids (see 
Patel & Roche, 1990; Perham, 1991; Mattevi e ta l, 1992b; Behai e ta l, 1993; 
Patel & Harris 1995, Berg & De Kok, 1997 for reviews).
Organisms wishing to obtain multiple catalytic functions in a single enzyme
'complex are faced with a choice. One solution is to incoiporate the required
activities in a single polypeptide chain. An example of this is the mammalian 
enzyme fatty acid synthase. The alternative is to aggregate the catalytic activities 
required into a multienzyme complex. Multienzyme complexes may be defined 
as an association of individual enzyme components, which typically catalyse 
successive steps in a metabolic pathway. These components are complexed in a
:non-covalent fashion and are usually present in multiple copies. The presence of 
multiple copies of the components in these complexes generates very large 
complexes (Mr of the 2-oxoacid dehydrogenase complexes 5-10x10^), In 
multienzyme complexes, the close proximity of the enzymatic components 
increases the efficiency of the pathway: off pathway reactions are minimised and 
the overall rate of catalysis increased. Additionally, the multienzyme complexes 
may permit unusual active site chemistries and allow the channelling of
substrates from one active site to the next (Perham, 1975; Reed & Hackert, 
1990; Perham, 1991; Wallis e ta l, 1996).
step in the catabolism of branched chain amino acids. However, these amino
i
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1.2 Metabolic roles of the 2-oxoacid dehydrogenase 
com plexes
The positions of the three 2-oxoacid dehydrogenase complexes in carbon 
and nitrogen metabolism are illustrated in Figure 1.1. All three complexes 
catalyse the irreversible oxidative decarboxylation of their respective substrates. 
From their positions in metabolism (Figure 1.1) and the irreversible nature of 
the reactions catalysed, it is evident that these complexes represent key control 
points in regulating metabolic flux within cells (for reviews of nutritional and /or 
hormonal regulation see Behai e ta l, 1993; Sugden e ta l, 1995; Harris e ta l,
1995). Indeed, their multi-enzymatic nature permits more sensitive and efficient
a
regulation of activity.
Positioned at the end of the glycolytic pathway, the pyruvate dehydrogenase 
complex (PDC) holds a pivotal position in carbon metabolism. The conversion 
of its three carbon substrate, pyruvate, to acetyl-CoA provides a source material 
for energy production, via further oxidation in the citric acid cycle, or the 
biosynthesis of other products. Acetyl-CoA serves as a substrate for the 
biosynthesis of important molecules notably fatty acids, sterols and, in neuronal 
tissue, the neurotransmitter acetylcholine (Behai et al, 1993).
BCOADC has a important role to play in nitrogen homeostasis. The 
disposal of excess branched chain amino acids, which cannot be stored and are 
potentially pathogenic (section 1.6), is a vital process. BCOADC catalyses a key
2 - 0X0 - isocoiprodte 
Z - 0X0 - 3 methj 1 valerdte
Leucine 
IsoleucineBCDC
Pyruvate 
PDC
etj^CoA
Fumarate TCA
Cycle
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OGDCSuccinyl CoA
Valine
Methionine
Threonine
BCDC
2-0X0- isovaLerabe
4-m e(k |t tkio  2 -o x o b u tg ra te  
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Figure 1.1 The role of the 2-oxoacid dehydrogenase multienzyme 
complexes in metabolism
acids are also essential for protein synthesis. Thus, tight regulation of their 
breakdown is required to ensure sufficient availability of these amino acids for 
biosynthesis of proteins (Harris et al, 1986). The reaction catalysed by OGDC 
is central to oxidative metabolism and energy production in mitochondria. It 
represents the rate-limiting step in the flux of intermediates through the later 
stages of the citric acid cycle.
1.3 The reaction catalysed by the 2-oxoacid 
dehydrogenase complexes
These multienzyme complexes are responsible for the oxidative 
decarboxylation of their respective 2-oxoacid substrates as detailed in tlie 
general reaction scheme shown below;
2-oxoacid+ CoA + NAD+ > Acyl CoA + CO2 + NADH + H+
The reaction is catalysed by the sequential reaction of the three catalytic
components: a 2-oxoacid decarboxylase (El); a dihydrolipoamide
acyltransferase (E2) and a dihydrolipoamide dehydrogenase (E3). The El and 
E2 components are substrate specific (with Elp, Elo, E lb  and E2p, E2o and 
E2b referring to the components which belong to PDC, OGDC and BCOADC 
respectively). In contrast, the E3 component, which catalyses the same reaction 
in each multienzyme complex, is common to all three complexes. In most of the
"systems studied to date, E3 would appear to be a product of a single gene, 
maintaining the principle of genetic parsimony usually observed when 
assembling biological structures. However, exceptions have been discovered.
There are three E3 genes in Pseudomonas putida (Palmer et al, 1991) and
4
distinct isoforms of the E3 component have also been observed in mitochondria 
and chloroplasts of Pisum sativum (Conner et al, 1996).
The reaction scheme for PDC is detailed in Figure 1.2. The four steps in the 
overall reaction are catalysed by the three catalytic components E l, E2 and E3.
The E l (pyruvate decarboxylase) is responsible for the first two steps: the 
decarboxylation of pymvate and the subsequent reductive acétylation of the 
lipoamide prosthetic group on the E2 component (Frey et al, 1989). The 
cofactor thiamine pyrophosphate (ThDP) is required for this catalysis and its 2- 
hydroxyethylidine-ThDP form is the substrate for the subsequent reductive 
acétylation of the lipoamide moieties on E2. Lipoamide groups are covalently 
attached via the e amino group of specific lysine residues on the E2 component.
The attached lipoamide group forms an extended (14 A) flexible arm which
■conveys the substrate between active sites. The E2 (dihydrolipoamide 
acetyltransferase) enzyme transfers the acetyl group from its lipoamide groups 
to coenzyme A. Finally, the E3 enzyme (dihydrolipoamide dehydrogenase) is 
responsible for regenerating the oxidised form of lipoamide on E2 and the 
transfer of reducing equivalents, via its FAD cofactor, to NAD+. It is possible 
to differentiate between the catalytic cofactors, ThDP, lipoamide and FAD, 
which remain unaltered from the net reaction, and the stoichiometric cofactors 
CoA and NAD+ (Reed, 1974).
OHI[R-C^ThDP]
[ThDP
R-C-COOH
OIIR-C-COOH + NAD+ + CoA-SH
NAD"
E 2
NADH+H "
OII[R-C-S-LipSH]
CoA-SH
O
R-C-SCoA
R-C-S-CoA + NADH -t- ED + CO,
Figure 1.2 Reaction scheme for the oxidative decarboxylation of 
2-oxoacids by the 2-oxoacid dehydrogenase complexes (adapted 
from Berg & de Kok, 1997)
R=CH3 for PDC; CH2CH2COOH for OGDC and R=CH(CH3)2 , 
CH2CH(CH3)2 or CH(C2H5)CH3 FOR BCOADC 
THDP, thiamindiphosphate 
Lip, lipoic acid
I
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1.4 Structure of 2-oxoacid dehydrogenase complexes 
1.4.1 The dihydrolipoamide acyltransferase (E2) 
component
The E2 component performs a vital structural as well as catalytic role within 
the 2-oxoacid dehydrogenase complexes. This E2 component self assembles 
into a stmctural lattice to which the other enzymes are noncovalently attached. 
Two forms of the E2 core have been observed (i) a 24mer exhibiting octahedral 
symmetry and (ii) a 60mer which forms a pentagonal dodecahedron (see section
1.4.2 for details). The characteristic segmented structure of E2 polypeptide 
chains is central to their multi-functional nature. Attempts to crystallise the entire 
E2 component have not been successful, probably as a result of the inherent 
flexibility displayed by N terminal regions of these proteins. Instead, the 
stmctures of the individual domains have been determined separately. The 
segmented structure displayed by the E2 component of mammalian PDC is 
illustrated in Figure 1.3. Each of the domains has been shown to be an 
independent folding entity. E2 displays three types of globular domain separated 
by alanine/proline rich sequences termed linker regions. The domain stmcture 
shown is common to all E2 components studied to date (Perham, 1991; Mande 
et al, 1996; Berg & De Kok, 1997), with the notable exception of mammalian 
OGDC (Rice era/., 1992).
The lipoyl domains on mammalian E2 each contain a specific lysine residue 
to which a lipoic acid moiety is covalently attached (Fujiwara et al, 1996). The 
role of this prosthetic group in overall complex catalysis has been discussed
previously (section 1.3). The number of lipoyl domains on E2 varies between
■-one and three, independent of complex type or tissue/species source.
■>.
Interestingly, one lipoyl domain has been shown to be sufficient for catalysis.
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(Allen et al, 1989). A study in E. coli of PDC E2, which has three lipoyl 
domains, also showed that one lipoyl group was sufficient for full E2 catalytic 
activity in vitro. However in genetic studies, three lipoyl domains, with the 
outer being lipoylated and the two inner domains not requiring cofactor 
attachment, were considered optimal for complex activity. The authors conclude 
that the function of the two inner domains is to extend the reach of the lipoyl 
cofactor on the outer domain, generating the so called "swinging arm" of E2 
(Gu&st e ta l, 1997).
Solution structures, employing nuclear magnetic resonance (NMR), have 
been obtained for lipoyl domains from Bacillus stearothermophilus PDC 
(Dardel et al, 1993) and OGDC (Ricaud et al, 1996); E. coli PDC (Green et 
al, 1995); Azotobacter vinelandii FDC (Berg et al, 1997). Nuclear magnetic 
resonance (NMR) spectroscopy and site directed mutagenesis have identified a 
surface loop of the lipoyl domain which makes contact with the E l component 
of B. stearothermophilus PDC, in addition to contacts at the back of the 
domain. It is believed that this interaction forms the molecular basis for 
substrate channelling (Wallis et al, 1996). However, the basis of the specificity 
of such interactions (i.e. the fact that E lp  will only react with E2p and not 
E2o/E2b) is not yet understood. Evidence also exists that, as an additional role, 
the lipoyl domain is involved in binding complex specific kinases and 
phosphatases in mammalian PDC and BCOADC (Liu et al, 1995; Popov et al,
1994). Activation/inactivation of these multienzyme complexes is thought to 
involve a mechanism which peimits the transferral of the kinase/phosphatase 
enzymes between the lipoyl domains of the E2 subunits. This allows the 
relatively few copies of these regulatory enzymes present rapid access to their 
target substrate, the E l component.
-I
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The binding domain on the E2 component (E2BD) consists of 30-50 amino 
acids. This size represents the smallest functional globular domain observed to 
date. It is then somewhat surprising that, in prokaryotic icosahedral E2 cores 
(see section 1.4.2), it is responsible for binding both the E l and E3 components 
to the multienzyme complex. NMR structures have been obtained for E2BD 
from B. stearothermophilus PDC (Kaliaer a/., 1993) andE. coli OGDC 
(Robien et al, 1992). Elegant studies (Lessard & Perham 1995; Lessard et al, 
1996) employing surface plasmon resonance (SPR) measurements and native 
PAGE have probed the interaction of E2BD with both the El and E3 
components. These investigations led to the conclusion that an individual E2BD 
of B. stearothermophilus PDC was unable to simultaneously bind E l and E3 
components. While the association constant for both enzymes with the E2BD 
was found to be identical, the two components exhibited different rate constants 
for their dissociation. Both E l and E3 components were able to displace each 
other from complexes formed with the E2BD and the capacity for E l to bind 
was shown to rest with the El|3 component.
The catalytic (inner) domain of E2 represents, at typically 250 amino acids 
in length, the largest part of the protein. It is responsible for catalysing the 
acyltransferase reaction and contains sequences which mediate the self-assembly 
of the E2 lattice. In addition, the catalytic domain is involved in binding the E l 
component to some complexes displaying octahedral E2 core symmetry. The 
domain has been crystallised and the catalytic mechanism investigated (Mattevi 
e ta l,  1992a; 1993b; Hendle 1995).
The flexible linker regions which segregate the domains in E2 are also 
critical to component function. Typically, linker regions are rich in alanine and 
proline residues. There are also a number of charged residues. These linkers 
provide the flexibility which allows the lipoyl moiety access to all three active
sites within the multienzyme complex (Radford et al, 1989; Green et al, 
1992).
1.4.2 E2 core formation
2-oxoacid dehydrogenase complexes are built around an E2 oligomeric core 
to which multiple copies of the E l and E3 components are noncovalently 
attached (see Mande et al, 1996 for review). Electron microscopy (Oliver & 
Reed, 1972; Wagenknecht n/., 1990, 1991; Stoops a/., 1992, 1997) and 
X-ray crystallography (DeRosier et a l, 1971; Fuller e ta l, 1979; Mattevi et al, 
1992a) have identified two forms of E2 core morphology. (1) Cubic structures, 
consisting of 24 E2 monomers exhibiting octahedral (432) symmetry, have been 
characterised in all OGDC, all known BCOADC, E. coli and A. vinelandii 
PDC, OGDC. (2) Pentagonal dodecahedron structures, consisting of 60 E2 
monomers exhibiting icosahedral (532) symmetry, have been observed in PDC 
from mammalian, avian, fungal and Gram-positive bacterial 
{B. stearothermophilus) sources (Figure 1.4). In all cases, the basic building 
block of the core structures appears to be a trimeric E2 unit. In addition, the 
structural and functional similarity of E2 to chloramphenicol acetyltransferase, 
CAT (Guest, 1987), active as a trimer, has led to the suggestion that the 60- 
meric mammalian E2 core represents an association of twenty trimeric units, an 
idea which has received experimental support from recent publications (Behai et 
al, 1994; De Marcucci et al, 1995). These trimers interconnect to form the cage 
like inner core. Refolding and assembly studies on the E2 core of mammalian 
PDC (Behai et al, 1994; McCartney et al, 1997) have also indicated that this 
trimeric E2 unit serves as an assembly intermediate in mature E2 core formation.
Figure 1.4 Schematic representation of the E2 core assembly of mammalian PDC
D
1.4.3 2-oxoacid decarboxylase (E l) component
Two forms of E l have been observed: (1) an a2 homodimer (subunit = 
100, 000) which is found with octahedral PDC and OGDC E2 cores; (2) an 
a2p2 heterotetramer (subunit Mr values 40-46, 000 and 35-38, 000 
respectively) associated with icosahedral PDC E2 cores and all BCOADC E2 
cores characterised to date. In mammalian PDC, 20-30 heterotetramers of E l are 
associated per complex. In complexes exhibiting octahedral symmetry, the 
number is around 6 E l components per complex. There appears to be little 
correlation between the E2 core structure and the subunit structure of the 
associated E l enzyme (Perham, 1991).
In contrast to the other catalytic 2-oxoacid dehydrogenase components, no 
crystal stmcture for any El is to be found in the literature. The three 
dimensional structure of another ThDP dependent enzyme, transketolase, has 
provided insights into the residues required in the binding of the cofactor to 
such enzymes (Lindquist et al, 1992). The active site chemistry of ThDP 
requiring enzymes is well understood and recent work has highlighted the 
biphasic (first ThDP fast, second ThDP slow) nature of the binding of the two 
ThDP molecules to E l (Yi et al, 1996). In eukaryotes, E l components 
associated with icosahedral PDC complexes and all BCOADC complexes play 
an additional role in the regulation of complex activity by a phosphorylation- 
déphosphorylation mechanism (Yeaman, 1989) (see sections 1.4.6 and 1.5 for 
details).
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1.4.4 Dihydrolipoamide dehydrogenase (E3) component
E3 exists as an FAD containing homodimer with a subunit Mr = 55 000. It 
is part of a large family of pyridine disulphide oxidoreductases (Williams, 1992; 
Perham et al, 1995). Evidence to date, indicates that the E3 component, present 
in all three mammalian multienzyme complexes, is the product of a single gene. 
In mammalian PDC, 6-12 copies of this homodimer are present in each 
mammalian PDC complex. The role of E3 is to reoxidise the reduced lipoamide 
prosthetic group and thus prepare it for another round of catalysis (Figure 1.2). 
Three dimensional structures, from X-ray crystallography studies, exist for E3 
derived from A. vinelandii and P. putida sources (Mattevi et al, 1991,
1992b; 1993) and, more recently, yeast (Toyoda et al, 1998). The stmcture of 
the protein has been well conserved throughout evolution. Despite this, in 
reconstitution studies with bovine PDC, pig and yeast E3 produced poor levels 
of PDC activity in comparison with levels obtained with native E3. This points 
to subtle differences in the subunit interactions between the heterologous E3s 
and the core preparations investigated (Sanderson et al, 1996). Functional 
analysis of the human E3 has recently been performed (Lanterman et al, 1996). 
In this study the human enzyme was able to restore function to a yeast strain 
deficient in this component.
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1.4.5 Protein X
PDCs from mammalian and yeast sources, in addition to the E l, E2 and E3 
catalytic components, have been shown to contain another polypeptide, teianed 
protein X, (see Figure 1.3 for outline of domain structure). This subunit was 
first identified as an immunologically distinct polypeptide within mammalian 
PDC (De Marcucci & Lindsay, 1985). Subsequent studies have been successful 
in characterising the key role of protein X in the specific binding of E3 to the 
PDC complex in higher eukaryotes (Jilka et al, 1986; Powers-Greenwood et 
al, 1989; Neagle & Lindsay, 1991; Lawson e ta l, 1991a,b; Maeng et al,
1994). This has led to the protein also being termed the E3 binding protein 
(E3BP). Typically, binding of the E l and E3 components is mediated by the E2 
component in 2-oxoacid dehydrogenase multienzyme complexes from 
prokaryotic sources (section 1.4.1). The presence and function of protein X in 
mammalian PDC would appear to indicate a higher level of complexity. Another 
exception, appears to be in mammalian OGDC. The E2 component lacks any 
apparent E3 binding domain (Nakano et al, 1991) and the E l component is 
thought to be responsible for E3 binding (Rice et a l, 1992).
The protein X gene has been cloned from Saccharomyces cerevisiae (Behai
et al, 1989) and 12 copies of the protein have been shown to be associated per
PDC complex (Maeng et al, 1994; Sanderson et al, 1996a). Protein X is
tightly bound to the E2 core. In contrast to the other subunits of PDC, which
dissociate readily from the E2 core under conditions of high ionic strength,
protein X requires the use of denaturing concentrations of chaotropic reagents
for its removal. While each E2 molecule has the ability to bind 1 protein X, a
recent study points to steric hindrance by protein X itself as limiting the
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numbers of this component associated with the E2 core to 12 (Maeng et al,
1996). In support of this, evidence presented in a recent elegant study of 
mammalian PDC (Stoops et al, 1997), employing cryo-electron microscopy, 
shows the presence of 12 large openings in the E2 core assembly which permit 
the molecules of protein X to bind to the E2 core. a
Recently, the protein X gene from human PDC has been cloned and 
characterised (Harris et al, 1997). The authors employed a search of the 
expressed sequence tag database at NCBI (National Centre Biological 
Information), based on reported protein X amino acid sequences (Rahmatullah 
et al, 1989; Neagle et al, 1989; Sanderson et al, 1996b), to identify four 
possible clones. Two of these were sequenced and mature human protein X was 
characterised as a 448 amino acid protein with a calculated Mr of 48, 040. This 
Mr value agrees with that obtained by ES/MS for protein X from a bovine 
source 47, 982 (see section 3.2.3). The sequence data also confirmed the 
presence of only one lipoyl domain on protein X as indicated by a previous 
study (Neagle et al, 1989).
In terms of its segmented structure, the protein is very similar to the E2
...
enzyme and displays high levels of sequence similarity throughout its length to 
this component. This is in contrast to yeast protein X where similarity to the E2 
component is confined to the N terminal region only. The C- terminal regions of 
yeast and human protein X exhibit no sequence similarity. The sequence data 
also appeared to exclude the role of protein X as an acyltransferase. The protein 
was shown to lack a histidine residue in its C-terminal which is common to all 
other 2-oxoacid dihydrolipoamide acyltransferases and is thought to be involved 
in catalysis. Instead, the authors suggest an additional role for protein X in the 
regulation of the isoforms of pyruvate dehydrogenase kinase which have been
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discovered (Popov et al., 1994; Gudi et al, 1995) and are known to regulate 
PDC activity (see section 1.4.6).
1.4.6 PDC kinase and phosphatase
The PDC and BCOADC multienzyme complexes are also subject to 
regulation via a phosphorylation (inactive) /dephosphorylation (active) 
mechanism. This involves specific, complex-associated kinase and phosphatase 
activities (see Behai et al, 1993 for a review). Short and longer term regulation 
of their activities is discussed in section 1.6. Recent work has been successful
in cloning four isoforms (PDKl, PDK, 2, PDK 3, PDK 4) of human PDC 
kinase and Northern blot analysis has provided evidence for their tissue specific
PDKl expression is confined in the main to the heart, PDK 2 appears to be the 
present in all human tissues tested. PDK 3 is expressed in the testis and PDK 4 
mRNA is concentrated in skeletal muscle and heart tissue. The family of protein 
kinases exhibit no sequence similarity to other eukaryotic protein kinase groups 
but appear related to histidine protein kinases expressed in prokaryotes (Harris 
e ta l,  1995b).
Phosphorylation of PDC by PDC kinase leads to inactivation of the 
complex activity, often in response to the prevailing metabolic conditions (see 
section 1.6). The target for the kinase and phosphatase enzymes is the El a  
subunit, specifically 3 serine residues on E lp  (El PDC ) and 2 serine residues 
on E lb  (El BCOADC). PDC kinase activity is tightly associated with the E2 
core. In contrast, the association of the phosphatase component appears to be 
considerably weaker. Recent evidence suggests that the catalytic unit of PDC
phosphatase does not behave as a soluble mitochondrial matrix protein. Instead,
14
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expression (Gudi fl/., 1995; Harris ef a/., 1995b; Rowles era/., 1996). While
|:I
3
it is strongly associated with the mitochondrial inner membrane (Simonot et al,
1997). The number of kinase and phosphatase molecules associated with the 
multienzyme complexes is small, as few as 1 kinase per complex (Liu et al,
1995).
1.5 Regulation of the 2-oxoacid dehydrogenase 
com plexes
The position of all three multienzyme complexes (as detailed in section 1.2 
and Figure 1.1) in relation to carbohydrate, protein and lipid metabolism 
underlies the importance of their regulation. Modulation of the levels of activity 
of the complexes may result from a change in nutritional circumstance 
(starvation/diabetes) and/or hormonal stimulation (Yeaman, 1989; Behai et al,
1993; Sugden & Holness, 1994; Denton et al, 1996). Levels of individual 2- 
oxoacid dehydrogenase complex activity may vary in a tissue specific fashion.
■For example, if gluconeogenic conditions prevail in the liver, the levels of PDC 
activity must be suppressed to prevent the irreversible decarboxylation of the 
gluconeogenic substrate pyruvate. Conversely, tissues carrying out lipogenisis 
would require high levels of PDC activity, to supply acetyl CoA for fatty acid 
and sterol synthesis.
All three multienzyme complexes respond to end product inhibition of their 
activities. In addition, PDC and BCOADC from higher eukaryotes contain 
complex specific kinases and phosphatases (section 1.4.6) which modulate the 
level of overall complex activity by a phosphorylation 
(inactivation)/dephosphorylation (activation) mechanism. The short-term 
regulation of the PDC specific kinase and phosphatase is summarised in Figure
i
I
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1.5. The details of the regulation of BCOADC have been the subject of a recent 
review (Harris et al, 1995) and displays parallels to that of PDC.
PDC kinase activity is stimulated by an increase in the ratios of [ATP:ADP],
[acetyl CoA:CoA], [NADH:NAD+]. The substrate for PDC, pyruvate, and the 
E l cofactor, ThDP, both serve to inhibit the activity of this cAMP independent 
kinase (Sugden & Holness, 1994). The redox and acétylation status of the L2 
(inner) lipoyl domain of mammalian PDC also modulates the activity of PDC
'kinase, with reduced and acetylated states stimulating the activity of the kinase 
(Ravindran et al, 1996). The long term regulation of PDC kinase has also been 
studied. In response to prolonged starvation, elevated levels of PDC kinase 
activity have been observed (Randle et al, 1988). In muscle it has been possible 
to attribute this as a response to elevated intracellular cAMP and the high levels 
of fatty acids in circulation (Ofali et al, 1993).
PDC phosphatase activity is a member of the protein phosphatase 2C 
family. Its activity is stimulated by Ca^+ ions and, in adipocytes, the hormone 
insulin (Yeaman, 1989). PDC phosphatase interchange among mobile L2 (inner 
lipoyl) domains has been shown to be a Ca^+ mediated process. This increased 
mobility leads to enhanced dephosphorylation of El a  PDC and concomitant 
increase in complex activity (Liu et al, 1995). Insulin activation of PDC 
phosphatase in adipocytes is believed to result from its effect on the regulatory 
subunit of the heterodimer (Yang et a l, 1996). Studies have also begun to 
investigate the longer-term regulation of the PDC complex, in response to 
prolonged hormonal stimulation and/or nutritional conditions (Hu et al, 1983;
Da Silva et al, 1993). The evidence to date suggests that long-term regulation 
of mammalian PDC involves co-ordinate regulation of the components at 
transcriptional/ post-transcriptional levels.
16
Pyruvate  
Dehydrogenase
Inact ive
\ Ca
Phosphatase (-)
A TP
Pyruvate
DehydrogenaseActive
P y r u v a t e A c e t y l - C o A  
^  ^  COo
' N A D N A D H
Figure 1.5 Metabolic regulation of mammalian pyruvate dehydrogenase complex 
(Adapted from Behai et at, 1993)
.1.6 Gene structure and disease states associated with 
2-oxoacid dehydrogenase complexes
cases to date (>90%) have involved lesions in the E la  component. The nature 
of the mutations in this gene studied have indicated that missense mutations 
represent over half of those detailed. Limited genetic analysis of familial
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For the majority of the component enzymes of the 2-oxoacid dehydrogenase
complexes cDNA, or genes coding for the protein product, from human or other
eukaryotic sources, have been cloned (see Patel & Harris 1995 for details).
Studies of gene structure and regulation for PDC (Johanning et a l, 1992;
Changera/., 1993),BCOADC (Lau gf a l, 1992; Chuang e?a/., 1993) and
OGDC (Koike, 1995) have been carried out. All of the genes studied to date
have the appearance of housekeeping genes. The exception appears to be the
PDC E l a  gene located on the X chromosome (there are known to be two E l a
genes, one on the X chromosome and the other on chromosome 4). In this case,
the presence of TATA and CAAT boxes upstream are suggestive that expression
has the potential to be regulated in a tissue specific or temporal fashion. It has
.also been observed that the human E3 promoter contains putative hormone
■yresponsive elements.
PDC deficiency is a common, but by no means exclusive, cause for the
metabolic disorder congenital lactic acidosis. The disease is associated with
,effects on the central nervous system and clinical presentation can range from 
mild ataxia to severe neuroanatomical lesions (Stacpoole, 1997; Patel & Harris,
1995; Kerr et al, 1996). Defects in all the individual components of human 
PDC, with the exception of E lp, have been documented, but the majority of
ÎI
histories has been unable to define patterns of inheritance and it appears that the 
majority of cases represent a new mutational event.
PDC is also implicated in the auto-immune disease primary biliary cirrhosis 
(PBC). Final stage PBC is the commonest indication for liver transplantation in 
the UK. In its early stages the disease is characterised by immune-mediated 
destruction of the bile ducts (O’ Donohue & Williams, 1996; Yeaman & 
Diamond, 1996). Protein X and E2 components of PDC have been identified as 
the major auto-antigens (Fussey et al, 1988), although E2 of all multienzyme 
complexes and E la  of PDC also elicites a significant immunological response 
in a significant proportion of patents. The disease is thought to arise from 
environmental factors acting upon a person who is genetically sensitive to them. 
Bacterial infection has been suggested as a possible trigger for the disease. The 
hypothesis relies on the cross-reactivity of human antibodies, raised against the 
PDC E2 component of rough forms of E. coli or strains of mycobacteria, with 
the major autoantigens. This has been termed the molecular mimicry hypothesis 
(Burroughs et al, 1992). However, the autoantibodies produced appear to only 
cross-react strongly with the mammalian complexes. Thus, the cause of the 
disease, or indeed the significance of the auto-antigen response in its pathology, 
remains unclear.
Genetic defects in the subunits of BCOADC result in maple syrup urine
disease (MSUD). This results in the inability of the body to catabolise excess
branched chain amino acids and their 2-oxoacids, leading to their accumulation
in blood, tissue and urine of patients (Patel & Harris, 1995; Indo & Matsuda
1996). If untreated, MSUD can lead to mental retardation, coma or death. A
wide variety of insertion deletions, substitutions and missense mutations have
been detected in the components of BCOADC (Chuang et al, 1991; Zhang et
al, 1991). Treatment has traditionally relied on dietary control. However, the
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Typically, native proteins exhibit a very low free energy of stabilisation 
(A Gstab of around 50kJ/mol), corresponding to a few weak interactions in a
protein molecule (Jaenicke, 1995). This apparent low level of stability is
19
correction of the disorder by retroviral gene transfer of noimal E la  precursor 
into cultured lymphoblasts from an MSUD patient has been reported (Chuang et 
al, 1995).
1.7 Protein folding
The translation of the linear, two dimensional genetic code, from its mRNA
form, into an active, three dimensional protein structure remains one of the most
intensely studied areas of biochemistry. The body of work, accumulated from 
the early experiments of Anfinsen and colleagues, to present day investigations 
into the role of molecular chaperones, is certainly impressive. However, despite 
these considerable advances, attempts to produce a definitive “protein folding 
code” have not been successful, although the field of structure prediction 
continues to improve (for recent reviews see Fenton & Horwich, 1997; Lithgow 
et al, 1997; Visick & Clarke, 1995; Jaenicke, 1996 and references therein)
To be of any use to an organism, the proteins that it synthesises must fold 
to their native form within a biofeasible time frame. This is usually taken to 
mean a time frame much shorter than the lifetime of the organism. Based on this 
premise, an entirely random search of protein conformational space can be 
excluded and one is forced to consider kinetic pathways of protein folding. The 
central dogma of protein studies comes from Anfinsen’s work on ribonuclease. 
It states that the active three dimensional protein stmcture is an inherent quality 
of the primary amino acid sequence (Anfinsen, 1973).
important for protein function. Higher stability would lead to a decrease in 
flexibility, a feature essential to protein function in terms of catalysis, regulation 
and turnover.
I7t vitro studies of protein folding have traditionally relied upon either heat, 
acid or chemical dénaturants as a means of perturbing protein structure. Despite 
a long history of use, details of the molecular mechanism by which they exert 
their effects remains limited. In the case of chemical dénaturants, such as urea, 
guanidinium hydrochloride (GdnHCl), and potassium thiocyanate (KSCN), 
two effects need to be considered: (i) the effect of dénaturant on solvent 
behaviour (Breslow & Guo, 1990); (ii) the direct interaction of dénaturant with 
the protein itself (Makhatadze & Privalov, 1992). Recent crystallographic 
studies of dihydrofolate reductase with urea and ribonuclease A with GdnHCl 
(Dunbar et al, 1997) point to a decrease in protein flexibility as a result of 
binding dénaturant molecules.
A general mechanism for the folding and assembly of proteins is detailed in 
Figure 1.6 (adapted from Jaenicke, 1987). In this scheme M, M ’, M represent 
unfolded, intermediate and stmctured monomer, N is a native dimer and ki and 
k.2 represent first and second order rate constants respectively.
The mechanism corresponds to:
1) Formation of elements of super-secondary structure
2) Hydrophobic collapse to a domain/subdomain, leading to the formation of a 
structured monomer
3) The assembly of the structured monomer into the dimer
4) Molecular rearrangement of the near-native oligomer to maximise packing 
density and minimise hydrophobic surface area.
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Figure 1.6 Proposed kinetic pathway for the folding and association of a 
dimeric protein
(Adapted from Jaenicke, 1995)
M, M', and M represent unfolded, intermediate and structured monomeric 
states
N is the native dimeric protein
I* and r* are kinetically trapped intermediates, prone to aggregation 
kl and k2 are first and second order rate constants respectively
The rate limiting step in the kinetic pathway proposed above is believed to 
occur during its later stages. Possible rate limiting steps include disulphide bond 
formation, proline isomérisation and subunit association. Steps 1-3 focus on 
intramolecular events and, as the localised concentration of the reactive elements 
is relatively high, these tend to exhibit first order kinetics. They also represent 
the steps in the pathway during which the nascent polypeptide is vulnerable to 
incorrect intra or inter molecular associations which result in aggregation. 
However subunit association, as it is governed by collision theory, is a 
concentration dependent process and typically displays second order kinetics. 
The oligomeric assembly process requires correct intermolecular recognition to 
occur to be successful. This requires that monomers are in a native/near native 
state. As a consequence of this, one would expect incorrect aggregation is 
minimised during this step (Goldberg et al, 1991; Jaenicke, 1995).
The mechanism for protein folding proposed above can be extended to 
larger multidomain proteins, such as the component enzymes of the 2-oxoacid 
dehydrogenase complexes, by virtue of evidence to date that proteins fold in 
parts. Studies of proteins both in vitro and in the cellular context (Jaenicke 
1993a) reveal that proteins can be considered to fold and unfold on a domain by 
domain basis; each domain appears to act as an independent folding entity.
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1.8 Role of molecular chaperones
The first successful attempt to address the protein folding question was 
made by Anfinsen nearly thirty years ago (reviewed in Anfinsen 1973; Jaenicke, 
1987). He and his co-workers were able to show that despite destruction, in 
vitro, of the 3D structure of ribonuclease by denaturing agents, it was still 
possible to refold the protein to its active and therefore native state. No 
additional protein factors, or energy input were required to promote 
reconstitution of this enzyme. Thus, it appeared, all the information required for 
protein assembly/folding was contained in its primary amino acid sequence, 
specified originally by the genetic code.
However, work over the past decade, beginning with studies on ribulose 
1,5 bisphosphate carboxylase (Barraclough & Ellis, 1980), has shown clearly 
that in vivo protein folding is not so straightforward and is neither spontaneous 
nor energy independent. In fact, a very complex cellular mechanism involving 
sequential action by a series of moleeular chaperones has been shown to be 
essential for effective cellular protein folding in both prokaryotic and eukaryotic 
systems (for reviews see Ellis, 1987; Landry & Gierasch, 1994; Martin & Haiti 
1994; Hard, 1996). The novel observation that protein assembly in vivo was 
protein assisted led to a proliferation of biochemical studies which demonstrated 
that molecular chaperones were involved in: the association with 
nascent/unfolded protein chains (Bole et al., 1986), enhancement of in vitro 
folding and assembly reactions (Zheng et al, 1993), protection against 
aggregation/heat dénaturation (Lindquist, 1992) and improved yields of 
heterologous proteins co-expressed with the molecular chaperones of E. coli 
(Wynn et al, 1992). Meanwhile, genetic approaches (Zeilstrya-Ryalls et al,
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1991) yielded data which illustrated that strains with mutant chaperone 
phenotypes often failed to fold and assemble proteins. It was also possible to 
demonstrate using a combined genetic and biochemical approach that 
chaperones were essential for the translocation of proteins across biomembranes 
(Stuart ef a/., 1994; Martinus et al., 1995).
Protein studies earried out in vitro often seek to minimise the problem of 
protein aggregation by ensuring that the concentration of protein is controlled, 
typically to levels lower than 1 mg/ml. However, this does not reflect conditions i
within the cell. In this environment the concentration of macromolecules, 
including protein and RNA, has been estimated as being in the 200-400mg/ml 
range (Zimmerman & Minton 1993). This leads to what has been termed 
macromolecular crowding. This phenomenon is predicted to increase the 
effective protein concentration, at a ribosome, active in protein synthesis, to 
levels estimated at lOO-lOOOmg/ml (Ellis, 1997).
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The term molecular' chaperone was first used to describe nucleoplasmin, a 
histone binding protein involved in nucleosome assembly (Laskey et al., 1978). 
These proteins function to prevent aggregation of par tially folded protein 
intermediates. The chaperone systems studied to date have clearly indicated that 
several chaperones act in conceit during protein folding; with individual 
chaperones having evolved to specifically deal with discrete steps along the 
pathway. It is also important that they co-operate with one another to deliver the 
folding protein to the next step in the process. It would appear the molecular 
chaperones do not act to violate the protein self-assembly principle, rather they 
function to prevent incorrect protein-protein interactions from occurring, which 
would result in incorrectly folded/aggregated forms of the protein.
I
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Two key types of molecular chaperones have been identified during the 
course of work in the field, which has accelerated in the last decade. These have 
been termed the small and large molecular chaperones (Ellis, 1997). Each has, 
within the cell, a distinct function; but they do interact with each other and 
constitute the molecular chaperone pathway (Hartl, 1996). Small chaperones of 
the DNA J and DNA K (Hsp 70) families are stress proteins which function to 
prevent premature folding of the nascent polypeptide as it emerges from the 
ribosome. They also serve to prevent hydrophobic aggregation of the 
polypeptide with other proteins (see table 1.1 for details).
A second type of molecular chaperone, often termed chaperonins, (Ellis, 
1994) include the (GroEL/ES) family (Fenton & Horwich, 1997). Genetic 
studies (Horwich et al, 1993) into the role of the GroEL/ES chaperonin family 
in E. coli have demonstrated that they serve to prevent protein aggregation. A 
possible mechanism for this action has been elucidated in vitro (Jackson et al, 
1993 ; Todd et al, 1997). It is proposed that aggregation prevention permits a 
partial unfolding of kinetically trapped protein intermediates, and this in turn is 
sufficient to promote their return to productive folding pathways. The model 
allows for successive iterations of binding and release of the polypeptide to 
occur before the native state is reached (see table 1.1 for details).
In addition to preventing aggregation, this chaperonin family directly
facilitates productive protein folding. The central cavity of the GroEL oligomer,
with its GroES cap bound, provides an isolated space in which the aggregation
sensitive protein can fold. Binding of the chaperonin GroES to one end of the
GroEL oligomer promotes release of the bound, folding protein from its contact
sites on GroES. Protein residence time within this Anfinsen cage (Ellis, 1994),
is determined by the ATPase activity of the GroEL molecules and subsequent
GroES release (see Figure 1.7 for proposed mechanism). The two central
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cavities within the GroEL molecule are thought to exhibit positive intra domain 
co-operativity, but negative interdomain co-operativity. Thus, as one half of the 
oligomer binds to ATP the other side will favor ATP hydrolysis and ADP 
formation. ATP binding has been shown to increase cavity size. This 
enlargement is aided by GroES binding and results in a cavity up to 65Â high 
and 80Â wide. This facilitates protein entry into the central cavity where the 
ADP-bound state of the oligomer has an enhanced affinity for the polypeptide. 
The folding polypptide is thought to undergo a number of iterations before it 
gains biological activity and is released from the chaperonin machinery (Todd et 
al., 1996; Martin & Hartl, 1997a; Fenton & Horwich, 1997).
Recent work has begun to investigate the effects of molecular crowding, 
conditions expected within the cell, on chaperonin function (Martin & Hartl, 
1997b). In this study the molecular crowding agents, such as ficol, dextran 70 
and cytoplasmic xenopus egg extracts, were used to mimic cytoplasm 
conditions. In such a system release of the partially folded protein from the 
uncapped GroEL cavity was minimised. This greatly enhances the possibility of 
the partially folded protein rebinding the same GroEL oligomer. This limited 
diffusion and rapid recruitment of the partially folded protein intermediate serves 
to minimise the danger of aggregation.
Thus, molecular chaperones can be defined as functional classes of 
unrelated families of protein that mediate the correct non-covalent assembly of
other polypeptide-containing structures. However, they do not serve as 
components of these assembled structures when the latter are carrying out their 
normal biological functions. All of the molecular chaperones studied to date act 
not by providing steric information essential for assembly, but by preventing 
incorrect interactions which would produce non-functional structures and in
■ ■■some cases large insoluble aggregates.
■ :v-
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The production of native protein may require that the unfolded polypeptide 
undergoes successive iterations (cycles of unbinding and rebinding), involving 
steps 3-6 outlined above, before this can be achieved.
1.9 Folding and assembly of 2-oxoacid dehydrogenase 
com plexes
In eukaryotes, the 2-oxoacid dehydrogenase complexes are located in the 
mitochondrial matrix. However, they are not coded for by the mitochondrial 
genome, which, in mammals, only codes for 13 polypeptides involved in the 
electron transport chain and ATP synthesis. Instead, all components of the 2- 
oxoacid dehydrogenase complexes are the products of nuclear encoded genes. 
This has important implications for their synthesis and delivery to the correct 
cellulai' compartment.
The delivery of proteins to mitochondria and their subsequent import and 
functional maturation has been an area of intense study (see Glover & Lindsay 
1992; Martinus et a l, 1995; Lithgow et al, 1997 for reviews). In particular, the 
modulation of the above by a molecular chaperone mediated pathway, exhibiting 
a division of labour and functional complementation, has been demonstrated 
(see Figure 1.8). Thus, proteins destined for mitochondria, undergo cytosolic 
synthesis and, decorated in cytosolic hspTO molecules to prevent premature 
folding, are transferred to receptor sites situated on the mitochondrial outer 
membrane. Import into the mitochondria is driven by energy (ATP), membrane 
potential (\|f) and the mitochondrial hsp70 molecules, which appear to “pull” the 
precursor protein into the matrix (Kang et a l, 1990). Maturation of the 
precursor protein involves the removal of the mitochondrial targeting sequence 
and the folding and assembly of the protein into its active form. In many 
instances, the folding and assembly process is thought to require the assistance 
of the mitochondrial hsp60/cpnl0 machinery. These proteins, homologues of
the well characterised bacterial GroEL/ES system (see Hartl, 1996; Fenton &
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Figure 1.8 Role of molecular chaperones in the biogenesis of mitochondrial 
proteins (adapted from Martinus et al.^  1995).
Horwich, 1997 for recent reviews) are thought to promote the correct folding of 
the polypeptide via repeated ATP driven cycles of binding and release.
It is probable that the pathway used to produce functional 2-oxoacid 
dehydrogenase multienzyme complexes in the mitochondrial matrix bears a 
good deal of similarity to the one outlined above. However, the regulatory 
mechanisms required to ensure co-ordinated expression of all the individual 
polypeptides necessary for complex formation is not as yet understood. In vitro 
refolding studies of some of the individual components of the multienzyme 
complexes employing (a) a truncated E2 of B CO ADC (Wynn et a l, 1994) and 
(b) E l of BCG ADC (Wynn et al., 1992) have used the GroEL/ES chaperonin 
machinery to successfully refold chemically denatured/unfolded forms.
1.10 Oxidative stress
As a consequence of the aerobic environment in which most organisms live, 
oxidative damage to biological macromolecules is a potential hazard. Protein 
oxidation, lipid peroxidation, and DNA damage, incorporating both base 
modifications and strand breaks, represent the major modifications observed 
when cellular components are exposed to reactive oxygen species (for a recent 
review see Stacpoole, 1997). Accumulation of these damaged macromolecules 
contributes to, or has the potential to accelerate, any senescence or disease 
process. In addition to its role in the normal ageing process (Harman, 1981), 
oxidative stress has been implicated in a number of age related diseases, 
including Parkinson’s disease and Alzheimer’s disease.
To combat this destmctive process, organisms have evolved mechanisms to
sense and prevent oxidative stress situations, as well as repair any damage
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which may arise. A complex system of defence involving chemical agents and 
enzyme families, which appear designed specifically for the task, is required to 
achieve this (Stacpoole, 1997; Fridovich, 1997; Berlett & Stadtman 1997).
Hydrogen peroxide, hydroxide radicals and reactive thiol species all pose a 
threat to biological macromolecules. However the commonest cause of 
component damage is the superoxide anion radical (O2 -) and its reactive 
progeny. This radical can be generated either in a spontaneous fashion (i.e. 
light, radiation), or by enzymatic reactions, such as those catalysed by xanthine 
oxidase (Fridovich, 1997). In the cellular environment, mitochondria, where 
90% of the oxygen utilised is reduced to water (Stacpool, 1997), serve as a 
major source for this and other reactive oxygen species (Nohl & Hegner, 1978; 
Farmer & Sohal, 1989). Thus, mitochondrial proteins, many of which rely on 
their redox state for their cellular function and mitochondrial DNA which is not 
afforded the protection of histone proteins, are particularly vulnerable to damage 
(Wallace 1992; Shigenaga et al, 1994). Indeed, recent work has identified the 
mitochondrial enzyme aeonitase as a target for oxidative damage during ageing 
(Y anera/., 1997).
Chemical agents, such as ascorbate, glutathione and lipoic acid, along with
the catalayse, peroxidase and superoxide dismutase families of enzymes, play
important roles in the defence against oxidative damage. In eukaryotes, the
superoxide dismutase (SOD) family of enzymes constitutes the main line of
defence (Fridovich, 1997). In addition to the cytosolic Cu-Zn form of the
enzyme, two other forms, an extracellular Cu-Zn form and a mitochondrial Mn
form, have been characterised. Extracellular SOD (EC-SOD) is found
principally in the extracellular spaces and the function of this glycosylated
heterotetramer appears to be to inactivate superoxide anion radicals generated by
phagocytic leukocytes (Sandstrom et al, 1992). Work on the Cu-Zn form of the
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enzymes implicates mutations in the gene(s) as being a causative agent for the 
disease amyotrophic lateral sclerosis (ALS), which involves motor neurone 
degeneration, skeletal muscle atrophy, paralysis and death (Gurney, 1997;
Shaw et al, 1998; Kong & Xu, 1998). Mitochondrial Mn-SOD serves as a 
primary defence mechanism against the high levels of reactive oxygen generated 
by the organelle. The importance of mitochondrial SOD to organism viability 
has been highlighted by gene knockout studies performed in mice (Li et al, 
1995; Lebovitz et al, 1996). Mice lacking this enzyme displayed a dramatic 
shortening of life expectancy to 1-2 weeks and faulty mitochondrial activity 
was detected in tissues investigated, especially the heart.
Studies in E. coli of the SoxRS regulon, representing a group of genes 
expressed in response to oxidative stress, has begun to provide information on 
the molecular mechanism underlying the sensing of such events and 
mobilisation of a concerted defence (Ding et al, 1996).The protein SoxR acts as 
a redox sensor. Specifically, oxidation of the protein’s [2Fe-2S] cluster causes 
it to act as a transcriptional activator of the SoxS gene; which is responsible for 
switching on the entire regulon. Another regulon, directed against peroxide 
stress has also been identified in E. coli (Storz et al, 1990). It is possible to 
speculate that similar control systems may be implicated in the concerted 
response of eukaryotes to such stress conditions.
Organisms require systems to sense and then prevent, or limit, damage
caused to cellular components by reactive oxygen species. Systems which rely
on both enzymatic and non enzymatic antioxidants have been described. The list
includes glutathione and thioredoxin systems; the enzymes superoxide-
dismutase, catalase and glutathione peroxidase. These and others, depending on
their specific function and localisation, have important roles in protection,
prevention, interception and repair of oxidative damage
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Studies on the E2 component of mammalian PDC concern the folding and 
assembly of the 60meric core structure. The ability of refolded E2 eores to 
reconstitute PDC activity, upon the addition of the E l and E3 components, is 
examined and the presence of specific, low affinity binding sites on the E2 
component for E3 is demonstrated.
During the course of purification development work, a protein was 
discovered which appeared to associate with mammalian PDC. N-terminal 
amino acid analysis identified it as SP-22, a thiol antioxidant protein. To allow
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1.11 Aims of this thesis
The principal area of investigation contained in this thesis relates to the 
subunit interactions between the component enzymes of the 2-oxoacid 
dehydrogenase multienzyme complexes. To carry out the studies outlined 
below, it was first necessary to develop purification protocols which facilitated 
the production of the individual components of the 2-oxoacid dehydrogenase
■complexes in their active forms, and in sufficient quantities (Chapter 3)
Previous work in the laboratory had implicated a possible role for the El 
component of mammalian OGDC in binding the E3 component to this 
multienzyme complex (Rice et al, 1992). Further studies, which include 
component purification, whole complex reconstitution and gel permeation 
analysis, confirm that the E l and E3 components of mammalian OGDC do 
interact directly with each other (Chapter 5).
future study of the role of this protein, and its proposed relationship with 
mammalian PDC, a clone was obtained , from bovine brain cDNA (chapter 6).
31
CHAPTER 2: MATERIALS AND METHODS
Section A: Protein Biochemistry
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2.1 Protein Biochemistry Materials
2.1.1 Chemical reagents
The majority of reagent grade chemicals were obtained from either Fisher 
Scientific, Loughborough, Leicestershire, U.K. or BDH laboratory supplies, Poole, 
Dorset, U.K. These included:
glycine, sodium dodecyl sulphate (SDS), sodium hydroxide, magnesium chloride, 
polyethylene glycol 6000, acrylamide, N,N-methylenebisacrylamide, ammonium 
persulphate, citric acid, trichloroacetic acid (TCA).
Ultrapure guanidine hydrochloride (GdnHCl) and dithiothreitol (DTT) were 
supplied by Gibco BRL, Paisley, Scotland. Additional chemicals were of the highest 
grade commercially available.
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The following reagent grade chemicals were purchased from the Sigma 
Chemical Co, Poole, Dorset, U.K.
Acetyl phosphate (lithium potassium salt), glutaraldehyde (grade 1), 3-[N- 
morpholinoj-propane-sulphonic acid (MOPS), imidazole base, triethanolamine, 
Coomassie Brilliant Blue R250, Pyronin Y, antifoam A (concentrate), L-cysteine- 
HCl (anhydrous), p-nicotinamide adenine dinucleotide (oxidised form, P-NAD+), 
thiamine diphosphate (ThDP), DL-6,8-thioctic acid amide (DL-lipoamide, oxidised 
form), benzamidine-HCl, phenylmethylsulphonyl fluoride (PMSF), coenzyme A 
(lithium salt), acetyl coenzyme A (C2:0) lithium salt, pymvic acid (sodium salt) and 
2-oxoglutaric acid (disodium salt), 2,6- dichlorophenolindophenol (DCPIP)
—
2.1.2 Proteins and enzymes
The majority of proteins and enzymes were supplied by Sigma Chemical Co., 
Poole, Dorset, U.K.
Lipoamide dehydrogenase, type VI, B.C. 1.8.1.4, isolated from bovine intestinal 
mucosa (170 U/mg protein); lipoamide dehydrogenase, E C. 1.8.1.4, from Candida 
utilis (40-100U/mg protein); phosphotransacetylase, E.C. 2.3.1.8 isolated from 
Bacillus stearothermophillus (4,000-10,000 U/mg protein); bovine serum albumin, 
(fraction V); leupeptin protease inhibitor.
Low molecular mass electrophoresis marker proteins were purchased from 
PHARMACIA LKB Biotechnology, Milton Keynes, U.K.
Bovine gamma globulin was purchased from BIO-RAD Laboratories Ltd., Herts., 
U .K.
2.1.3 Biological materials
Bovine hearts were obtained from Paisley Abbatoir, Sandy ford Rd., Paisley, 
U.K. shortly after slaughter, transported on ice to the laboratory and diced before 
storage at -80°C. New Zealand rabbits, used in the production of antibody, were 
purchased from Medical Research Council accredited sources. Freund’s adjuvant 
(incomplete & complete) was purchased from Sigma Chemical Company Ltd., 
Dorset, U.K.; and heat inactivated donkey serum supplied by the Scottish Antibody 
Production Unit (SAPU), Glasgow & West of Scotland Blood Transfusion Service, 
Law Hospital, Carluke, U.K.
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2.1.4 Chromatographic materials
Mono Q strong anion exchange resin, Superose 6 (prep grade) and Superose 12 
gel matrices were purchased from PHARMACIA LKB Biotechnology, Milton 
Keynes, U.K.
2.1.5 Photographic materials
High performance Hyperfilm-ECL was purchased from Amersham International 
pic., Buckinghamshire, U.K. LX-24 X-ray developer, FX-40 X-ray liquid fixer and 
X-omat S film were purchased from IBI Ltd. (Kodak), Cambridge, U.K. 
Autoradiography cassettes and high speed- intensifying screens were supplied by 
Genetic Research Institute Ltd., Essex, U.K.
2.1.6 Miscellaneous items
Slide-a-lyser dialysis cassettes and buoyancy aids were obtained from Pierce 
Chemical Co., Chester, U.K.
PVDF protein sequencing membrane was purchased from BIO-RAD Laboratories 
Ltd., Hertfordshire, U.K.
HYBOND-C extra supported nitrocellulose (0.45pm pore size) was purchased from 
AMERSHAM International pic., Buckinghamshire, U.K.;
Centricon microconcentrator tubes were purchased from AMICON, Danvers, Ma., 
U.S.A.
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2.2 Protein Biochemistry Methods
2.2.1 Determination of protein concentration
Protein concentration was determined using the method of Bradford (1976). In 
this instance, bovine gamma globulin was found to be a better relative standard than 
bovine serum albumin. For each set of samples a standard curve was constructed 
and absorbances read at 595nm.
2.2.2 Dialysis of protein samples
Visking tubing was boiled in lOmM sodium bicarbonate pH 8.0, ImM EDTA 
for 30 min to remove chemical contaminants. It was then rinsed and boiled in 
distilled water for a further lOmin, before storage in iOO%(v/v) ethanol. Dialysis 
was carried out at 4°C at a minimum ratio of 1:1000 (sample; dialysis buffer) and 
usually employed multiple changes of dialysis buffer.
2.2.3 Concentration of protein samples
For sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
of dilute protein samples, or those which contained interfering material (i.e.,
guanidine hydrochloride), trichloroacetic acid (TCA) precipitation was carried out
(Hames, 1981). Typically, following the addition of 10%(w/v) TCA and incubation
of the sample for 15min at 4°C, precipitated protein was pelleted by
microcentrifugation at 10,000g in a bench top centrifuge for 15min. Subsequently,
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the pellets were washed with ice cold acetone before resuspension in Laemmli 
sample buffer and the pH adjusted to 7.0 using 2M Tris base.
Pooled fractions from the preparative dissociation of PDC (see section 2.2.9) 
into E2/X and E1/E3 were concentrated, after extensive dialysis to remove salt, by a 
second dialysis step directly into storage buffer which contained 50%(v/v) glycerol. 
Occasionally the desalted pools were concentrated by submerging the dialysis tubing 
in fresh, dry poly(ethylene glycol) (PEG 6000) flakes at 4°C until the desired 
decrease in volume was achieved.
Ultrafiltration/concentration of protein samples was carried out using the 
Amicon Centricon system when very small sample volumes were required. This 
involved, multiple 20-30min spins at 5000g.
2.2.4 Protein analysis by gel electrophoresis under 
denaturing conditions
Proteins were compared and characterised using sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE). Resolution was achieved using the 
discontinuous Tris/glycine system of Laemmli (1970).
Protein sample preparation
After the addition of an equal volume of Laemmli sample buffer (62.5mM 
Tris/HCl pH6.8, 2%(w/v) SDS, 10%(w/v) sucrose, 0.2%(w/v) Pyronin Y) and 
DTT to a final concentration of lOOmM, samples were boiled for 5min. Prior to
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loading, samples were spun briefly in a benchtop microcentrifuge to remove any 
particulate material.
Analytical SDS-PAGE gel preparation
Gels with dimensions 170mm x 145mm x 1.5mm were prepared from the stock 
solutions below:
a) Acrylamide stock solution (22.2% (w/v) acrylamide, 0.6%(w/v) bis acrylamide).
b) 2x Resolving gel buffer (0.75M Tris/HCl pH 8.8, 0.2%(w/v) SDS).
c) 1.4x Stacking gel buffer (0.17M Tris/HCl pH 6.8, 0.14%(w/v) SDS).
I
fl
I
d) Ammonium persulphate (0.1 mg/ml)
Stock solutions were filtered and degassed prior to use. Polymerisation of the 
acrylamide was initiated by the addition of TEMED yielding resolving gels of 7-15% 
(w/v) acrylamide (0.375M Tris/HCl pH 8.8, 0.1%(w/v) SDS, 0.1%(w/v) 
ammonium persulphate, 0.08%(v/v) NNN’N ’-tetramethylethylenediamine 
(TEMED); and stacking gels of 4.4% (w/v) acrylamide (0.12M Tris/HCl, pH 6.8, 
0.1%(w/v) SDS , 0.1%(w/v) ammonium persulphate, 0.08% (v/v) TEMED).
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Conditions for electrophoresis
Gels were run using vertical electrophoresis kits purchased from BRL 
employing a constant 40-70 mA current in running buffer (24mM Tris/192mM 
glycine pH 8.3, 0. l%(w/v) SDS) for 3-4 h. Gels were stained for protein bands 
(>0.1 pg) overnight using 0.04% (w/v) Coomassie Brilliant Blue R, 10%(v/v) acetic 
acid and 25%(v/v) methanol, and destained employing multiple changes of 20%(v/v) 
methanol, 10%(v/v) acetic acid. Addition of 10% (v/v) glycerol to the destain 
allowed storage of the gel before photography.
Relative molecular mass estimation of SDS-PAGE resolved 
proteins
Since protein migration in SDS-PAGE is generally proportional to subunit Mr 
value it was possible to estimate the relative molecular mass by constructing a 
standard curve of the log of known protein molecular mass as a function of their Rf 
values (relative mobilities) where:
Rf= distance of protein migration
distance of tracking dye migration
Distances were measured from the beginning of the resolving gel to the leading edge 
of the protein band.
Two sets of standard proteins were employed: (note that the Mr values below
refer to those quoted by the manufacterers).
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1) Low molecular weight calibration kit (Pharmacia):
Protein Subunit Mr value
Phosphorylase b 94, 000
Bovine seram albumin 67, 000
Ovalbumin 43, 000
Carbonic anhydrase 30, 000
Soya bean trypsin inhibitor 20, 000
a-lactalbumin 14, 000
2) Wide range protein standards (Novex)
Protein Subunit Mr value ■i
Myosin 200 , 000 1
p-galactosidase 116,000 #À
Phosphorylase b 97, 000 i''l;v
Bovine serum albumin 67, 000 *i:
Lactate dehydrogenase 36, 500 ÎCarbonic anhydrase 31, 000 fî
Soya bean trypsin inhibitor 20, 000 S
Lysozyme 14, 000 4
f
:|,ï%
i
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2.2.5 Immuiioblotting
Proteins, after resolution by SDS-PAGE, were transferred to and immobilised 
on a matrix for subsequent immunological detection (Towbin et al., 1979; Gershoni 
and Palade, 1983)
The first step involved electrophoretic transfer of the proteins from the 
polyacrylamide gel to nitrocellulose using a wet tank blotting method. Pre-wetted 
Hybond-C immobilizing matrix was used to overlay the gel, sandwiched between 
wet filtei-papers and placed in a transfer cassette. This cassette was then submerged 
in transfer buffer (25mM Tris, 0.19M glycine, pH 8.2-8.4, 0.02%(w/v) SDS,
20%(v/v) methanol) contained in a Bio-Rad Trans Blot apparatus and a cuiTent of 
40mA applied overnight. The non-fixative stain, Ponceau S, was used to determine 
efficiency of transfer to the nitrocellulose.
Subsequently, the membrane was blocked overnight at 4°C, or all day at room 
temperature, with blocking buffer (20mM Tris-HCl, pH 7.2, 15mM NaCl, 5%(w/v) 
non fat milk, 5%(v/v) normal donkey serum, 0.2%(w/v) Tween 20). Incubation 
with the primary antibody (diluted between 1:10,000 and 1:50,000 in 20mM Tris- 
HCl, pH 7.2, l%(w/v) non fat milk, 5%(v/v) normal donkey serum, 0.1 %(w/v)
Tween 20) took place overnight at 4°C. Following extensive, multiple washes with 
low salt buffer (20mM Tris, pH 7.2, 15mM NaCl, l%(w/v) non fat milk, l%(v/v) 
normal donkey serum) to remove unbound primary antibody, the secondary anti­
rabbit horseradish peroxidase (HRP) conjugate antibody was applied (1:1000 
dilution in 20mM Tris-HCl, pH 7.2, 150mM NaCl, l%(w/v) non fat milk, l%(v/v) 
normal donkey semm). After a 2h incubation at room temperature, blots were
■
subjected to an extensive wash procedure employing multiple washes with the low
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salt buffer followed by a single high salt wash (20mM Tris-HCl, pH 7.2, 150mM 
NaCl). Detection was carried out using enhanced chemiluminescence (ECL reagents 
Amersham) as per the manufacturer's instructions.
2.2.6 Resolution and preparation of proteins for N-terminal 
sequencing
Protein resolution was performed as described in section 2.2.4 using reagents 
of the highest purity available. Following SDS-FAGE protein bands were 
transferred to Hybond C as described in section 2.2.5. After transfer, the
bags before delivery to the BBSRC Protein Sequencing Facility at Aberdeen 
University (Matsudaira, 1987). Sequencing performed by Brian Dunbar.
2.2.7 Negative ion electrospray mass spectrometry (ES/MS)
IMMOBILON was rinsed in distilled water, stained for 5min with 0.1 %(w/v) 
Coomassie blue, 50%(v/v) methanol and destained for 10 min with 50%(v/v)
methanol followed by thorough rinsing with distilled water before the membrane 
was allowed to dry. Protein bands were excised using a scalpel and sealed in plastic
Protein samples were analysed in the negative ion mode at a concentration of 5- 
lOpmol/pl. They were introduced into the electrospray source at 5|ll/min. Typically,
scanning was in the range mass:charge ratio (m/z ) 900-1700 and data were summed
over approx. 5 min to obtain final spectra. These data, on an m/z scale, were
transformed onto a tme molecular mass scale using maximum entropy (Max-Ent)
software. Mass scale calibration employed the multiply charged negative ion series
from separate introductions of horse heart myoglobin (Sigma) sequence moleculai'
mass=16951.5 Da (see Nairn et al, 1995 for details). Molecular masses are based
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upon the following atomic weights of the elements: C= 12.011, H= 1.00794, 
N=14.00674, 0=15.9994, P=30.97376, S=32.066 (ÏUPAC commission on atomic 
weights and isotopic abundances, 1993). ES/MS operated by Tino Krell.
2.2.8 Purification of the pyruvate dehydrogenase and 2- 
oxoglutarate dehydrogenase complexes from bovine heart
Isolation of bovine heart PDC and OGDC, performed, unless otherwise stated, 
at 4°C, was based upon the standard protocols (Stanley & Perham, 1980; De 
Marcucci et a l, 1985) incorporating the modifications as detailed below:
Fresh, diced ox heart, trimmed of fat deposits/connective tissue, was either used 
on the day, or stored frozen at -80°C and thawed overnight before use. To 600g of 
the prepared and washed ox heart, two volumes of ice cold extraction buffer (50mM 
MOPS, pH 7.0, 3%(v/v) Triton X-100, 3mM EDTA, ImM DTT, ImM PMSF,
ImM benzamidine, 0.1%(v/v) anti-foam A) was added. Following homogenisation 
for 5 min, a cell/nuclear free supernatant was prepared by centrifugation at 10,000g 
for 20 min. The pH of the supernatant was adjusted to 6.45 using 10%(v/v) acetic 
acid and the first PEG precipitation step was performed by the addition of 0.12 
volumes of 35%(w/v) PEG. After stirring the solution on ice for 30 min to ensure 
complete precipitation, the pelleted material was recovered by centrifugation at 
18,000g for 15 min.
1
Pellet resuspension was in 300-400ml of l%(v/v) Triton buffer (50mM MOPS, 
pH 6 .8 , l%(v/v) Triton X-100, 3 mM EDTA, ImM DTT, ImM PMSF, ImM 
benzamidine, 1.5pM leupeptin) using a loose fitting glass Teflon homogeniser.
Material which failed to resuspend was removed by the subsequent clarification spin 
at 25, OOOg for 40 min. After filtration of the resulting supernatant through layers of
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muslin to remove fat droplets, 0.05 volumes of IM sodium phosphate buffer and 
0.013 volumes of IM MgCl2 were added dropwise. Throughout this addition the pH 
was maintained at 6.8 by the addition of 0.5M NaOH. The pH was readjusted to 
6.45 with 10%(v/v) acetic acid before a second PEG precipitation was performed. 
This involved the addition of 0.12 volume of 35%(w/v) PEG to the stirring 
supernatant on ice and, as previously, after 30 min, the material precipitated was 
pelleted by centrifugation at 25, OOOg for 10 min. Before storage overnight at 4°C, 
the pellets were resuspended in l%(v/v) Triton buffer (150-200ml) with an 
additional cocktail of protease inhibitors: ImM PMSF, ImM benzamidine, l|iM  
leupeptin, 0.5%(v/v) rat serum.
Prior to further purification the following day, it was necessary to re~ 
homogenise the material and subject it to another clarification spin at 25,OOOg for Ih. 
The third and final PEG fractionation was then carried out. After adjusting the pH to 
6.45, with 10%(v/v) acetic acid, 0.06 volumes of 35%(w/v) PEG was added and the 
solution left to stir on ice for 30 min. This differential cut enabled the separation of 
OGDC, insoluble at the prevailing PEG concentration, to be removed by 
centrifugation at 25,OOOg from the PDC which retains its solubility and was thus 
present in the supernatant. Ultracentrifugation of the PDC/PEG supernatant in a Ti 
70 Rotor (Beckman) at 200,000g for 2.5 h resulted in the pelleting of the PDC and 
thus allowed for removal of the remaining PEG. Both PDC and OGDC were then 
resuspended in l%(v/v) Triton buffer, containing no protease inhibitors, and stored, 
at 4°C with no significant loss of activity, for over 2 weeks for OGDC and 3-4 
weeks in the case of PDC.
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2.2.9 Preparative dissociation of PDC into enzymatically
active E2/X and E1/E3 fractions
Preparative dissociation of PDC into active E2/X and E1/E3 fractions was 
performed on an FPLC system (Pharmacia) using a prep grade Superose 6 column 
(100ml) equilibrated with 50mM imidazole/HCl, pH 7.0, IM NaCl, 0.01%(v/v) 
Triton X-100.
PDC (15.0mg/ml) in lOOmM MOPS/NaOH, pH 6.8, 5mM EDTA, l%(v/v) 
Triton X-100 was microfuged in a benchtop centrifuge at 10,OOOg for 15min, to 
remove any particulate material, before incubation at a l:l(v/v) ratio with 50mM 
imidazole/HCl, pH 7.0, 4M NaCl on ice for Ih. A 2ml pre-injection of the 4M NaCl 
buffer was then performed prior to PDC sample loading (2ml) and subsequent 
elution at a flow rate of Iml/min. Fractions were pooled on the basis of A28O and 
dialysed and concentrated, at 4°C, against multiple changes of buffer into 50mM 
imidazole/HCl, pH 7.4, ImM EDTA, 50%(v/v) glycerol and stored at 4°C. Both 
pools were stable under these conditions for over one month 
(see stability data 3.2.2 ).
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2.2.10 Purification of the E l and E3 components of 
mammalian PDC by preparative anion exchange 
chromatography
■
Following the preparative dissociation of PDC as detailed in section 2.2.9, it 
was possible, using the E l, E3 fraction, to isolate the individual component 
enzymes. E1/E3, prepared as detailed in the previous section, was exchanged into 
20mM triethanolamine/HCl buffer, pFI 7.4, lOmM NaCl, ImM CHAPS either by 
extensive dialysis or centricon ultrafiltration. A microfuge spin in a benchtop 
centifuge at 10,OOOg for 15min was used to remove any precipitated/particulate 
material before the sample was loaded (maximum load 4mg of protein) onto an 8ml 
Mono Q column (Pharmacia) pre-equilibrated with 20mM triethanolamine/HCl 
buffer, pH 7.4, lOmM NaCl, ImM CHAPS (buffer A). The column was washed 
with 2 column volumes (8ml) of the buffer A to remove any unbound material before 
being developed with a linear gradient of 20mM triethanolamine/HCl buffer, pH 7.4, 
500mM NaCl, ImM CHAPS (buffer B) over 200ml.
ïr
The Mono Q column was then washed with 2 column volumes of buffer B to
remove any strongly retained material. In addition to monitoring the eluent 
continuously at 280 nm, individual fractions were assayed for E l or E3 activity. 
Pools of fractions which contained significant levels of non-contaminated activity 
were constructed and subsequently desalted using centricon-30 apparatus (Amicon) 
into storage buffer 50mM MOPS/KOH, pH 6 .8 , lOniM NaCl, 3mM EDTA before
use. %
•fli-
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2.2.11 Association state analysis of the E2/X subeomplex
Association state analysis of the E2/X subcomplex was performed using the 
FPLC system (Pharmacia). A Superose 6 column (24ml) was equilibrated, at 
0.2ml/min, with increasing concentrations of GdnHCl in 50mM imidazole/HCl, pH
7.4, 200mM NaCl. E2/X subcomplex in column equilibration buffer, in the absence 
of GdnHCl, was centrifuged at 10,OOOg for 15min and pre-incubated at room 
temperature for 15 min in the appropriate concentration of GdnHCl before re­
centrifugation and subsequent loading of 200jil onto the column at 0.05ml/min. 
Protein elution was detected at 280nm and the column calibrated using gel filtration 
molecular mass markers (Sigma).
Following the construction of a Ve/Vo versus log Mi- plot, the relative molecular 
mass of the E2/X species observed was estimated by interpolation 
Proteins used to construct Ve/Vo vs log molecular mass calibration curve:
Protein Protein M|*
bovine serum albumin 6 6 , 000
p-amylase 2 0 0 , 000
Apoferritin 443,000
Thyroglobulin 669,000
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2.2.12 Enzyme assays
All enzyme assays were perfomed on a Shimadzu UV-2101 PC nv-vis scanning 
spectrophotometer. Activities were expressed as U/ml unless otherwise stated 
(where one unit (U) of enzyme catalyses the conversion of 1 |imol of substrate to 
product per minute under the specified conditions of pH, temperature, ionic strength 
and substrate concentration).
Overall PDC/OGDC complex activity
PDC and OGDC activities were monitored spectrophotometrically at 340nm 
following the production of NADH (Brown & Perham, 1976). Typically l-5jxg of 
the complex was added to an assay cuvette pre-warmed to 30°C containing 670p,l 
solution A (50mM potassium phosphate buffer, pH 7.6, 3mM NAD+, 2mM MgCl2, 
0.2mM ThDP) and 14|il of solution B (0.13M cysteine-HCl, 0.13mM Li2CoASH) 
and 14|xl solution C (lOOmM pyruvic acid for PDC assays or lOOmM 2-oxoglutarate 
for OGDC assays).
Pyruvate dehydrogenase (E l)
This was measured by following the reduction of 2,6-dichlorophenolindophenol
(DCPIP) to its colourless form at 600nm (Khailova et al, 1976). Varying amounts
of either purified E l or intact PDC complex were added to a cuvette containing 670|iil
solution A (50mM potassium phosphate buffer, pH 7.6, 3mM NAD+, 2mM MgCl2,
0.2mM ThDP) and 14pl of DCPIP (1 mg/ml) pre-warmed to 30°C. The reduction of
the dye was initiated upon the addition of 14jil solution C (lOOmM pyruvate).
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Dihydrolipoamide acetyltraiisferase (E2)
The activity of the E2 component of PDC was assayed in the direction of 
formation of acetyldihydrolipoamide (Reed & Willms, 1966; Ono et al, 1993; Yang 
et al, 1996). The following assay conditions were used: 85mM Tris-HCl, pH 8.0, 
lOmM acetyl phosphate, 1.8mM dihydrolipoamide, 260|iM Co A, 
phosphotransacetylase (4U/ml). After the absorbance became constant (10-15sec), 
due to the foimation of acetyl CoA, the E2 source was added. Activity was measured 
directly following the increase in absorbance at 240nm, at 30“C and were recorded as 
change in absorbance/min, as the extinction of the immediate product, 8-acetyl- 
dihydrolipoamide, cannot be determined.
Dihydrolipoamide dehydrogenase (E3)
Dihydrolipoamide dehydrogenase activity, from a variety of sources, was 
determined spectrophotometrically following the increase in absorbance at 340nm, at 
30°C, due to the formation of NADH from the oxidation of dihydrolipoamide 
(Jackman et al, 1990). Routinely l-2pg of either intact PDC or isolated E3 were 
added to a cuvette containing 670ul solution A (50mM potassium phosphate buffer, 
pH 7.6, 3mM NAD+, 2mM MgC^, 0.2mM ThDP) and 14|xl freshly dissolved 
dihydrolipoamide (2mM in 70%(v/v) ethanol) and activity determined from the 
increase in absorbance at 340nm.
2.2.13 Preparation of dihydrolipoamide
Dihydrolipoamide substrate was prepared in the laboratory from DL-lipoamide 
according to the method of Kochi and Kikuchi (1976). Typically, 60mg DL- 
lipoamide was dissolved in 1.2ml IM potassium phosphate buffer, pH 8.0, 
50%(v/v) ethanol. Reduction to the dihydrolipoamide form was achieved upon the 
addition of 2.4ml fresh 5%(w/v) sodium borohydride in lOmM NaOH. The reaction 
was terminated after 10 min by the addition of 1.2ml of 3M HCl to neutralise the 
reaction and destroy excess reducing agent. The product, dihydrolipoamide, could 
then be extracted into toluene (3x3ml) and, after solvent evaporation under nitrogen, 
stored at -20*^0 as a white crystalline solid.
if
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2.2.14 Reconstitution of PDC activity from E2/X sub­
complex and E1/E3 fractions
Following dissociation of PDC by gel permeation chromatography (see section 
2.2.9), the E2/X and E1/E3 fractions were dialysed into 50mM imidazole/HCl, pH
7.4, ImM EDTA, 50%(v/v) glycerol and stored at 4°C.
,For reconstitution studies E2/X and E1/E3 fractions were activated by a 1:1 
(v/v) dilution in 50mM potassium phosphate/KOH, pH 7.6, 3mM NAD+, 2.7mM 
cysteine-HCl, 2mM MgCl%, 0.2mM ThDP, 0.02mM CoASH (buffer AB) and 
incubation at 4°C for 15 min. At this stage, 2-lOpg of E2/X was added to an assay 
cuvette containing 670pl 50iuM potassium phosphate/KOH, pH 7.6, 3mM NAD+,
2mM MgCl%, 0.2mM ThDP (solution A); 14pl 130mM cysteine-HCl, 1.35mM 
CoASH (Solution B) and 2-30|ig diluted E1/E3 pre-warmed to 30°C. The
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production of NADH was initiated by the addition 14jxl lOOmM pyruvate (solution 
C) and monitored at 340nm. Activities were recorded as U/ml and expressed as a 
percentage recovery relative to undissociated PDC.
Reconstitution studies on refolded E2/X cores, employing an excess of E3, 
were performed as above, except that, following reconstitution with the correct 
stoichiometric quantity of E1/E3, an additional 5 min incubation with purified E3 (1- 
lOOjLig) was incorporated, before the PDC activity was determined.
2,2.15 Unfolding and refolding studies on mammalian PDC 
and its component enzymes
GdnHCl dénaturation studies
The determination of dénaturation curves for PDC and its component enzymes 
was performed over a range of protein concentration and in a range of buffers using 
methods outlined in West & Price (1988) and Pace et a l (1990).
On the day of the experiment three fresh stock solutions were prepared:
A) a protein stock solution at the desired concentration
B) a buffer solution containing the desired additives
C) a dénaturant stock solution prepared in the above buffer.
The molarity of the GdnHCl stock solution can be subsequently determined
experimentally using recorded weights or refractive index measurements (Nozaki,
1972). Protein samples at the desired final concentration, in the molarity of
dénaturant required, were prepared by mixing solutions A, B and C in the
appropriate ratios and allowing this unfolding solution to come to equilibrium at the
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chosen temperature. After a sufficient time lapse to ensure the complete effect of the 
dénaturant on the protein sample, typically 15min at 20°C, it was possible to measure 
the degree of unfolding using the parameter under investigation i.e. activity or 
fluorescence. In the case of activity measurements, it was necessary to remove an 
aliquot (lO-lOOpl) from the unfolding solution and assay for the activity of interest, 
in the presence of an identical dénaturant concentration present in that particular 
unfolding sample. After careful measurement of the experimental parameter, the 
result was plotted on a graph from which it was possible to determine if any 
additional points were required. Typically, at least three unfolding samples were 
prepar ed for each dénaturant concentration and their individual activities determined. 
Details of specfic conditions, or deviations from the above, are presented in the 
relevant chapters.
Reactivation of PDC and its component enzymes after pre­
conditioning with GdnHCl
Intact mammalian PDC, or the individual component enzyme under 
investigation, was incubated for a fixed time in the desired concentration of GdnHCl 
as described in the previous section. Reactivation was initiated by rapid dilution,
(1:50 or 1:100), either, directly into a suitable assay buffer, or into a renaturation 
buffer which contained no dénaturant. Alternatively, refolding and reactivation were 
investigated by dialysis of the denatured protein for periods ranging from 20 min to
'24h. Enzyme assays were carried out immediately or after a suitable time-lapse. Care
'I
was taken to ensure that residual levels of chaotrope were lower than those which 
were determined to have an inhibitory effect on the enzyme (normally < 30mM). In 
generating refolding curves, the measurement of the parameter of interest, at each 
GdnHCl concentration, was performed in triplicate. Activity was expressed as a
percentage of the activity of an equal amount of undenatured enzyme. Details of
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specfic conditions or deviations from the above are presented in the relevant 
chapters.
2.2.16 Preparative dissociation of mammalian OGDC
Following purification of OGDC from bovine heart as detailed 
previously (De Marcucci e ta l, 1985), OGDC was dissociated into its E2 core 
and E1/E3 fractions by the following method; OGDC (30mg/ml) was incubated 
at a l:l(v/v) ratio with dissociation buffer (50mM MOPS/KOH, 7.6, 2M 
MgCl2, 20mM DTT, 0.2%(v/v) Triton X-100) for 1.5h on ice. The sample was 
spun at 10,OOOg in a bench top centrifuge for 15min to remove any particulate 
material. The E2 core of OGDC was separated from the E1/E3 fraction on an 
FPLC system (Pharmacia) using a 100ml bed volume prep grade Superose 6 
column (1.6x50cm) equilibrated with 50mM MOPS/KOH, pH 7.6, IM MgCl2 ,
0.1%(v/v) Triton X-100. A pre-injection of the dissociation buffer (2ml) was 
performed prior to OGDC sample loading (2ml) and subsequent column elution 
at a flow rate of Iml/min. The eluent was monitored on-line at 280nm. Pooled 
fractions were dialysed extensively, at 4°C, against multiple changes of buffer, 
into 20mM MOPS/KOH, pH 7.0, lOmM KCl, 0.1% (v/v) Triton X-100.
N;;:
■:g
i
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2.2.17 Reconstitution of OGDC activity from E2 core 
and E1/E3 fractions
The method used to reconstitute OGDC activity was derived from the one 
optimised previously for PDC (Sanderson et al, 1996b). Reconstitution was 
started by adding quantities of E1/E3 (0-30pg) to cuvettes containing E2 (10|Xg) 
and the appropriate assay solutions. Following a 15 min incubation at 20°C, the 
production of NADH was initiated by the addition of 14pl lOOniM 2- 
oxoglutarate. NADH production was monitored at 340nm and activities are 
expressed either as Units/ml or a percentage relative to the specific activity of 
undissociated OGDC (see chapter 5),
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2.2.18 Association state analysis of E l and E3 OGDC
Gel permeation analysis of E1/E3 quaternary structure was performed 
on a 24ml bed volume Superose 12 column (lx30cm) attached to an FPLC 
system (Pharmacia). The method employed derived from one reported 
previously (McCartney et al, 1997). The column was calibrated with gel 
filtration molecular mass markers (Sigma) for the construction of a calibration 
curve of Vg/Vo versus log Mr. The column was equilibrated, at 0.3ml/min, in 
20mM MOPS/KOH, pH 7.0, lOmM KCl, 0.1%(v/v) Triton X-100. E1/E3 
samples were clarified for 15min at 10,000g in a benchtop centrifuge prior to 
loading onto the column (500]Li1 of sample). The elution profiles obtained were 
from protein detection at 280nm and from E3 activity assays on the eluted 
fractions.
rji
Section B: Molecular Biology
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2.3 Molecular biology materials
2.3.1 Chemicals
Agarose was purchased from Appligene Oncor (Birtley, UK). Bacterial growth 
media was obtained from Merck (Darmstadt, Germany). Bovine brain cDNA was 
obtained from Clonetech (Cambridge, UK). p5s]-methionine (lOmCi/ml) and 
Amplify fluorescent detection reagent were obtained from Amersham Life Sciences 
Ltd (Amersham UK). All other chemicals were of analytical grade or better and are 
detailed in section 2.1.1.
2.3.3 Synthetic oligonucleotides
Oligonucleotides used as primers for PCR amplification of the SP-22 sequence
were synthesised by Gibco BRL (Paisley, Scotland). M l3 forward and reverse
primers were purchased from Pharmacia Ltd (Milton Keynes, UK)
56
2.3.2 Bacterial strains and plasmid vectors
pCR-Script Amp SK(+) Cloning kit was obtained from Stratagene Ltd (Cambridge, 
UK). This contained Epicurian Coli XL 1-Blue MRP’ Kan supercompetent cells. The 
vector pCR-Script Amp SK(+) was used to clone the purified products amplified by 
PCR (polymerase chain reaction) using bovine brain cDNA as a template (see Figure 
2.1 for vector map and polylinker sequence). pBluescript II KS(+/~) was also 
purchased from Stratagene.
i  RI
æ-
îS "S
: |ï
SB=î|I
#8 "
en*
I
§1
<M 2.
(ï w
n s>
■f §•!
xo a
S V
^ÿ -g =
■VI
■vl ui 00 Ln
“  ui Ln o  NJO
2.3.4 Enzymes and molecular mass ladders
Restriction endonucleases were obtained from Boehringer Mannheim (Lewes, 
UK) or New England Biolabs (Hitchin, UK). The Expand high fidelity PCR system 
was purchased from Boehringer Mannheim. The following molecular mass ladders 
were used in agarose gel electrophoresis:
1) 50 base pair ladder, Gibco BRL
2) Low DNA Mass Ladder, Gibco BRL
3) DNA Molecular Weight Marker III, Boehringer Mannheim
I
»I
2.3.5 Miscellaneous items
#
DNA was eluted from the agarose plugs using Gen Elute columns purchased 
from Supelco (Bellefonte, USA). In Vitro transcription/translation was carried out
'using the single tube protein system Novagen (Abingdon, UK). Wizard plus mini
■ ■:,i.preps, used to purify plasmid DNA, were obtained from Promeg a Ltd 
(Southampton, UK).
-I
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2.4 Molecular biology methods 
2.4.1 DNA electrophoresis
Agarose gels were routinely used to afford separation of DNA fragments 
(Andrews, 1991). Slab gels were prepared by dissolving agarose in (xO.5) TBE
2.4.2 Growth of bacteria
The growth media used for this work are detailed over. All solutions were 
sterilised before use by autoclaving. Alternatively, heat labile solutions were 
sterilised by passage through a 0 .22 |U.m sterile filter.
;
buffer, pH 8.3 (89mM Tris, 89mM boric acid, 2mM EDTA) to a final concentration 
of 0.7-2.5% (w/v). The set gel was placed in an electrophoresis tank and covered 
with (xO.5) TBE buffer. DNA samples were prepared in loading buffer (40% (w/v) 
sucrose, 0.25% (w/v) bromophenol blue, 50mM EDTA) and loaded into the 
submerged wells in the gel. Electrophoresis was carried out at a constant voltage (2-
5 volts/cm gel).
Following electrophoresis, DNA bands in the agarose gels were visualised with 
an ethidium bromide solution (0.5-l|ig/ml in dH2 0 ) by gentle agitation for Ih at 
room temperature. Background stain was removed by destaining for 2h with dH2 0 . 
DNA was visualised under 320nm UV light and photographed with a Polaroid DS34 
direct screen imaging camera.
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A) LB medium l%(w/v) NaCl, 1% (w/v) tryptone, 0.5% (w/v) yeast extract, 
pH to 7.0 with 5M NaOH
B) LB agar as above except 20g agar per litre LB
C) SOB Medium 2% (w/v) tryptone, 0.5%(w/v) yeast extract, 0.05%(w/v)
NaCl. Following autoclaving, 10ml of IM MgCl2 and 10ml 
of IM MgS0 4  were added. The solution was then filter 
sterilised
D) SOC Medium (prepared fresh) 2ml of 2 0 %(w/v) glucose solution added to
100ml SOB and filter sterilised.
Ampicillin was prepared as a 25mg/ml stock in dH2 0 ; IPTG as a 0.2M stock 
and X-gal freshly prepared at 10% (w/v) in dimethylformamide (DMF). All 
solutions were filter sterilised.
Transformed Escherichia coli (see section 2.4.8) were selected by plating out 
on LB-agar plates containing ampicillin (final concentration 50pg/ml) and overnight 
incubation at 37°C. Colonies were screened for an insert by blue/white 
(untransformed/transformed) identification employing IPTG/X-gal. E. coli bacterial 
cultures were grown at 37°C in LB media supplemented with ampicillin (final 
concentration 25jig/ml) overnight in an orbital shaker at 225rpm. Long term storage 
of cultures was achieved by the addition of glycerol to a final concentration of 15% 
(w/v) to an aliquot of the culture and storage at -80°C.
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2.4.3 Ethanol precipitation of DNA
Sodium acetate, pH 5.5 was added to a final concentration of 0.3M. DNA was 
precipitated from the aqueous solution by the addition of 2.5vol of 100% (v/v) 
ethanol and incubation for 30min at -80°C. Pelleted material was recovered by 
centrifugation at 10 OOOg for 15 min at 4°C. Subsequently, the pellet was washed 
with 70% (v/v) ethanol to remove any salt which may have co-precipitated. Finally, 
after removing the wash supernatant and air drying the pellet, the DNA was 
resuspended in the appropriate volume of dH2 0  or TE buffer (Gannon & Powell, 
1991)
2.4.4 Quantification and storage of DNA
DNA content of relatively concentrated samples was determined by UV light 
absorption at 260nm using a 1ml quartz cuvette. An absorbance unit of 1 
corresponds to an approx. concentration of 50|ig/ml for double stranded DNA 
(Sambrook et al, 1989). To obtain an estimation of purity, the absorbance at 280nm 
was also obtained to allow the construction of a 260/280 ratio for the sample. For 
dilute DNA samples, agarose gel electrophoresis and comparison with a Low DNA 
Mass Ladder, (Gibco BRL) was used.
DNA vectors, recombinants and oligonucleotides were routinely stored at -20°C 
in TE buffer (lOmMTris/HCl, pH 8.0, ImM EDTA). Under these conditions DNA 
remains stable for several years.
2.4.5 PCR amplification of the nucleotide sequence 
encoding SP-22 from bovine brain cDNA
Bovine brain cDNA (Clonetech) served as a template for amplification 
using the Expand PCR System (Boehringer Mannheim). The PCR reaction 
contained: Ing of cDNA, 0.2pM of each primer 1 and primer 2; 200pM dNTPs; 
1.5mM MgCl2; 2.6U of expand high fidelity PCR system enzyme mix. The 
PCR cycling conditions were as follows: 1 x 5min at 95°C; 30 x [55°C for 3min; 
65°C for 3min; 95°C for 30sec]; 1 x 65°C for 2min; 1 x 72°C for 5min. The 
products were analysed on a 2 % (w/v) agarose gel.
2.4.6 Quantification of recovery and size determination 
of amplified DNA fragments.
The major product of two PCR amplification reactions with bovine cDNA 
was excised from an agarose gel using sterile conditions. The DNA was eluted 
from the agarose plug using Gen Elute columns (Supelco) and precipitated 
using sodium acetate/ethanol. For quantitative recovery of DNA, the DNA 
pellets were resuspended overnight in 20pl TE buffer at 4°C. Samples (5|xl) of 
each purification were analysed on a 1.5% (w/v) agarose gel against a mass 
ladder.
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2.4.7 Cloning of PCR fragments into pCR-Script Amp 
SK (+)
Cloning of the purified SP-22 fragment into pCR-Script Amp SK(+) was 
achieved as detailed in the instmction manual (Stratagene). Briefly, the Expand 
generated PCR product was polished in a reaction mixture containing 0.5U of 
pfu polymerase and 2.5mM dNTPs in the appropriate buffer conditions. After 
gentle mixing, 20  pi mineral oil was overlayed and the polishing reaction 
allowed to proceed for 30 min at 72°C.
The polished inserts (l-4pl) were incubated in a reaction mixture containing 
lOng cloning vector, 5U srf I restriction enzyme, 4U T4 DNA ligase, under the 
appropriate buffer conditions, in a final volume of lOpl The reaction was 
mixed and incubated at room temperature for Ih.
2.4.8 Transformation of Epicurian Coli XLl«Blue MRF' 
Kan supercompetent cells
Transformation of the cloned insert was performed as detailed in the 
protocol provided with the pCR-Script Amp SK(+) cloning kit (Stratagene). (3- 
mercaptoethanol (final concentration 25mM) was added to a 40pl aliquot of 
supercompetant cells in a pre-chilled eppendorf tube and incubated on ice for 
lOmin. 2 pl cloning reaction was added, swirled gently to mix, and incubated on 
ice for a further 30min. Following a heat pulse at 42°C for exactly 45sec and a 
further 2min period on ice, 450pl fresh SOC media was added and the reaction 
incubated in an orbital shaker (250rpm) at 37°C for Ih. Aliquots (20-190pl) of
6 2
4pl plasmid DNA (l.l-2.1pg) was digested in each reaction with 12 Units 
of Bam HI (Boehringer Mannheim) in the appropriate buffer (lOmM Tris/HCl, 
pH 8.0, 100 mM NaCl, 5mM MgCl2, ImM 2-mercaptoethanol) at a final 
volume of 20pl for 2h at 37°C. Incubations of control (uncut) plasmid took
place in the same buffers and under the same conditions in the absence of Bam
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each transformation reaction were spread on LB ampicillin agar plates
containing X-gal and IPTG.
2.4.9 Plasmid purification
Plasmids were purified using the Wizard Plus Minipreps DNA purification ;
system (Promega) according to the manufacturer's instructions. Briefly, cells 
from 1.5ml of each overnight culture were pelleted and resuspended in 200ml of 
Cell Resuspension Solution (50mM Tris/HCl, pH 7.5, lOmM EDTA, lOOpg/ml 
RNase A). Cell lysis was propagated by the addition of 200ml of Cell Lysis 
Solution (0.2M NaOH, 1% (w/v) SDS) to each tube and neutralised with 200ml 
of Neutralisation Solution (L32M potassium acetate). After clarification of the 
lysate by centrifugation, it was transferred to a fresh tube containing 1ml of 
Wizard Mini prep resin and mixed. Employing a vacuum, the resin was washed 
with 2 X 1ml 80mM potassium acetate, 8.3mM Tris-HCl, pH 7.4, 40|liM 
EDTA, 55% (v/v) ethanol and centrifuged to remove all traces of the ethanol.
DNA was eluted by the addition of TE Buffer (50jil) and centrifugation.
2.4.10 Bam HI restriction analysis of the pCR-Script 
plasmids, potentially containing the coding region of 
SP-22 I
HI. After 2h, 5pl sample loading buffer (40% (w/v) sucrose, 0.25% (w/v) 
bromophenol blue) was added to each reaction and samples subjected to 
analysis by 0 .8% (w/v) agarose gel electrophoresis.
2.4.11 Restriction analysis, employing a Not 1/Xho 1 
double digest, of plasmids derived from clones 
potentially containing SP-22 sequence
3jil plasmid DNA (0.8-1.5pg) was digested in each reaction with 10 Units 
of Xho 1 and 5 Units of Not 1 (New England Biolabs) in 50mM Tris/HCl, pH 
7.9, lOOmM NaCl, lOiuM MgC^, ImM DTT, supplemented with BSA to a 
final concentration of lOOpg/ml. Digestion was in a final volume of 50fxl at 
37°C for 2h. Subsequently, lOpl electrophoresis sample buffer was added to 
each reaction tube and the samples subjected to analysis on a 2 % (w/v) agarose 
gel.
2.4.12 SDS-PAGE separation and fluorographic 
detection of the [^^S]-methionine labelled products 
derived from in vitro transcription/translation 
reactions
In vitro transcription/translation, using plasmids purified from the clones 
detailed above, was carried out using the Single Tube Protein System 2,T7 
(Novagen) according to manufacturer's instructions. The system is based upon 
transcription with T7 RNA polymerase, followed by translation in an optimised 
rabbit reticulocyte lysate (Perara & Lingappa, 1985). Protein products were
labelled by the inclusion of [^^S]-methionine in the translation reaction.
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Reactions (5|l i 1 each + 20jxl Laemmli sample buffer) were subjected to SDS- 
PAGE on a 10% (w/v) polyacrylamide gel. The gel was fixed in 25% (v/v) 
isopropanol: 65% (v/v) distilled water: 10% (v/v) acetic acid for 30 min and 
rinsed with distilled water. The gel was immersed and agitated slowly for 30 
min in Amplify (Amersham) to aid fluorographic detection before being dried 
under vacuum. Products were detected on Hyperfilm ECL (Amersham).
Unless otherwise indicated, data presented in this thesis is representative of a 
number of experiments.Where statistical analysis is performed, this value is 
representeted by n.
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Chapter 3
Purification and reconstitution studies on the components of mammalian PDC
6 6
3.1 Introduction
Purification of intact PDC to a high degree of purity from bovine heart and 
kidney was first described by Linn et al. (1972). In eukaryotes, the non- 
covalent nature of inter-component interactions within PDC precludes the use of 
some conventional protein purification techniques such as anion/cation exchange 
chromatography. Thus, over the years, purification regimes under non­
dissociating conditions have developed and evolved in a number of key papers 
(Linn et al, 1972; Stanley & Perham, 1980; De Marcucci & Lindsay 1985; 
Sanderson et al, 1996a). More recent protocols, based upon Stanley & Perham 
(1980), detail the purification of PDC and also OGDC from mammalian tissues. 
These have the added advantage that they do not require prior isolation of 
mitochondria and rely on membrane solubilisation in a suitable non-ionic 
detergent, usually Triton X-100. Subsequent protein fractionation, in the 
presence of detergent, is achieved by a series of polyethylene glycol 
precipitations. It is thus possible, using Triton X-100 as a solubilising agent and 
PEG fractionation to purify intact forms of PDC and OGDC to near 
homogeneity and in high yields.
Introduced as a protein fractionation agent over three decades ago (Poison 
et al, 1964), PEG precipitates proteins in a non denaturing fashion as a result 
of differing solubilities of individual proteins at specific PEG concentrations. 
For example, in the most recent methodologies developed for PDC purification 
(Stanley & Perham, 1980; Sanderson et al, 1996a), the final precipitation step 
in the purification, separation from OGDC, employs 0.06 vol of 30%(w/v)
PEG 6000 solution to precipitate all the OGDC in the sample; leaving pure PDC 
in the supernatant. Precipitation can be described qualitatively by a steric 
exclusion mechanism whereby proteins concentrate and eventually precipitate in
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the extra polymer space. Precipitation is dependent on factors such as protein 
size and concentration (for a full discussion, see Ingham, 1990).
In contrast to the associative conditions used to purify the intact 2-oxo acid 
dehydrogenase complexes, isolation of the individual enzymes requires that 
dissociative conditions be employed. This is performed routinely after the intact 
multienzyme complex has been isolated. In the case of mammalian PDC the 
protein X component is very tightly associated with the E2 core. It is not 
possible to remove it under conditions in which the proteins remain in a native 
state. In studies of mammalian PDC, the method of Linn et al, (1972) has 
continued to be used to dissociate PDC into its E2/X and E1/E3 fractions. This 
method utilises alkaline (pH 9.0) conditions and high salt (IM NaCl) to 
dissociate the PDC into its E2/X and E1/E3 fractions for subsequent separation 
on a Sepharose 4B column. Examination of the papers using this approach 
(Behai et a l, 1994; De Marcucci et al, 1995 and Kuroda et al, 1996) highlight 
some of the problems associated with the method. One major drawback is that 
the E2/X core produced is heavily contaminated with undissociated E la  and P 
subunits. Further examination of E2/X core samples resolved by SDS PAGE in 
De Marcucci et a l (1995) displays the presence of a 55 000 Mr protein, 
corresponding to the E3 subunit.
One further significant consideration is that PDC dissociated in this
fashion, over a prolonged time interval and at alkaline pH, is able to support
only minimal levels of reconstitution (15-20%) (Sanderson e ta l, 1996b). In
light of these facts one can conclude that dissociation of PDC based on the
method of Linn et a l (1972), while suitable for some proteolytic and
immunological studies, is not ideal for analysis of component folding, assembly
and reconstitution of complex enzymatic activities. Clearly, a separation
protocol which maintains the overall structural integrity and provides for a
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higher level of recovery of individual components of mammalian PDC in their 
active forms is desirable.
In this chapter, I detail the development of an improved method for PDC 
dissociation into an E2/X core and an E1/E3 fraction. The fractions were able to 
support high levels of PDC reconstitution (60-80%) upon the re-introduction of 
stoichiometric quantities of E1/E3 to the E2/X core. The improved purity of the 
E2/X subcomplex permitted the application of electrospray mass spectrometery 
(ES/MS) to determine the subunit Mr of the individual transacetylase (E2) and 
protein X components. It also facilitated the detailed study of the folding, 
assembly and reconstitution of the E2/X core presented in this thesis (see 
chapter 4 ). A novel protocol to facilitate the purification of milligram quantities 
of E l and E3 was also developed. This provided a valuable source of
mammalian E3 for later reconstitution studies (chapter 4) and should permit 
future folding and assembly studies on these individual enzymes.
t
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3.2 Results
3.2.1 Preparative dissociation of mammalian PDC
In order to study the folding and assembly of the component enzymes of 
mammalian PDC a suitable dissociation protocol is required. To this end two 
alternative protocols were investigated. Previously, our laboratory had 
developed a dissociation method for mammalian PDC, employing NaCl 
treatment at a neutral pH, which facilitated high levels of overall complex 
activity upon reconstitution of the E2/X core with E1/E3 (Sanderson et al, 
1996b). However, a number of drawbacks remained evident: low levels of PDC 
activity was still associated with both E2/X and E1/E3 fractions and thus had to 
be taken into consideration when calculating levels of PDC reconstitution; SDS- 
PAGE analysis displayed small but significant levels of E l a  and P still 
associated with the purified E2/X core. One approach to method development 
was to try to improve this protocol. Another possibility was to scale-up 
successfully the analytical dissociation of PDC employed by (West et al,
1995). This used intermediate levels of GdnHCl to dissociate PDC, leaving no 
E l components associated with the E2/X core. Preliminary studies focused on 
the effects of these two salts, NaCl and GdnHCl, on purified PDC. In addition, 
as purified bovine OGDC was also readily available, these studies were also 
extended to this member of the 2 -oxo acid dehydrogenase complex family.
Figure 3.1a illustrates the effect of NaCl and GdnHCl on the overall 
complex activities of mammalian PDC and OGDC. As the concentration of both 
salts increase they exert an inhibitory effect on the activities of both multienzyme 
complexes. GdnHCl concentrations above 300mM cause complete inhibition of
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Figure 3.1a Effect of NaCl/GdnHCI on the overall 
activities of mammalian PDC and OGDC
PDC and OGDC were incubated at 0.5mg/ml in 50mM MOPS/KOH, pH 7.4 
containing the stated concentration of NaCl/GdnHCl for 15min at 20°C. 
Aliquots were removed and activity assays were performed (see Materials and 
Methods section 2.2.12) in the presence of the stated concentration of salt. All 
activities are expressed relative to control samples incubated in the absence of 
NaCl/GdnHCl. PDC NaCl (O); PDC GdnHCl (#  ); OGDC NaCl ( a ) ;  OGDC 
GdnHCl ( « ).
enzyme activity in both multienzyme complexes. NaCl present at concentrations 
>500mM exert the same effect. These inhibitory levels of GdnHCl and NaCl 
represent levels which have shown to have no effect on the gross conformation 
of the components enzymes of PDC, as measured by circular dichroism (CD) 
and tryptophan fluorescence (West et al, 1995). It was also observed that levels 
of GdnHCl below 50mM had a negligible effect on the enzyme activities 
investigated. This apparent maintenance of conformational integrity, but loss of 
associated PDC/OGDC activity has been attributed to the highly flexible nature 
of enzyme active sites, relative to the rest of the protein molecule, and their 
particular susceptibility to perturbation (Tsou, 1986).
While ion effects on protein activity/solubility are generally non-specific at 
levels lower than 0.15M, at higher concentrations ion specificity does exist 
(Franks, 1989). Figure 3.1b illustrates this ion specificity and compares the 
capacity of PDC and OGDC to reassociate spontaneously, following 
pretreatment with either the chaotrope GdnHCl or the neutral salt NaCl. In these 
experiments the levels of both salts were reduced to below 50mM, by dilution 
prior to assay, as the effects of the two salts on enzymatic activity appear 
minimal below this concentration (see Figure 3.1a). It is clear that the effects of 
NaCl treatment on PDC and OGDC activity remain reversible over the range of 
concentrations investigated (Figure 3.1b). This includes levels of NaCl (>2.0M) 
in excess of those which are known to promote dissociation of E1/E3 of PDC 
and E3 of OGDC from their respective cores. Treatment of intact PDC or 
OGDC with low levels of GdnHCl still allows recovery of maximal activity. In 
contrast, following pre-exposure to higher levels of this chaotropic salt (>0.5M) 
it was not possible to recover all the respective complex activity by diluting out 
the chaotrope.
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Figure 3.1b Reactivation/renaturation profiles of PDC 
and OGDC activity following pre-treatment with 
NaCl/GdnHCl
S
$
J,
'I:
î
ï
S
3
PDC and OGDC were incubated in NaCl/GdnHCl at the concentration stated for 
15min at 20°C. Reactivation /renaturation was initiated by a rapid dilution into the 
appropriate assay buffer. The final protein concentration in the renaturation 
mixture was 10-30p.g/ml and residual GdnHCl reduced to below 30mM. After a 
15 min period at 20°C, activity assays were performed for PDC activity: following 
NaCl pre-treatment ( a  ); following GdnPICl pre-treatment ( » ) and OGDC 
activity following NaCl pre-treatment ( o ); following GdnHCl pre-treatment (@). 
All activities are expressed relative to control samples of enzyme incubated in the 
absence of NaCl/GdnHCl.
Data for mammalian PDC agree with that in a previous study (West et al, 
1995) which showed that treatment of PDC with levels of GdnHCl in excess of 
0.4-0.5M caused gross conformational changes, as judged by CD and 
fluorescence measurements. The authors were also unable to regain all PDC 
activity, by simple dilution, once this threshold level had been exceeded. 
Dénaturant sensitivity of the native complex was found to be superimposable on 
that of the E l component enzyme, suggestive that loss of overall PDC activity 
reflects irreversible conformational changes in its most sensitive component.
The effects of individual ions are in accordance with the Hofmeister (lyotrophic) 
series for reasons that still remain unclear but, in proteins, may relate to the 
hydration of hydrophobic residues (Franks, 1989).
Following preliminary investigations of the effect of GdnHCl on PDC 
activity, a scaled-up version of the dissociation protocol detailed in West et a l 
(1995) was performed. Accordingly, the protocol was scaled up from a 25ml 
Superose 12 column (separation range 1x10^-5x10^) to a 100ml prep grade 
Superose 6 column (separation range 5x10^-5x10^). The pre-incubation time 
(15 min at room temperature in the desired concentration of GdnHCl) and flow 
rate were kept constant with a view to maintaining the chromatographic 
characteristics of the successful small scale separation. However, is was not 
possible to produce E2/X core which showed any real decrease in the levels of 
associated E la  and p when compared to untreated PDC (results not shown). 
Furthermore, dissociation at higher levels of GdnHCl (0.6M), where the 
chaotrope is beginning to cause irreversible conformational changes (Figure 
3.1b), did not improve resolution (results not shown).
Another possible solution to the problem of PDC dissociation lay in the
refinement of the salt dissociation treatment already employed in the laboratory
(Sanderson et al, 1996b). Initial analysis suggested one immediate refinement:
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conditions (Kiesyl et al, 1980), However, the more pronounced decline in 
reconstitution of complex activity was observed in the imidazole/HCl buffered
a reduction in the amount of protein being loaded onto the column. Although for 
GPC (gel permeation chromatography) partition of the protein between the 
mobile and stationary phase is not concentration dependent, high protein 
concentrations (> 20mg/ml) can lead to problems associated with their viscosity. 
Specifically, previous loadings of PDC in excess of 20mg/ml may have resulted 
in sub-optimal resolution as a result of diffuse leading boundaries in the viscous 
samples during chromatography (Preneta, 1994). To alleviate this, the maximal 
loading was decreased to 15mg/ml in a 2ml loading volume.
Another improvement came from a study of the ability of PDC and OGDC 
to reconstitute whole complex activity after prolonged treatment in 2M NaCl in 
different buffer systems (Figure 3.2). The impetus for this work came from 
studies on pyruvate decarboxylase from Zymonas mobilis which had 
highlighted different reactivation profiles for the enzyme following urea pre­
treatment in different buffer systems (Pohl et al, 1994). The enzyme was 
shown to be less stable in the citrate buffer system traditionally used than in 
others buffers studied. In this context, a series of buffers, with optimal capacity 
in the pH 7.0-8.0 range, were studied for their ability to promote maximal 
recovery of PDC and OGDC activity, following pre-treatment with 2M NaCl.
Of the buffers examined, only imidazole/HCl buffered solutions showed a 
marked difference from the Tris/HCl buffered system traditionally used (Figure 
3.2). While mammalian OGDC fails to discriminate between the two buffer 
systems, PDC in the Tris/HCl system reconstitutes activity poorly following 2M INaCl treatment, even at neutral pH, when compared to PDC treated in a similar
'fashion in the imidazole/HCl buffer system. The decline in both PDC and 
OGDC activities was obvious in both buffer systems at more alkaline pH. This 
is related to the documented sensitivity of the E la  component to alkaline
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Figure 3.2 Buffer and pH dependence of PDC/OGDC 
reactivation following treatment with 2M NaCl
PDC and OGDC (2mg/ml) were incubated in the appropriate buffer (50mM) at 
the pH indicated, in the presence of 2M NaCl, for 15min at 20°C. Aliquots 
(5p.l) were removed and added to the appropriate assay buffer (670pl Buffer 
A+14pl Buffer B) and allowed to reactivate for 15min at 20°C. Assays were 
initiated by the addition of the appropriate substrate (pyruvate for PDC, 2- 
oxoglutarate for OGDC). All activities are expressed relative to control samples 
of complex incubated in the appropriate buffer and pH in the absence of NaCl. 
PDC, Tris/HCl buffer (O ); PDC, imidazole/HCl buffer (#  ); OGDC, Tris/HCl 
buffer (n ) ;  OGDC, imidazole/HCl buffer (m).
system at pH values close to 8.0 may be attributable to the loss of buffering 
capacity of the system at this pH (the pKa for imidazole =6.95).
The decrease in total PDC loading to 15mg/ml, coupled with the 2M NaCl
■treatment in the imidazole/HCl buffer system, was integrated into the preparative 
dissociation of PDC by gel permeation chromatography (for more details see 
Materials and Methods section 2.2.9). Using these modifications, it was 
possible to achieve baseline dissociation of PDC into its E2/X and E1/E3 
fractions on a preparative scale. Figure 3.3a represents the absorbance at 280nm 
exhibited by the fractions eluted from the column.The first protein peak to elute 
from the Superose 6 column, at or near the void volume, corresponds to the 
E2/X core (Ve=32ml).The second peak corresponds to the E1/E3 fraction of
PDC (Ve==60ml). Subsequent SDS-PAGE analysis of the pooled fractions from 
the preparative dissociation serves to confirm the identity of the peaks (Figure
i
3.3b). Lane 3 corresponds to the first eluted peak and confirms this to be the 
E2/X core. Significantly, there was no apparent contamination of the E2 core 
with E3. The E l a  and p subunits, which stain more heavily with Coomassie 
blue than the other PDC components (compare Lanes 1 and 4), show a marked 
reduction in their association with the E2/X core when compared to untreated 
PDC (lane 1). Enzymatic analysis of the pooled, dialysed fractions confirmed 
this depletion with less than 5% of the E l activity still associated with the E2/X 
sub-complex. Examination of the E1/E3 fraction (lane 4) corresponding to the 
second peak eluted from the Superose 6 column confirmed the lack of E2/X 
core contamination. The presence of a small protein (<30 000 Mr),which co­
elutes with the E1/E3 fraction, is discussed later (see Chapter 6). This E1/E3 
fraction contained all the recovered E3 activity and 95% of the E l activity 
(results not shown). Another noticeable improvement was that neither the E2/X 
core or the E1/E3 fraction alone exibited any overall PDC activity, in contrast to 
previous studies (De Marcucci et a l, 1995; Sanderson et al, 1996b)
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Figure 3.3a Absorbance profile of the preparative 
dissociation of PDC into active E2/X and E1/E3 
fractions
Preparative dissociation of PDC into active E2/X and E1/E3 fractions was 
performed on an FPLC system (Pharmacia) using a prep grade Superose 6 
column (100ml) equilibrated with 50mM imidazole/HCl, pH 7.0, IM NaCl, 
0.01%(v/v)Triton X-100. PDC (14.0mg/ml) in lOOmM MOPS/NaOH, pH 6.8, 
5mM EDTA, l%(v/v) Triton X-100 was microfuged at 13000 rpm for 15min 
before incubation at a 1:1 ratio with 50mM imidazole, pH 7.0, 4M NaCl on ice 
for 1 h. A 2ml pre-injection of the 4M NaCl buffer was then performed prior to 
PDC sample loading (2ml) and subsequent elution at a flow rate of Iml/min. 
Fractions were pooled on the basis of A28O and dialysed extensively, at 4°C, 
against multiple changes of the appropriate buffer before subsequent 
concentration, as required, using dry PEG.
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Figure 3.3b Preparative dissociation of PDC into active 
E2/X and E1/E3 fractions: SDS-PAGE analysis of 
pooled fractions
Samples were analysed for purity by SDS-PAGE (10%, w/v gel) and stained 
with Coomassie blue. Lane 1, lOpg low-Mr marker proteins; lane 2, intact PDC 
(20p,g); lane 3, E2/X core (15pg); lane 4, E1/E3 fraction (15|Xg)
»
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As shown in the previous section, the modified protocol for dissociating 
PDC on a preparative scale was successful in producing E2/X and E1/E3 
fractions free from significant cross contamination; with both fractions 
recovered in high yield. A second important criterion upon which the usefulness
3.2.2 Reconstitution and stability of the E2/X and E1/E3 
fractions of mammalian PDC
Î
of the separation was to be judged was that the E2/X and E1/E3 fractions 
produced were able to re-associate and reconstitute overall PDC activity to high 
levels, relative to undissociated PDC. To test this, increasing quantities of 
E1/E3 were titrated into a reaction assay mixture containing a set amount of 
E2/X. After allowing the components time to re-associate, PDC activity was 
assayed. The results presented in Figure 3.4a show that it was possible to 
reconstitute high levels of PDC activity from the dissociated fractions. It is also 
clear that the two fractions can be combined to reconstitute high levels of PDC 
activity (typically 60-80%), relative to untreated, native PDC. Significantly, the 
E2/X:E1/E3 ratio at which one attains maximal levels of reconstitution (1:1.4 )
is in agreement with the known native stoichiometry of mammalian PDC (i.e. a 
60meric E2 core containing 12 molecules of protein X with 30 Ela2p2 >■
tetramers and 6-12 E3 dimers ).
The measurements of PDC activity performed in Figure 3.4a were carried 
out after a 15 min incubation period. This was as a result of the previous 
observation that time periods less than this resulted in lower levels of PDC
reconstitution (S.J. Sanderson, PhD thesis). However, it was unclear if such a
lag phase was as a result of the time taken for the E1/E3 component to
reassemble onto the E2/X lattice or represented some reactivation/cofactor
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Figure 3.4a Reconstitution of PDC activity from the 
E2/X subcomplex and E1/E3 fraction: levels of 
reconstitution and component stoichiometry
Following the dissociation of PDC, the E2/X and E1/E3 fractions were dialysed 
into 50mM MOPS/KOH, pH 7.4, ImM EDTA, 50% (v/v) glycerol and stored 
at 4°C. E2/X and E1/E3 fractions were activated by a 1:1 dilution in 50iuM 
potassium phosphate buffer, pH 7.6, 3mM NAD+, 2.7 mM cysteine-HCl,
2mM MgCh, 0.2 mM ThDP, 0.02mM CoASH (buffer AB) and incubated for 
15min at 20°C. To initiate reconstitution, increasing quantities of E1/E3 (0- 
20p,g) were added to cuvettes containing E2/X (5pg) and the appropriate assay 
solutions. The production of NADH was subsequently initiated by the addition 
of 14pl lOOmM pyruvate (Solution C). Activity was monitored at 340nm and 
activities are expressed relative to the specific activity of undissociated 
PDC.(n=3)
binding requirement. Specifically, it was possible that the purification and 
dissociation protocol led to a degree of oxidation of the thiol containing 
components of PDC; lowering the measured activity upon reconstitution. To 
discriminate between the two possibilities a 15min incubation in buffer AB 
containing the reducing agent cysteine-HCl was incorporated into the 
reconstitution protocol (see Figure legend). The levels of reconstitution of PDC 
activity observed were compared to those obtained in the absence of such a pre­
treatment (Figure 3.4b). It is evident from the data that, following incubation in 
buffer AB, reconstitution can occur instantaneously to maximal levels. In 
comparison, untreated E2/X and E1/E3 fractions exhibit a 15-20 min lag period 
before they are fully active. This would suggest that component assembly is not 
the reason for the lag phase observed when the two fractions have not been pre­
conditioned in buffer AB. Instead, the presence of cysteine in buffer B would 
appear to be the active component, reversing adventitious oxidation which may 
have occurred to one or more of the components of PDC during the 
dissociation.
Following the gel permeation chromatography (GPC) dissociation of PDC, 
the E2/X and E1/E3 fractions were dialysed immediately into their storage 
buffer (50mM MOPS/KOH, pH 7.0, 50%(v/v) glycerol) before any 
reconstitution analysis was performed. A recent study employing sedimentation 
velocity analysis of the E2/X core of PDC (Behai et al., 1994) employed a 
different storage buffer (O.IM glycine, pH 9.5, IM NaCl) which was claimed 
to maintain the components of E2/X in an active form for up to 1 month at 4°C. 
To test this, the two buffer systems were compared in the stability study detailed 
in Figure 3.4c which measured the ability of the E2/X, dialysed into the 
appropriate buffer system, to reconstitute overall complex activity upon the 
addition of a stoichiometric quantity of E1/E3. In this study the E1/E3 fraction 
was always stored in the MOPS/glycerol buffer system, owing to the
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Figure 3.4b Time dependence of reconstitution of PDC 
activity from the E2/X subcomplex and E1/E3 fraction
Equal volumes of E2/X and E1/E3 were diluted 1:1 in assay solutions A (O ) or 
A plus B (d  ) to 0. l-0.2mg/ml and were pre-incubated together at 30°C in a 
cuvette containing solutions A and B without substrate for the times indicated. 
The assay was initiated by the addition of pyruvate and the production of 
NADH monitored at 340nm. Reconstitution of PDC activity is expressed 
relative to undissociated PDC. (n=3)
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Figure 3.4c Reconstitution of PDC activity from the 
E2/X subcomplex and E1/E3 fraction: Comparison of 
E2/X core stability in different storage buffers
Maximal levels of PDC activity was reconstituted with E2/X core stored in 
50mM MOPS/KOH, pH 7.4, ImM EDTA, 50% (v/v) glycerol at 4°C (0  ) and 
E2/X core stored in 0.1M glycine, pH 9.5, 1M NaCl at 4°C ( O ) at the time 
points indicated. Activity was expressed as a percentage of the activity obtained 
following dissociation and dialysis (identical for the two samples).The E1/E3 
used for reconstitution was stored in 50mM MOPS/KOH, pH 7.4, ImM 
EDTA, 50% (v/v) glycerol at 4°C. (n=l)
documented loss of E l activity upon prolonged exposure to alkaline conditions. 
To our surprise, both buffers appeared to be equivalent in terms of their 
component stability over the time period studied. Thus, there was no apparent 
difference in in the ability of the two E2/X cores to reconstitute PDC activity. 
However, the decision was taken to continue to utilise the glycerol storage 
buffer as this has the added advantage of concentrating the two fractions during 
the course of the dialysis. This higher concentration of both E2/X and E1/E3 
fractions permits their study in denaturation/renaturation studies detailed later 
(see chapter 4) which depend upon dilution of dénaturant to below a threshold 
level (< 30mM for GdnHCl) prior to assay. These studies, incorporate an initial 
incubation in chaotrope which must take place at a high enough protein 
concentration so that, following dilution to below the required threshold level of 
chaotrope, sufficient levels of enzyme are present to permit assay.
3.2.3 Determination of the subunit Mr of E2 and protein 
X of PDC by electrospray mass spectrometery (ES/MS)
The development of the protocol detailed in section 3.2.1. which produced 
pure, active E2/X core also facilitated the exact molecular mass determination of 
both the transacetylase (E2) and protein X components of bovine PDC by 
electrospray mass spectrometry (ES/MS). (for a review of the application of 
ES/MS to protein characterisation, see Mann & Wilm, 1995). Previously, this 
had not been possible, as intact PDC is too complex a polypeptide system (nine 
individual polypeptides plus multiple phosphorylated forms of E la )  to study by 
ES/MS directly. By using high salt dissociation to produce the E2/X core the 
complexity of the polypeptide mixture is reduced sufficiently to allow accurate 
molecular mass determination (for methodology see figure legends).
Figure 3.5a Electrospray mass spectrum of the E2/X 
core of bovine PDC: MaxEnt deconvolution of ES/MS of 
dihydrolipoamide acetyltransferase (E2)
Mass spectrometry was performed on a VG Platform quadruple mass 
spectrometer (for full details see Materials and Methods section 2.2.7). E2/X 
core was dissolved in solvent at a concentration of 20pmol/|ll, centrifuged at 
5000g for 2 min to remove any particulate material, before being injected into 
the carrier stream. The m/z range 700-1500, containing >95% of the signal 
intensity if the protein sample, was scanned at least 10 times using a sweep time 
of 5s. Instrument calibration was carried out, just prior to sample application 
using horse heart myoglobin. Maximum entropy (MaxEnt) deconvolution 
procedure was used for quantitative analysis of raw data using l-1.5Da peak 
width and 1 Da/channel resolution. Routinely, the programme was stopped after 
8-10 iterations
i :
8
Figure 3.5b Eiectrospray mass spectrum of the E2/X 
core of bovine PDC: MaxEnt deconvolution of ES/MS of 
protein X
Mass spectrometry was performed on a VG Platform quadruple mass 
spectrometer (for full details see materials and methods section 2.2.7). E2/X 
core was dissolved in solvent at a concentration of 20pmol/|il, centrifuged at 
5000g for 2 min to remove any particulate material, before being injected into 
the carrier stream. The m/z range 700-1500, containing >95% of the signal 
intensity if the protein sample, was scanned at least 10 times using a sweep time 
of 5s. Instrument calibration was carried out, just prior to sample application 
using horse heart myoglobin. Maximum entropy (MaxEnt) deconvolution 
procedure was used for quantitative analysis of raw data using 1-1.5Da peak 
width and 1 Da/channel resolution. Routinely, the programme was stopped after 
8-10 iterations
.I
I
I
I
It was possible to obtain subunit Mr values for both the E2 and protein X 
components of bovine PDC (table 3.1). The presence of contaminating levels of 
the detergent,Triton X-100, prohibited the detennination of the moleculai­
masses of the E l and E3 from bovine PDC. Triton X-100 is used throughout 
the purification of PDC. It is required for cell membrane solubilisation and is 
present in the final resuspension buffer used to maintain the solubility of PDC. 
In the E1/E3 sample, dialysis and multiple rounds of ultrafiltration of the sample 
into HPLC grade water proved insufficient to remove the detergent, due to the 
large detergent micelle size. The levels of detergent remained above a level 
which, in effect, served to obscure any signal from the E l and E3 components 
obtained by ES/MS.
Table 3.1 Molecular mass of bovine E2 and protein X by 
ES/M S
Component
Dihydrolipoamide
acetyltransferase
(E2)
Protein X
Molecular mass
59963
47982
On-line searching of the Genbank data base of DNA sequences and 
Swissprot protein database revealed no apparent clones of either the E2 or 
protein X component of bovine PDC (see Table 3.2). However transacetylase 
components from other sources, including human E2 (Thekkumkara et al, 
1988) were available. In addition, the Mr of the protein X gene cloned from S.
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cerevisiae was available (Behai et al, 1989). The molecular masses determined 
by ES/MS for E2 and protein X were in close agreement with the published 
masses of the equivalent enzymes found in other organisms (Table 3.2). The 
molecular mass of bovine protein X is similar to that of its yeast homologue 
(47982 and 42052, respectively). Both gene products are known to posses one 
lipoyl domain. The molecular mass of the bovine transacetylase component 
(59963) agrees with the figure published for other higher eukaryote E2s, 
notably human E2 (59555), which also contain two lipoyl domains.
3.2.4 Purification of the E l and E3 components of 
mammalian PDC
In order to study the folding and assembly of the individual E l and E3 
enzymes and produce pure E3 for further reconstitution studies (see chapter 5) it 
was necessary to continue purification of the dissociated E1/E3 fraction. 
Attempts to follow purification protocols employed in the laboratoiy/ (Ruth 
Fullerton PhD thesis), while successful in purifying E3, were unable to recover 
any significant levels of E l. This failure was suspected to result from non­
specific aggregation of E l prior to, or during, chromatography (results not 
shown). As a preventative step, a triethanoIamine/HCl buffer system 
supplemented with the detergent CHAPS was developed. This zwitterionic 
detergent (head groups containing both positive and negative charges) increases 
protein solubility and does not interfere with the separation characteristics of ion 
exchange chromatography. For full details of the methodology used to isolate 
pure El and E3 refer to the Materials and Methods section 2.2.10.
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The chromatographic separation obtained using this buffer system was 
successful in separating the E3 component from the El component (see Figures 
3.6a and 3.6b). It was also possible to recover substantial quantities of both 
enzymes following chromatography (see Table 3.3). All the E l activity 
recovered eluted from the Mono Q column much later in the gradient than E3, 
suggestive of a higher affinity to the positively charged matrix under the 
conditions employed. E l activity eluted as a single peak of activity spread over 
12ml. No E3 activity was associated with the peak (Figure 3.6a) and no E3 
protein was detectable in the pool by SDS-PAGE (Figure 3.6b, lane 2). In 
contrast, E3 activity did not elute as a single peak of activity. Instead two peaks 
of activity, not fully resolved to a baseline level, were eluted (Figure 3.6a). 
However, there was no evidence of contamination by E l. Instead, SDS-PAGE 
analysis showed the presence of a small polypeptide, with a molecular mass of 
less than 30000, associated with E3 in the second peak of activity (Figure 
3.6b). Subsequent N-terminal sequence analysis of this small protein (Materials 
and Methods section 2.2.6) identified it as SP-22, a mitochondrial protein with 
putative antioxidant properties (for a full discussion of this see chapter 6). This 
protein, barely visible in the load (lane 3), appears to concentrate in the second 
E3 peak (lane 5). This may provide preliminary evidence that the role of this 
antioxidant protein may be more specific than had been envisaged (Watabe et 
al, 1994). Rather, it may have a role in preventing the adventitious oxidation of 
the components of mammalian PDC, notably E3.
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Figure 3.6a Separation of E l and E3 of PDC by anion 
exchange chromatography
The E1/E3 fraction, prepared by high salt dissociation of PDC as detailed in the 
section 3.2.1, underwent buffer exchange into 20mM triethanol amine (TEA), pH 
7.4, lOmM NaCl, ImM CHAPS (buffer A) by extensive dialysis. Typically, 4mg 
protein was loaded onto an 8mi Mono Q column (Pharmacia) pre-equilibrated with 
buffer A. The column was washed with 2 column vol of buffer A, before being 
developed with using a linear gradient of 20mM triethanolamine (TEA), pH 7.4, 
500mM NaCl, ImM CHAPS (buffer B) over 200ml. In addition to monitoring the 
eluent continuously at 280 nm ( D ), individual fractions were assayed for E l (A ) 
andE3 (O ) activity.
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Figure 3.6b SDS-PAGE analysis of pools obtained from 
anion exchange chromatography on the E1/E3 fraction of 
mammalian PDC
Samples were analysed for purity by SDS-PAGE (10%, w/v gel) and stained 
with Coomassie blue. Lane 1, lOpg low-Mr marker proteins; lane 2, El fraction 
(lOpg); lane 3, E1/E3 column load (15pg); lane 4, pure E3 fraction (lOpg); 
lane 5, E3 fraction + < 3 0  000 Mr protein ( 1 Opg).
Table 3.3 Purification table for E1/E3 on Mono Q anion exchange 
chromatography
A) E3 Purification
Volume (ml)
Protein (mg/ml)
Total protein (mg)
E3 Activity (U/ml) 
Total E3 activity (U) 
% E3 recovery 
Specific Activity 
(U/mg)
Purification Factor
B) E l Purification
Volume (ml)
Protein (mg/ml) 
Total protein (mg) 
El Activity (U/ml) 
Total E l activity (U) 
% E l recovery 
Specific Activity 
(U/mg)
Purification Factor
Load fraction
4
0.50
2.00
18.81
94.05
100
46.83
Load Fraction
4 
0.50 
2.00 
2.51 
10.04
100
5
E3 (peakl)pool
18
0.02
0.37
3.44
62.08
66
174.33
3.75
E l pool*
5
0.23
1.02
1.16
5.8
57.7
5.68
1.136
II
I
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* Assays on the pooled E l fractions were carried out after dialysis and 
concentration into storage buffer (50inM MOPS/KOH, pH 7.4, 50% (v/v) 
glycerol).
3.3 Discussion
The overall complex activities of OGDC and PDC were shown to be 
susceptible to inhibition by low levels of NaCl and GdnHCl. Effects of 
individual ions observed are in accordance with the Hofmeister (lyotrophic ) 
series for reasons that still remain elusive but which may relate to to the 
hydration state of the individual proteins. At low concentrations, the effects 
mediated by GdnHCl apparently cause no gross conformational alterations in 
PDC (West et al, 1995). However, it is easy to envisage that, at low 
concentrations, perturbations in the spatial geometry of key active site residues 
would be sufficient to eliminate catalytic activity. Stop flow spectroscopic 
studies of creatine kinase (Yao et a l, 1984) removes the possibility that this 
effect is similar to reversible inhibition; as the rates of inactivation observed in 
this study are several orders of magnitude lower than that which would be 
expected for a reversible inhibitor,
Common dénaturants, such as GdnHCl, are thought to exert their effects
via general solvent modification. Treatment of mammalian PDC and OGDC
complexes with higher levels of GdnHCl (>0.6M) lead to loss of activity which
could not be recovered by diluting out the dénaturant. Previous data (West et
al, 1995) shows this corresponds to GdnHCl concentrations which elicit large-
scale alterations in protein structure, as judged by CD and tryptophan
fluorescence measurements. Thus, by altering the solvation around the protein,82
and in turn altering its stability; one eliminates the small AGgtab (around 
50kJ/mol for most proteins) associated with the native state, leading to 
component dénaturation (Jaenicke, 1995).
Separation of biomolecules using gel permeation chromatography (GPC) 
depends on moleculai* shape as well as size with the best resolution usually 
obtained employing long columns and slow flow rates. A successful high salt 
dissociation of PDC into its E2/X fraction and E1/E3 fractions was achieved by
(i) lowering the protein concentration loaded onto the Superose 6 column and
(ii) altering the dissociation and column running buffers. The E2/X core 
produced contained no trace of the E3 component and minimal levels of E l. No 
PDC activity was detected in either fraction. In contrast, we were unable to 
scale-up the GdnHCl dissociation protocol used on an analytical scale in West et 
a l (1995). Possible explanations for this could arise from subtle differences in 
the chromatographic matrices used (Superose 6 (prep grade) for the scale-up 
and Superose 12 in the original work). These resins differ not only in their 
fractionation range, but also more subtly, in terms of their bead and pore size. 
These differences may have affected separation. Equally, failure of the scale-up 
may reflect increased band diffusion problems which can be associated with the 
larger, self packed Superose 6 column, compared to the smaller pre-packed 
Superose 12 matrix.
Reconstitution studies with the E2/X and E1/E3 fractions achieved the
return of high levels of PDC activity (typically 60-80%). Maximal levels of
activity were found to be returned by E2/X:E1/E3 ratios at or near to the native
stoichiometry of the complex. Previous studies (Rahmatullah et al, 1989;
Powers-Green wood et al, 1989) failed to report the levels of reconstitution
obtained, relative to native PDC. This can make the data presented difficult to
interpret. For example, it would give cause for concern if conclusions were
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drawn from data resulting from only modest levels of PDC reconstitution (10- 
20%), which, in turn, could be suggestive of critical levels of protein 
dénaturation. Initial reconstitution studies exhibited a 10-15min reactivation 
period before maximal levels of reconstitution were obtained. The abolition of 
this lag period was achieved by pre-incubating both fractions in a cysteine 
containing buffer. This would suggest that adventitious oxidation of the thiol 
groups on the components of PDC was responsible for the lag period observed 
before maximal activity was reconstituted in the absence of reducing agent. 
These data are also indicative of instantaneous assembly of the El and E3 
components onto the E2/X structural lattice upon addition. Interestingly, an 
activation lag period was observed in recent work looking at the regulation of E. 
coli PDC activity by its cofactor ThDP (Natalia et al, 1996).The lag period 
observed was thought to result from the slow binding of a second ThDP 
molecule to the E l dimer. However the concentration of the co-factor needed to 
observe this were at least an order of magnitude lower that employed in our 
reconstitution assay system and thus represents an unlikely explanation for our 
data.
The purity of the E2/X core produced, as a result of the refined high salt 
dissociation, facilitated the determination, for the first time, of the subunit 
molecular masses of the E2 and protein X components. The masses determined 
were similar to that of their homologues found in other eukaryotic species. It is 
also of note that the apparent molecular mass that bovine E2 (72 000) and 
protein X (51 000) display on SDS-PAGE differ considerably from those 
deteimined by ES/MS. The reasons for such a large discrepancy remain unclear, 
but may have to do with the presence of the covalently attached lipoyl domains 
inhibiting SDS binding. It has been observed previously that succinylated, 
maieylated or acidic proteins display reduced electrophoretic mobility (Weber et
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al, 1971). It is possible that lipoyl domains have a similai' ability to retard 
subunit mobility in SDS-PAGE.
The separation of E1/E3 components of mammalian PDC from each other 
was achieved using anion exchange chromatography. This produced milligram 
quantities of both proteins in high purity and provided a source of bovine 
(native) E3 for reconstitution studies (see chapters 4 and 5). The presence of the 
zwitterionic detergent CHAPS helped to mitigate the loss of the E l component 
during the separation, although it did not completely eliminate this problem. The 
separation also led to the N-terminal sequencing and subsequent identification of 
the small (<30 000 Mr) protein associated with part of the E3 fraction as the 
mitochondrial protein SP-22 (Watabe et al, 1994).The presence of two proteins 
in a single fraction on a high resolution of anion exchange column, may be 
indicative of a direct interaction between the dihydrolipoamide dehydrogenase 
component and SP-22. The possible role of SP-22 in preventing thiol oxidation 
is the subject of later investigation (see chapter 6).
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Chapter 4
Refolding and reconstitution studies on the 
transacetylase-protein X (E2/X) subcomplex of 
mammalian pyruvate dehydrogenase complex 
(PDC):evidence for specific binding of the 
dihydrolipoamide dehydrogenase component (E3) to sites
on reassembled E2.
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4.1 Introduction
Located in the mitochondrial matrix, in close association with the inner membrane, 
the pymvate dehydrogenase complex (PDC) is one of the largest multienzyme 
complexes detected to date with an apparent molecular mass of 9-10x10^. This 
macromolecular assembly is responsible for the oxidative decarboxylation of pyruvate, 
yielding acetyl Co A, CO2 and NADH. It thus occupies a key site in flux regulation of 
two carbon units into the TCA cycle. Central to the catalysis is the consecutive action 
of its constituent enzymes: a pyruvate decarboxylase, E l; a dihydrolipoamide 
acetyltransferase, E2 and, a dihydrolipoamide dehydrogenase, E3. PDC from 
mammalian sources is organised around a 60-meric E2 core with icosahedral (532) 
symmetry to which are attached a maximum of 30 aife  E l tetramers and 6-12 E3 
homodimers (for recent reviews see Behai et al., 1993; Patel & Harris, 1995).
Mammalian PDC contains an additional subunit, protein X, 12 copies of which are 
very tightly associated with the E2 core assembly. Its major role appears to be that of 
binding and positioning the E3 component at the correct sites on the surface of the E2 
core (Maeng et at., 1994; Sanderson et a i, 1996a). In addition, several copies of 
tightly associated kinase and loosely associated phosphatase are responsible for the 
regulation of PDC activity by a phosphorylation/dephosphorylation mechanism 
involving covalent modification of the E la  subunit (Yeaman, 1989).
PDC deficiency is one of the commonest causes of congenital lactic acidosis (Patel
et at., 1992). The cases of human pyruvate dehydrogenase deficiency studied to date
implicate defects in the E la  component as the major cause, with considerably fewer
lesions specifically associated with other enzymes of the complex. However, recent
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studies (Marsac et al, 1993; Geoffroy et a l, 1996 ) have identified patients, suffering 
from chronic lactic acidosis, with reduced levels (15-20%) of PDC activity and an 
apparent absence of protein X. In these cases, while the levels of E3 appeared normal, 
no immunologic ally detectable protein X was present in cultured fibroblast cells from 
the patients. Further studies have successfully cloned the cDNA for human protein X 
and localised it to chromosome 1 Ip 13 (Aral et al, 1997; Ling et al, 1998). 
Interestingly, one study identifies a case of patient protein X deficiency resulting from 
a 4bp deletion in the mitochondrial targeting signal sequence of the polypeptide (Aral et 
al, 1997). Further cases of deletion mutations in the protein X gene have been 
identified, in addition to a single case where the patient did not appear to express 
protein X mRNA (Ling et al, 1998).
Association of the individual enzymes of the complex is achieved solely by non- 
covalent forces, with the E2 component providing the structural lattice to which the 
constituent enzymes are attached. Evidence from genetic studies of PDC from 
Saccharomyces cerevisae (Niu et a l, 1990; Lawson et al, 1991a, b) indicate that this 
core must be in a native or near native state for whole complex assembly to occur. 
More recent reports (Behai et a l, 1994; De Marcucci et al, 1995) using dénaturation 
and sedimentation velocity analysis, provide compelling evidence that assembly of the 
E2/X subcomplex proceeds in an ordered fashion, involving a lower molecular weight 
(8S) intermediate, as opposed to other possible random or sequential assembly 
mechanisms. However, the dissociation method employed by these authors has been
shown to be suboptimal as the harshness of the dissocation conditions promoted a 
significant degree of component dénaturation and resulted in poor levels of 
reconstitution (i.e., <20%) of original overall complex activity (Sanderson et a l, ■r
1996b).
Recently our laboratory has developed a gentle but effective method of separating 
the E2/X subcomplex from E1/E3 which has facilitated reconstitution studies. It has
#been possible to utilise the improved separation protocol to produce a more detailed 
picture of the processes involved in PDC folding and assembly (Sanderson et ah,
1996b).
'jn
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In this chapter we demonstrate that dissociation of the E2/X subcomplex, and by 
implication its assembly, is an ordered, co-operative event. Complete unfolding of 
mammalian E2/X in guanidine hydrochloride and subsequent removal of the 
dénaturant by either, (i) slow dialysis or (ii) rapid dilution, results in both instances in 
complete restoration of E2 catalytic activity and reassembly of the multimeric stmcture. 
However, compared to the native E2/X core, the reassembled E2 cores exhibit, 
respectively (i) a reduced level of bound protein X, or (ii) no immunologically 
detectable protein X. Further, both core preparations can still mediate E3 binding, 
through proposed low affinity, specific sites on E2, and thus support PDC activity, a 
property not previously observed. This ability provides in vitro evidence in support of 
previously reported clinical data (Geoffroy et al., 1996) and clarifies data from a 
previous study (Sanderson et al., 1996b) where low affinity binding to proteolytically 
cleaved protein X remained a possible explanation.
{
4.2 Results
4.2.1 Association state analysis of E2/X subcomplex
Analysis of the quaternary structure of the purified E2/X subcomplex involved 
pretreatment with 0, 2 or 4M GdnHCl prior to gel permeation analysis on a Superose 
12 column equilibrated at the same concentration of dénaturant (Fig. 4.1). The results 
provide evidence for an ordered, cooperative decline in the apparent Mr value of the 
E2/X core produced at discrete increments in the concentration of chaotrope. No initial 
dissociation of the native core was observed in the presence of 0-1.5M GdnHCl; 
thereafter, there was a rapid transition to an approx. 200,000 Mr species which was 
stable in the range 1.8-2.8M GdnHCl. At higher GdnHCl levels, there was a further 
rapid conversion to a partially or fully-unfolded monomeric form with an apparent Mr 
value of 82, 000.
Previous attempts (West et al, 1995) to produce GdnHCl-induced dissociation of 
the E2/X core resulted in the production of non-specific aggregates. In this study, 
inclusion of 200mM NaCl in the gel permeation buffer appears to stabilise stmcture 
and minimise aggregation of E2/X dissociation products. Moreover, the appearance of 
an intermediate species, stable in 2M GdnHCl, between that of the native core and the 
monomeric form present at 4M GdnHCl, is consistent with the reversible perturbations 
in tertiaiy and/or quaternary structure observed by intrinsic tryptophan fluorescence 
(West e ta l, 1995) whereas little or no corresponding dismption of secondary 
structure (as judged by circular dichroism measurements) was detected under these 
conditions. This result suggests that assembly of the E2 stractural lattice may occur 
through a lower order intermediate, as opposed to possible random or sequential 
mechanisms (Behai et al, 1994). Molecular mass estimations produce an apparent Mr
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Figure 4.1. Gel permeation analysis of E2/X association
Association state analysis of the E2/X subcomplex was performed on a 
Pharmacia Superose 12 FPLC column (24ml) equilibrated, at 0.2ml/min, with 
increasing concentrations of GdnHCl in 50mM imidazole/HCl pH 7.4, 200mM 
NaCl. E2/X subcomplex (lOOjig), in column equilibration buffer, was pre­
incubated at room temperature for 15 min in the appropriate concentration of 
GdnHCl and then subjected to analysis on the Superose 12 column. Protein 
elution was detected at 280nm. Elution profiles in the absence of GdnHCl (D), 
2M GdnHCl (A) and 4M GdnHCl (O) are shown.
of 200,000 +/- 24,000 (n=4) for the species in 2M GdnHCl and a Mr of 82,000+/- 
12,000 (n=4) for that formed in 4M GdnHCl. These Mr values are consistent with 
formation of E2 trimers at 2M GdnHCl and further dissociation to fully or partially- 
unfolded monomers when the chaotrope concentration is increased to 4M. Available 
crystallographic data on the truncated transacetylase core ixom Azotobacter vinelandii 
argues for strong intra-trimeric interactions between transacetylase monomers as the 
basic unit for core association (Mattevi et al, 1992a). In addition, the structural and 
functional similarity of E2 to chloramphenicol acetyltransferase, CAT (Guest, 1987), 
active as a trimer, led to the suggestion that the 60-meric mammalian E2 core 
represents an association of twenty trimeric units, an idea which has received 
experimental support from recent publications (Behai et a l, 1994; De Marcucci et a l, 
1995) and current evidence.
4.2.2 Kinetics of E2 refolding/reassembly
We have reported previously that overall PDC activity is rapidly inhibited at low
levels of GdnHCl (0-0.2M) under conditions which have only a limited effect on the
catalytic functions of its three constituent enzymes. The susceptibility of the intact
complex to GdnHCl results from its ease of dissociation into the individual E l, E2/X
and E3 components. All three constituent enzymes display similar susceptibilities to
the presence of GdnHCl with approx. 50% inhibition occurring by 0.3M and complete
inhibition in the range 0.7-1.CM with the E2 component proving slightly more
refractory to dénaturant treatment. However, in all cases, inhibition oceurs at levels of
dénaturant which are significantly lower than those which produce any major structural
impact (West et al, 1995). Since, in multidomain proteins, individual domains can be
viewed as separate folding entities, it is probable that each domain displays a particular
sensitivity to dénaturant. Thus, initial loss of component activity usually reflects minor
architectural changes in the most sensitive domain which are readily reversible. It has
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been proposed that in a number of proteins the active site is particularly sensitive to 
dénaturant perturbation (Tsou, 1986).
Fig. 4.2 illustrates the profiles of irreversible loss of overall complex activity and 
that of its individual component enzymes with increasing GdnHCl concentrations as 
judged by their inability to recover spontaneously following rapid dilution directly into 
assay buffer. In each case, the concentration of GdnHCl was reduced to below 
30mM, given the acute sensitivity to GdnHCl demonstrated previously (West et al., 
1995). Irreversible loss of constituent enzyme activities correlates closely with the 
onset of major structural perturbations as judged by circular dichroism and intrinsic 
tryptophan fluorescence measurements (West et a l, 1995). Recovery of intact 
complex activity is intrinsically coupled to the sensitivity of the E l and E3 enzymes 
which are most susceptible to GdnHCl-induced dénaturation. Interestingly, however, 
major differences were observed in the ability of the E2/X subcomplex to support PDC 
reconstitution compared to the return of its intrinsic transacetylase activity. Whereas 
irreversible loss of E2-linked transacetylase activity occurs in the range 3.8-5 M 
GdnHCl (Fig. 4.2), the ability of the GdnHCl-treated E2/X core to promote overall 
complex reconstitution declines rapidly at lower levels of GdnHCl (2.8-4M).
Extension of the renaturation/ reconstitution period prior to assay had no effect (results 
not shown). This discrepancy between the ability of the reactivated core assembly to 
support PDC reconstitution and the return of its transacetylase activity raised the 
possibility of a renaturation /refolding process dependent on the correct re-integration 
of protein X into the refolded core (see later).
Refolding by rapid dilution was optimised to maximise the recovery of
transacetylase activity from fully unfolded monomers and found to exhibit a marked
temperature and protein concentration dependence. The kinetics of refolding/
reassociation of the E2 core at 4°C (the optimal temperature) were monitored by
activity assays (Fig. 4.3A). There is a rapid and efficient reconstitution of E2 activity
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Figure 4.2. Reactivation/renaturation profiles of PDC, 
E2/X, E1/E3 and E2 (transacetylase) activity following 
pre-treatment with GdnHCl
Purified PDC, E2/X or E1/E3 preparations were incubated in 50itiM 
MOPS/KOH, pH 7.4 containing the stated concentration of GdnHCl for 15min 
at 20°C. Renaturation/reactivation was initiated by a rapid dilution into the 
appropriate assay buffer. The final protein concentration in the renaturation 
mixture was 10~30|Xg/ml and residual GdnHCl concentration was less than 
30mM. After a 15 min period at 20°C, reconstitution/activity assays were 
performed (see experimental) for PDC activity on: intact PDC (O); pre-treated 
E2/X (□); pre-treated E1/E3 (A). E2 transacetylase activity was also determined 
for pre-treated E2/X (■). All activities are expressed relative to control samples 
incubated in the absence of GdnHCl.
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(at 50|ig.ml“l) with 60-80% of original transcetylase activity appearing within 30-45 
min and complete recovery occurring in 4-6 h.
The biphasic nature of the kinetic profiles is consistent with two populations of 
folding intermediates. Fast folders are thought to collapse rapidly to the native state 
whereas slow folders undergo incorrect nucléation and are thus trapped in non- 
native/misfolded states. These molecules must unfold to some degree before 
proceeding further along the correct folding/assembly pathway (Todd et a i, 1996). 
Similar biphasic kinetics for E2 recovery, although over a prolonged time scale (25h), 
have been reported previously (Behai et a i, 1994; De Marcucci et aL, 1995). The 
improved rates of E2 core assembly reported here may reflect the milder conditions 
employed in the initial purification of the E2/X core (Sanderson et a i, 1996b) in 
comparison to the original protocol of Linn et a l (1972) routinely used by other 
investigators which results in significant component dénaturation and poor levels 
(<20%) of overall complex reconstitution (Sanderson e ta l,  1996b). Attempts to 
refold at elevated temperatures and protein concentrations resulted in dramatic declines 
in the yield of active E2, presumably resulting from promotion of competing non­
specific aggregation reactions.
Despite the rapid and complete reconstitution of E2-linked catalytic function on 
dilution from 6M GdnHCl, these reassembled E2 cores were unable to sustain PDC 
activity on addition of the correct stoichiometric levels of E1/E3. As a result, a slow 
dialysis protocol was developed which permitted the return of approx. 35% of PDC 
activity (Fig. 4.3B) upon addition of the appropriate amounts of native bovine E1/E3. 
Slower removal of the chaotrope appears to minimise incorrect hydrophobic 
interactions within the E2/X core during folding and allow a more controlled passage
through the critical, aggregation-sensitive, midpoint of folding. This observation
represents the first report of the recovery of PDC complex activity following complete
unfolding of the E2/X core. In addition, renaturation by slow dialysis still allows the
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Figure 4.3A. Renaturation of E2/X subcomplex initiated 
by rapid dilution
Renaturation of E2/X, after complete dénaturation in 6M GdnHCl for 2h at 20‘^ C, 
was initiated by a rapid dilution into renaturation buffer (50mM potassium 
phosphate, pH 7.0 5mM cysteine-HCl) at 4°C. The protein concentration in the 
renaturation buffer was 50|ig.ml-i or 200p,g.ml'^ Aliquots were removed at the 
time points indicated and assayed for transacetylase (■ ) SOqg.ml'i, (D) 
200|Ug.ml’ * and reconstituted PDC activity (A) SOqg.mP^ and 200p.g.ml"l (A). 
Activities are expressed relative to control samples which underwent the entire 
protocol in the absence of GdnHCl.
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Figure 4.3B. Renaturation of E2/X subcomplex by 
dialysis
Following complete dénaturation of the E2/X subcomplex in 6M GdnHCl for 2h 
at 20°C, reactivation and reassociation was initiated by dialysis against 41 of 
50mM potassium phosphate buffer, pH 7.5, 250mM NaCl, ImM MgCH,
0. ImM EDTA, 5mM p-mercaptoethanol at 4°C. At the time points indicated, 
aliquots were removed and assayed for transacetylase activity: (■ ) 0.5mg.mh^ 
(D), Img.ml"^ and the ability to reconstitute PDC activity: (A) 0.5mg.ml“l, (A) 
Img mpl, upon the addition of the correct stoichiometric quantity of E1/E3. 
GdnHCl concentration (♦), at the time points indicated, was determined by 
refractive index measurements. Activities are expressed relative to control 
protocols carried out without GdnHCl.
complete return of E2 activity within 6h and is effective at protein concentrations 20- 
50-fold higher than the rapid dilution method with no marked concentration/ 
aggregation effects. From direct measurement of GdnHCl concentrations during the 
dialysis step (Fig. 4.3B), it is clear that a rapid decrease in dénaturant concentration 
occurs in the initial stages. A slower stepped dialysis was developed which allowed 
the removal of GdnHCl at a much reduced rate. However, this did not produce any 
improvement in the levels of reconstituted PDC activity (results not shown).
4.2.3 Immunological analysis of refolded/assembled E2/X 
subcomplexes
the reduced ability (approx. 35%) of this reassembled core to promote PDC 
reconstitution (Fig. 3B) while the absence of immunologically-detectable protein X 
(lane 3) provides an explanation for the ineffectiveness of this core in sustaining PDC 
activity in view of the known participation of protein X in high-affinity E3 binding 
(Fig. 4.3A).
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It was anticipated that the differing efficiencies of the two types of reassembled E2 
cores in promoting overall PDC function could be correlated with the extent of re­
incorporation of the peripherally-located protein X subunit during in vitro assembly. 
Immunological analysis of the purified, reconstituted cores (Fig. 4.4) confirmed a 
reduction in bound protein X (to 30-40% of normal levels) from the subcomplex 
reassembled by slow dialysis (lane 2) and an elimination of protein X from the 
reassembled core produced by rapid dilution (lane 3) when compared to untreated
E2/X core (lane 1). In contrast, identical loadings showed no detectable differences in 
the levels of the E2 component (lanes 4-6). Thus, loss of protein X does not affect E2
core assembly, as previously demonstrated using a genetic approach in S. cerevisiae 
(Niu et a l, 1990). The extent of depletion of protein X (lane 2) correlates closely with
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Figure 4.4. Immunological analysis of 
refolded/reassembled E2/X cores
Samples (500|ll) containing renatured transacetylase and native untreated core 
were pelleted by ultracentrifugation using an optima TL ultracentrifuge 
(Beckman) for 25min at 100,(X)0g through a 200|xl 30%(w/v) sucrose cushion. 
Following resuspension and protein assay, identical quantities of each sample 
(5p,g) were subjected to SDS-PAGE and subsequent immunological analysis 
with anti-protein X (lanes 1-3, panel A) or anti-E2 (lanes 4-6, panel B) serum. 
Lanes 1 and 4 untreated E2/X core (control); Lanes 2 and 5 refolded E2/X core 
(slow dialysis); Lanes 3 and 6 refolded E2/X core rapid dilution.
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4.2.4 Reconstitution studies with E2(X) refolded cores
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As indicated in Fig. 4.3, levels of PDC reconstitution, obtained after incubating 
either reassembled E2 core, devoid of protein X, or X-deficient E2 core with 
stoichiometric amounts of E1/E3, yielded values of 0% and 30-35%, respectively 
compared to recoveries with native E2/X. Both types of reconstituted E2 subcomplex 
were then tested for their ability to promote PDC activity in the presence of an 
increasing excess of bovine heart E3 (Fig. 4.5). In both cases, this resulted in the 
restoration of appreciable levels of PDC activity in the reassembled complexes. Thus, 
E2/X subcomplex deficient in protein X could support 60-65% of control PDC 
activity, virtually double its basal activity, in the presence of a 100-fold molar excess 
of E3. Importantly, reassembled E2 core lacking protein X can now be induced to 
reconstitute significant levels of PDC activity (25-30%) by a similar molar excess of 
native bovine E3. Thus, it appears that mammalian E2 oligomer can interact physically 
and functionally with E3, albeit with low affinity. No similar stimulation of PDC 
activity on addition of excess E3 is evident with native E2/X core which can sustain 
maximal yields of PDC activity with minimal (stoichiometric) amounts of E l and E3. 
In support of these findings, patients with genetic disorders in PDC function, have 
been described recently which are characterised by the total absence of the protein X 
subunit. Interestingly, these patients still have measurable, although much reduced 
(<20%), PDC activity (Geoffroy et a l, 1996). Such evidence is also consistent with a 
limited ability of the E2 core to interact physically and functionally with E3 in the 
absence of its protein X subunit.
Reconstitution analysis with these refolded E2/X core preparations employing a 
number of heterologous E3s in vast excess (Fig. 4.6), confirm the specificity of the 
E3-induced stimulation of PDC activity, indicating that it is not the result of non-
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Figure 4.5. Reconstitution of PDC activity of refolded 
E2/X cores in the presence of excess parent E3
Renatured/reassembled E2/X cores (5]ig) were reconstituted with the correct 
stoichiometric quantity of E1/E3 in assay mixture without substrate. Additional 
E3 was added at the amounts shown and allowed to associate prior to addition of 
pyruvate and assay of PDC activity; native E2/X core (D); refolded E2(X) core, 
slow dialysis (0 ); refolded E2(X) core, rapid dilution (O). Values expressed as 
+/- S.E.M (n=2).
specific interaction or random collision of E3s with the reconstituted EÎ/E2 
subcomplex. As control, Fig. 4.6A illustrates that bovine, bacterial and porcine E3, 
when added in excess over and above stoichiometric amounts of parent E1/E3, have 
no additional stimulatory effect on reconstituted PDC employing native (untreated) 
E2/X core; however, addition of yeast E3 produces a marked inhibition of PDC 
activity. This phenomenon has been observed previously with protease argC-treated 
E2/X core and native E1/E2 core from OGDC. It apparently reflects tight and specific 
binding of yeast E3 to these cores in an orientation which is unable to support complex 
catalysis (Sanderson et aL, 1996b). This marked inhibition is also observed when 
yeast E3 is added to the E2/X core produced by slow dialysis (Fig. 4.6B). In this 
instance, while bacterial E3 has no detectable effect, presumably because it is unable to 
bind, porcine E3 does produce a small stimulation. However, it is much less 
pronounced, representing only 25% of that observed with native bovine E3.
The specificity of the E3 response is also observed with E2 core totally lacking 
protein X (Fig. 4.6C). A small but significant level of stimulation is obtained with 
porcine E3 (again around 25% that of bovine heart E3) whereas bacterial and yeast E3s 
are completely ineffective. This ability of porcine E3 to promote the final step in PDC 
catalysis reflects the high degree of conservation between bovine and porcine E3s. 
However, usage of porcine E3 is clearly suboptimal in reconstitution studies and may 
explain why previous investigators were unsuccessful in detecting any PDC 
reconstitution after refolding of the denatured E2/X core (De Marcucci et aL, 1995).
Figure 4.6. Reconstitution of PDC activity of refolded 
E2/X cores with excess heterologous E3
Renatured/reassembled E2/X cores (5g.g) were reconstituted with the correct 
stoichiometric quantity of E1/E3 in assay mixture without substrate. Additional 
E3 was added at the amounts shown and allowed to associate prior to addition of 
pyruvate and assay of PDC activity. (A) native (untreated) E2/X core; (B) 
refolded E2/X core produced by slow dialysis; (C) refolded E2/X core produced 
by rapid dilution. Parent E3 (A); yeast E3 (D); bacterial E3 (<»; porcine E3 (O). 
No results are presented for bacterial E3 in panel C as it also gave zero 
reconstitution. Values expressed as +/- S.E.M (n=2).
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4.3 Discussion
Gel permeation analysis of mammalian E2/X core indicates that it can be 
dissociated into discrete intermediates corresponding to trimers and subsequently 
fully-unfolded monomers as judged by Mr analysis in specific ranges of GdnHCl 
concentration. Thus, the 200, 000 +/- 24,000 Mr intermediate is close to the expected 
value for a trimeric species since bovine monomeric E2 has an Mr value of 59,963 as 
determined by electrospray mass spectrometry . Although the monomeric species has 
an appaient Mr value of 82, 000 +/- 12,000 on gel filtration, this is compatible with 
monomeric E2 existing in a loosely or fully-unfolded state at high dénaturant 
concentrations which would result in its more rapid elution from the gel permeation 
matrix relative to a globular intermediate of equivalent size. Interestingly, a stable 
trimeric species of bovine branched-chain 2-oxoacid dehydrogenase complex 
(B CO ADC) E2 has been isolated after dissociation in GdnHCl (Wynn et aL, 1994). 
Moreover, previous sedimentation velocity analysis of chaotrope-treated E2/X 
subcomplexes of PDC from bovine kidney in sucrose gradients produced data 
consistent with an ordered assembly of this subcomplex (Behai et aL, 1994). Notably 
a range of subcomplex species were detected intermediate to the purported trimer and 
native 60-mer, thus arguing for a non-cooperative transition. In contrast no evidence 
of such species were detectable during our study.
In this context, the recent discovery that sucrose and other polyhydric compounds 
oppose the effect of dénaturants on water stmcture, thus increasing the concentration 
of dénaturant required to unfold an enzyme is of considerable interest (Taylor et aL,
1995). In addition to influencing the state of aggregation of E2 dissociation products
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located at different levels in the sucrose gradient, this could explain discrepancies 
between the critical chaotrope concentrations required for trimer formation and 
complete unfolding of monomers stated in (Behai et aL, 1994) in relation to those 
determined in this publication and in other studies (West et aL, 1995).
The rapid and successful chaperone-independent refolding and functional 
maturation of the mammalian E2(X) core in high yield in vitro is somewhat surprising, 
given its complex multidomain organisation and quaternary structure. Elevated ionic 
strength (200mM) has been suggested as a key factor which enables kinetically trapped 
intermediates to return to productive folding by lowering the activation energy barrier 
between the trap and its normal folding pathway (Todd et aL, 1996). For example, 
ribulose bisphosphate carboxylase (RUBISCO) does not fold successfully at low ionic 
strength but behaves as a slow folder in elevated ionic strength buffers (Schmidt et aL, 
1994). Previous successful folding and assembly of a truncated 24-meric core of 
BCG ADC could only be achieved with the inclusion of molecular chaperones (Wynn 
et aL, 1994). It is possible that the absence of the N-terminal region of this 
polypeptide prevents the establishment of critical transient associations which are 
essential for promoting ordered folding of the B2-BCOADC oligomer. In this study, 
although functional re-assembly of the E2 oligomer in high yield could be achieved by 
rapid dilution or slow dialysis, partial re-integration of the protein X subunit was 
critically dependent on both the controlled removal of dénaturant and the presence of 
200mM NaCl (Fig. 4.3B). These findings on E2/X core formation of PDC, however, 
do highlight its high intrinsic capacity for self-assembly and provide further evidence 
in support of the hypothesis (currently under investigation in our laboratory) that the 
extended presequences on the cytosolic precursor forms of the various complex- 
specific E2s may be involved in preventing their premature association prior to 
mitochondrial import (Hunter and Lindsay, 1986; De Marcucci et aL, 1988; Clarkson 
and Lindsay, 1991).
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Whereas regeneration of active E2 cores displaying complete restoration of 
dihydrolipoamide acetyltransferase (E2) activity, occurs rapidly in high yield on 
removal of GdnHCl by either slow dialysis or rapid dilution, these reassembled 
stmctures have distinctive properties, reflecting their differing protein X content which 
influences their ability to support overall complex reconstitution on addition of 
stoichiometric amounts of E l and E3. Thus, reconstitution by rapid dilution is 
incompatible with re-incoiporation of the protein X subunit into the re-assembled E2 
cores whereas 30-40% of expected protein X levels can be functionally re-integrated 
by controlled removal of dénaturant. As expected, no significant reconstitution of PDC 
can be obtained with the E2 oligomer lacking protein X whereas corresponding levels 
of reconstitution (30-40%) are readily achieved with the X-depleted core in the 
presence of stoichiometric levels of El and E3. The possibility of achieving complete 
functional integration of wild-type levels of protein X into reassembled E2 oligomers 
in the presence of moleculai' chaperones is currently under investigation.
Interestingly, maximal levels of PDC reconstitution (30-35%) are restored within 
30-45 mill using re-assembled E2(X) cores formed by slow dialysis whereas only 50- 
60% of intrinsic acetyltransferase activity has re-appeared at this stage with complete 
re-activation of E2 occurring over 4-6h. Such data suggest that initial formation of E2 
oligomers and subsequent incorporation of protein X occurs on a relatively rapid time 
scale whereas further more subtle rearrangements of enzymatically-inactive E2 
polypeptides incorporated into the repolymerised core structures (slow folders) are 
necessary to effect the complete recovery of acetyltransferase activity. These 
observations are compatible with the observation that E2 does not catalyse the rate- 
limiting step in the overall reaction; moreover, as the lipoyl domains of individual E2 
molecules form a complex interacting network within the core assembly, it has been 
shown previously that removal of a substantial fraction of E2 lipoyl domains can be 
accommodated without significant effects on overall complex activity (Ambrose- 
Griffin et aL, 1980; Stanley et aL, 1981).
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In yeast, sequence similarities between protein X and transacetylase E2 
components have been documented previously (Behai et a l, 1989). This extends over 
most of the N-terminal region and also includes putative peripheral subunit 
(specifically E1/E3) binding domains. The major differences appear in the C-terminal 
regions which, in the E2 component, are known to be involved in catalysis and also 
self-association. The presence of equivalent putative subunit binding domains in both 
mammalian and yeast E2 and X components displaying significant homology may 
suggest that E2 oligomers have retained a residual affinity for E3 (Sanderson et a l, 
1996b; Maeng et al, 1996).
Evidence reported here demonstrates for the first time that reconstituted PDC, 
deficient in or totally devoid of its protein X subunit can, in the presence of a large 
excess of its E3 component, still support overall complex activity via specific low 
affinity E3 interactions with the putative peripheral subunit binding domains on the E2 
component. Thus, E2 cores containing 30-40% of normal levels of protein X are able 
to support an equivalent level of reconstitution with stoichiometric amounts of E l and 
E3 in contrast to E2 core totally stripped of protein X which is totally ineffective under 
similar conditions. Thereafter, both types of core can sustain an additional 25-30% of 
control PDC activity in the presence of a 100-fold excess of parent E3, consistent with 
the involvement of protein X in mediating high affinity E3 binding and a residual 
capacity of E2 to promote low affinity E3 interactions.
In support of this hypothesis, a group of patients with genetic defects in PDC
function have been discovered who contain no immunologically-detectable protein X
subunit (Geoffroy et a l, 1996). These patients display residual levels of PDC activity
(10-20% of controls) which can now be accounted for in terms of low affinity E2-
mediated interactions with the E3 component. Current studies also represent a
significant advance on previous analysis of the role of protein X in E3 binding
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employing selective proteolysis of this subunit with protease arg C (Sanderson et ah, 
1996b). In this investigation, the single arg C cleavage site on protein X was located 
at the N-terminal boundary of its putative E3 binding domain and the truncated 35,000 
Mr fragment remained tightly-associated with the E2 core. Consequently, 
reconstitution of complex activity in the presence of excess E3 could have been 
mediated directly via the E2 component or reflect low affinity interaction with a 
partially-disrupted E3 binding domain on the truncated protein X component.
In summary, these results demonstrate unequivocally for the first time that the 
presence of the protein X subunit of mammalian PDC is not absolutely essential for 
maintaining partial complex function in vitro and probably also in vivo. Thus, 
significant levels of complex reconstitution can be attained in the presence of an excess 
of the E3 component using the purified constituent enzymes of PDC in dilute solution. 
Partial PDC activity also appears to be maintained in vivo where protein concentrations 
are in order of 200mg.ml'^ in the mitochondrial compartment. These observations 
highlight the distinctive but overlapping roles of the E2 and protein X subunits of 
mammalian PDC. Whilst the dihydrolipoamide acetyltransferase (E2) component has 
a prominent role in complex catalysis, specifically the acétylation reactions, in the 
absence of E2-lipoyl domains, a degree of complex activity (approx. 20%) can be 
mediated exclusively via lipoyl groups on protein X (Sanderson et ah, 1996b).
elucidation of possible additional catalytic functions of the protein X subunit.
1 0 1
Similarly, as shown here, the primary involvement of protein X in mediating optimal 
high affinity binding of dihydrolipoamide dehydrogenase (E3) homodimers can be 
replaced, at least partially, by direct E3 association with equivalent regions situated on
the E2 oligomer. Access to a catalytically-active form of PDC, lacking protein X, will 
permit more detailed investigation of the properties of the modified PDC and facilitate
Chapter 5
The 2-oxoglutarate dehydrogenase (El) component 
of mammalian 2-oxoglutarate dehydrogenase 
complex (OGDC) is responsible for binding the 
dihydrolipoamide dehydrogenase (E3) component 
to the multienzyme complex
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5.1 Introduction
The 2-oxoglutarate dehydrogenase complex (OGDC), along with the 
pyruvate dehydrogenase complex (PDC) and the branched chain 2-oxoacid 
dehydrogenase complex (B CO ADC), constitute the family of mammalian 2- 
oxoacid dehydrogenase multienzyme complexes important in carbon flux into 
and around the citric acid cycle. Located in the mitochondrial matrix, these 
complexes catalyse the irreversible oxidative decarboxylation of their respective 
2-oxoacid substrates; yielding acylCoA derivatives (succinyl CoA in the case of 
OGDC), NADH and CO2 as the final reaction products. Central to this catalysis 
is the consecutive action of three catalytic components, present in multiple 
copies; 2-oxoacid dehydrogenase (El); dihydrolipoamide acyltransferase (E2), 
and dihydrolipoamide dehydrogenase (E3) (see Patel & Harris, 1995; Behai et 
al, 1993 for recent reviews).
2-oxoacid dehydrogenase complexes are composed of multiple copies of the
three constituent enzymes, assembled in a tight but noncovalent fashion. Their
multi-component and multi-copy nature results in the formation of very large
complexes (M r, 5-10 x 10").These structures are composed around 24/60meric
E2 cores (dependent on the specific multienzyme complex and source
organism), exhibiting octahedral/icosahedral symmetry respectively. In
prokaryotes, in conjunction with its catalytic role, the E2 component is
responsible for binding and orientating both the E l and E3 components within
the multienzyme complexes (for reviews of structure-function relationships, see
Reed & Hackert 1990; Mattevi e ta l, 1992a; Mande et al, 1996). In higher
eukaryotes the identification of an additional component of PDC, protein X,
with similarities in domain structure to E2, suggested a possible devolution of
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subunit function (De Marcucci and Lindsay 1985; Jilka et al, 1986).
Subsequent studies of protein X (also termed E3BP) have shown that it is 
responsible for mediating the binding of the E3 component to the PDC 
multienzyme complex in these organisms (Powers-Greenwood et al, 1989; 
Neagle & Lindsay 1991; Lawson et a l, 1991a,b; Maeng et al, 1994).
Furthermore, a study of mammalian OGDC in this laboratory, employing 
specific proteolysis and N-terminal sequence analysis, identified a “lipoyl like” 
region of the El component with significant sequence similarity to protein X 
and E2 components of mammalian PDC (Rice et al, 1992). This similarity 
suggested that the E l component may perform the function of E3 binding in the 
case of mammalian OGDC. Further evidence, in support of this putative 
additional role for E l of OGDC, also came when the genes for rat and human 
OGDC E2 were cloned ( Nakano et a l, 1991 and 1994). Analysis of the amino 
acid sequences deduced from the genes failed to locate any apparent E1/E3 
binding motifs. Such sequences have been located in OGDC E2 genes cloned 
from other organisms, notably Escherichia coli (Spencer et al, 1984) and 
Azotobacter vinelandii (Westphal & de Kok 1990).
Previous studies of OGDC have successfully purified the intact 
multienzyme complex to homogeneity (Stanley & Perham 1980; De Marcucci et 
al, 1985). However, no method for the dissociation of OGDC into functionally 
active E2 and E1/E3 fractions has been reported. This has prevented the study 
of any potential E1/E3 interaction. In this chapter we report the development of 
a method for the successful dissociation of mammalian OGDC into its E2 and 
E1/E3 fractions. Subsequent reconstitution studies with the E2 core recovered
I
1
appreciable levels (30%) of OGDC activity, upon the addition of E l and B3.
Gel permeation analysis of the E1/E3 fraction of OGDC, under associative
conditions, demonstrated that the two components interact with each other to
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form a subcomplex with an apparent Mr consistent with an E1/E3 subunit 
interaction in a 1:1 ratio. Immunological analysis, employing antisera raised 
specifically to the E l subunit of OGDC identified distinct cross-reactivity with 
E2 of mammalian PDC, indicative of similarity between the two proteins. The 
cross-reactivity of El with antisera specific for mammalian protein X is also 
presented. These studies provide biochemical evidence that the E l of 
mammalian OGDC is responsible for binding the E3 component to the 
multienzyme complex.
. . . s
;
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5.2 Results
5.2.1 Preparative dissociation of bovine heart OGDC
Proteolytic studies and N-terminal sequence analysis (Rice et al, 1992) 
indicated that the E l component of OGDC contained protein X/E2 like 
sequences which had the potential to direct the binding of the E3 component to 
the E l. Attempts within this laboratory to purify the native E1/E3 fraction away 
from the E2 core remained elusive. The development of such a protocol 
remained highly desirable as it would facilitate the study of the putative E3 
binding properties of E l by direct methods. Figure 5.1 details preliminary 
studies on the combined effect of treatment of OGDC with IM MgCl2 at a 
variety of pH conditions. The data suggest that the high salt conditions have a 
minimal effect on enzyme activity at pH 6.5 and 7.0 (neutral/slightly acidic 
conditions). In contrast, treatment of OGDC in more alkaline conditions (pH 
8.0) caused an immediate inactivation of enzyme activity (i.e. 70% loss at to) 
with a further decreases over the time course investigated; leading to almost 
complete extinction of OGDC activity after 5h. The treatment with MgCl2 at pH 
7.6 (mildly alkaline conditions) caused some inactivation of the enzyme, but 
more than 50% of the enzyme remained functional after a l-2h period. Alkali 
treatment on its own had no effect (results not shown). It was probable that the 
salt treatment at pH 7.6 was having a dissociative effect on the multienzyme 
complex and was integrated into a dissociation protocol for OGDC (see below).
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Figure 5.1 Reactivation profiles mammalian OGDC activity 
following pre-treatment with IM  MgCl2 over the pH range 6.S-8.2.
OGDC was incubated in IM MgCh at the pH stated at 20°C. During the time 
course, samples were removed and reactivation /renaturation was initiated by a 
rapid dilution into the appropriate assay buffer. The final protein concentration in 
the renaturation mixture was 10-30pg/ml and residual MgCl2 reduced to below 
30mM to prevent enzyme inhibition. Samples were assayed for OGDC activity. 
All activities aie expressed relative to control samples of enzyme incubated in the 
absence of MgCl^. pH 6.5, O; pH 7.0 □ ; pH 7.6 A; pH 8.2, A, (Experiment 
performed by Mrs H. Lindsay)
Preparative dissociation of OGDC was performed on a Superose 6 prep 
grade column (see Materials and Methods section 2.2.16). The elution profile 
obtained from measuring the absorbance at 280nm suggested that the protocol 
had indeed achieved some degree of separation of OGDC, with apparently two 
peaks eluting from the column (Figure 5.2a). The initial peak of absorbance, 
corresponding to the high Mj- E2 core, eluted at or near the void volume of the 
column (Ve, 30-32ml). The second peak, subsequently shown to contain the E l 
and E3 enzymes, eluted in the later column fractions (Ve 60-66ml). The nature 
and extent of the dissociation achieved was evident from SDS PAGE analysis of 
the column fractions (Figure 5.2b). Clearly, the MgCl2 treatment and column 
chromatography had been successful in removing E l and E3 from the E2 core 
of OGDC. Lanes corresponding to the E2 core (column fractions 14-16) show 
no apparent E3 still core associated, and minimal levels of El still present. The 
elution profile obtained appears consistent with elution from the Superose 6 
column on the basis of size: thus, the oligomeric E2 component elutes first, 
close to the void volume of the column, followed by the E l and finally the E3 
component. The El and E3 components appear as a single unresolved peak in 
the absorbance 280nm trace. However, the SDS-PAGE analysis reveals that, in 
IM MgCl2 elution buffer, E l elutes before E3 (lanes corresponding to column 
fractions 18-32), although there is a degree of overlap. This is also suggestive 
that, under the column conditions, that the E l and E3 components are not 
associated as a single complex.
5.2.2 Reconstitution studies with bovine OGDC
While the protocol detailed above appeared successful in promoting the
dissociation from the E2 core of the E l and E3 components of OGDC, the effect
of the dissociation on the three enzyme activities remained unclear. For OGDC it
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Figure 5.2a Elution profile of the p reparative  dissociation of bovine 
heart OGDC
Preparative dissociation of OGDC into active E2 and E1/E3 fractions was 
performed on an FPLC system (Pharmacia) using a prep grade Superose 6 
column (100ml) equilibrated with 50mM MOPS/KOH, pH 7.6, IM MgCl2,
0.1% (v/v) Triton X-100 (see Materials and Method section 2.2.16). Fractions 
were pooled on the basis of A28O &rid dialysed extensively, at 4°C, against 
multiple changes of the 20mM MOPS/KOH, pH 7.0, lOmM KCl, 0.1% (v/v) 
Triton X-100.
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Figure 5.2b SDS-PAGE analysis of resolved OGDC fractions after 
dissociation on a Superose 6 column
Samples (1ml) of the eluent fractions were subjected to TCA precipitation prior to 
protein analysis by SDS-PAGE (10% w/v gel). Protein was stained with Coomassie 
blue. Lane L, OGDC column load (15pg); Lanes 14-34, TCA-precipitated samples 
from column fractions.
is possible to examine all three enzyme activities at once by adding amounts of 
the E1/E3 pool back to the E2 core, reconstituting overall complex activity (see 
experimental). The levels of reconstitution obtained can be expressed as a 
percentage of the activity of undissociated OGDC and thus provide an index of 
the degree to which the dissociation protocol has maintained the structural 
integrity of the components. SDS-PAGE analysis indicated, that the pooled, 
dialysed fractions were representative and exhibit no apparent cross 
contamination (Figure 5.3b). The data in Figure 5.3a illustrate the ability of the 
E2 and E1/E3 components to reconstitute OGDC activity up to 0.8 U/ml. This 
figure corresponds to recovery of approximately 30% OGDC complex activity, 
when compared to native untreated complex. Hence the components have 
retained their ability to bind each other and produce a native/near native OGDC 
capable of catalysis. Neither the E2 core nor the E1/E3 fraction were able to 
support OGDC activity by themselves, indicative of good fraction resolution 
during the dissociation and illustrating clearly that the recovery of OGDC 
activity measured results only from reconstitution of the complex (results not 
shown). Maximal levels of reconstitution were obtained with E2:E1/E3 ratios 
above 1:2. No increase in the levels of OGDC activity was obtained by adding 
additional quantities of E1/E3. In the case of OGDC reconstitution, maximal 
levels of overall complex activity are regained with sub-stoichiometric levels of 
E1/E3 (the native ratio being E2:E1/E3=1:3). The reason for this remains 
unclear, but may indicate the functional inactivation of a fraction of the E2 
acyltransferase component in the preparation. Alternatively, this reconstitution 
of maximal OGDC activity with sub-stoichiometric quantities of E1/E3 may 
reflect the situation in the native enzyme where the ratio of 1:2 is indeed 
sufficient for maximal rates of catalysis. Optimal levels of reconstitution of 
mammalian PDC were previously obtained employing sub-stoichiometric levels 
of E1/E3 (Sanderson etal., 1996b).
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Figure 5.3a Reconstitution of overall OGDC activity from E2 core 
and E1/E3 fractions: levels of reconstitution and component 
stoichiom etry
Following the dissociation of OGDC, the E2 and E1/E3 fractions were dialysed 
into 50mM MOPS/KOH, pFI 7.4, ImM EDTA, 50% (v/v) glycerol and stored at 
4°C. E2 and E1/E3 fractions were pre-conditioned by a 1:1 dilution in 50mM 
potassium phosphate buffer, pH 7.6, 3mM NAD+, 2.7 mM cysteine-HCl, 2mM 
MgCl2, 0.2 mM ThDP, 0.02mM CoASH and incubated for 15min at 20°C. To 
initiate reconstitution, increasing quantities of E1/E3 (0-40p.g) were added to 
cuvettes containing E2/X (lOpg) and the appropriate assay solutions. The 
production of NADH was subsequently initiated by the addition of 14p,l of 
lOOmM 2-oxoglutarate. Activities are expressed as Units/ml.
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Figure 5.3b SDS-PAGE analysis of the pooled E2 core and E1/E3 
com ponents
Samples were analysed for purity by SDS-PAGE (10% w/v gel) and stained with 
Coomassie Blue. Lane M, lOpg low-Mr marker proteins; lane 1 intact OGDC 
(10|Xg; lane 2 E1/E3 fraction (15|ig); lane 3 E2 core (15p,g).
5.2.3 Association state analysis of the E l and E3
components of mammalian OGDC
The levels of reconstitution of OGDC activity obtained were considered 
sufficient to validate any study of the direct interaction of the E l and E3 
components by gel permeation analysis. Following dissociation from the E2 
core as detailed above, the E1/E3 pool was rapidly dialysed, employing multiple 
changes of buffer, into a low salt buffer (20mM MOPS/KOH, pH 7.0, lOmM 
KCl, 0.1% (v/v) Triton X-100) and 500|il of the pool applied to a Superose 12 
column (24ml) already equilibrated in the low salt buffer (for details see 
Materials and Methods section 2.2.18). The monitoring of the column eluent at 
280nm revealed the presence of two peaks of absorbance, not fully resolved to 
baseline levels (Figure 4a). Assays of the fractions collected from the column 
showed that the two absorbance peaks coincided with two eluted peaks of E3 
activity (Figure 5.4a). The protein present in the two peak fractions was 
precipitated by TCA and subjected to SDS-PAGE analysis (Figure 5.4b). This 
revealed the presence of both E l and E3 in the higher molecular mass peak (PI) 
and the presence of free E3 in the lower molecular weight peak (P2). The 
Superose 12 column was calibrated with a range of marker proteins and the 
column ran under identical conditions as detailed in figure 4. The elution 
profiles obtained were used to construct a calibration curve for the determination 
of the apparent M,- of the E1/E3 complex and free E3 peak eluted under the low 
salt associative conditions. The equation of the line of best fit was used to 
determine the apparent molecular masses for the two peaks (Table 5.1).
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Figure 5.4a Elution profile of gel permeation chromatography 
analysis of the E l and E3 components of mammalian OGDC
Association state analysis of the E1/E3 pool of OGDC was carried out using a Superose 
12 column (for column conditions, see experimental). Protein elution was detected at 
280nm (A) and assays for E3 activity (o) performed on the column fractions.
M^(x 10-3)
-E 194“
6 7 - - E 3
4 3 -
3 0 -
M L P1 P2
Figure 5.4b SDS-PAGE o f peak fractions elated from Snperose 12 
coinm n
Peak fractions from the column were subjected to TCA precipitation and 
subsequent SDS PAGE analysis Lane M, low Mr markers; Lane L, E1/E3 load 
fraction; Lane PI, peak 1 fraction (E1/E3); Lane P2, peak 2 fraction (E3 only)
Table 5.1 Association state analysis of the E1/E3 components of 
mammalian OGDC
The Superose 12 column was equilibrated, at 0.3ml/min, in 20mM 
MOPS/KOH, pH 7.0, lOmM KCl, 0.1%(v/v) Triton Tx-100. E1/E3 samples 
were clarified for 15min at 10,000g in a benchtop centrifuge prior to loading 
onto the column. The column was calibrated with molecular weight marker 
proteins (Sigma) under identical conditions. The apparent My of El and E3 
species eluted from the column were obtained by interpolation.
Peak Apparent SEM n
Ml'
E1/E3 303,000 7500 3
E3 126,000 13500 3
i
I'"a-
Since E3 is a homodimer with a subunit Mj- corresponding to 55,000, the 
figure of 126,000 obtained from the data above is in broad agreement with the 
expected value 110,000 , given that elution volume is dependent upon 
hydrodynamic volume as well as size. For the larger molecular mass peak, an 
apparent Mr value of 303,000 is in good agreement with the expected Mr of an 
E1/E3 complex of 302,000; representing one E3 dimer (110,000) bound 
specifically to one E l dimer (192,000). The presence of this higher Mr 
complex, containing both E l and E3 in apparent 1:1 ratio, represents the first
direct biochemical evidence that the E l and E3 components of mammalian
:OGDC physically interact with each other.
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5.2.4 Immunological analysis of E l antisera cross­
reactivity
The evidence from the association state analysis details the interaction 
between E l and E3 of mammalian OGDC, It would appear that E l is 
responsible for E3 binding to the multienzyme complex. In this respect it is 
functionally equivalent to protein X  in mammalian PDC and E2 in prokaryotes. 
Immunological analysis employing El anti-sera, cieaiiy demonstrates a cross 
reactivity with the E2 component of mammalian PDC; as well as a strong 
specific response to the E l component of OGDC (Figure 5.5, panel a). In 
addition to this it is possible, employing mammalian protein X antisera, to 
demonstrate a specific cross-reactivity with the E l component of mammalian 
OGDC (Figure 5.5, panel b). Sequence similarities between E l of OGDC and 
mammalian E2 and protein X have already been documented (Rice et al., 1992). 
This immunological evidence indicates that such similarity extends beyond 
primary structure and that the three proteins share related antigenic epitope(s).
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Figure 5.5 Immunological analysis of OGDC E l cross-reactivity
Purified PDC and OGDC were subjected to SDS-PAGE and subsequent immunological 
analysis with anti-El (lanes 1-2, panel A) or anti-protein X (lanes 3-4, panel B) serum, 
identical quantities of each multienzyme complex was loaded (5pg). Lanes 1 and 3 
mammalian PDC. Lanes 2 and 4 mammalian OGDC. (Performed by Dr S.J. Sanderson)
5.3 Discussion
Previous proteolytic studies and subsequent N-terminal sequencing located 
a lipoyl-like domain within the N-terminal region of El of mammalian OGDC. 
Selective proteolysis of El with trypsin led to the release of an N-terminal 
peptide (Mr 10 000) and abolition of E3 binding; indicative that the E3 binding 
capacity of mammalian OGDC rests within the El component (Rice et al, 
1992).
Initial protocol development to dissociate OGDC into E2 and E1/E3 
fractions focused on the adaptation of the high salt dissociation protocol 
designed for the dissociation of PDC into its E2/X and E1/E3 fractions. While 
this met with some success in isolating the E3 component away from OGDC, 
the E l component remained tightly associated with the E2 core (results not 
shown). Attempts to use low nondenaturing levels of GdnliCl were also 
unsuccessful. However, reactivation studies carried out on intact OGDC 
indicated that there was some effect on multienzyme stracture following 
treatment with IM MgCl2 combined with mildly alkaline conditions (pH 7.6). 
Moreover, in contrast to more alkaline conditions, this did not abolish all of the 
OGDC activity. The successful dissociation, reported here, of mammalian
OGDC into its E2 and E1/E3 fractions uses the combination of high levels of
MgCl2 and slightly alkaline pH to achieve optimum resolution. Under the
'dissociative conditions employed it is clear that the El and E3 components are 
not interacting, presumably as a result of the high ionic strength of the column 
running buffer.
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An important criterion, on which the success of the OGDC dissociation was 
judged, was that it produced the components which maintained their native 
structure and were thus functionally active. Reconstitution analysis provides a 
good indication if this is achieved. The observed levels of reconstitution 
achieved (30%) are appreciably lower than those achieved with the E2/X and 
E1/E3 fractions of PDC of 60-80% (Sanderson et ah, 1996b). However given 
the functional overlap between OGDC El and PDC protein X the two 
reconstitution protocols are not equivalent, with considerably harsher treatment 
required to remove the El from the E2 core of OGDC. No method for removing 
protein X from the B2 core and maintaining its activity has been found. Given 
the possible functional overlap between the two proteins it is interesting to note 
that both E l of OGDC and protein X of mammalian PDC are very tightly 
associated with their respective E2 cores. Recent structural studies of the E2/X 
core of Saccharomyces cerevisiae position the protein X binding sites at 12 
large openings in the E2 core structure (Stoops et al, 1997). Similar studies on 
mammalian OGDC may be employed to shed light on whether the E l 
homodimers are positioned in a similar fashion.
Structurally, mammalian OGDC is built upon a structural E2 lattice which
forms 24meric core exhibiting octahedral symmetry. The absolute number of El
and E3 homodimers associated with the E2 core has not been determined in
mammalian systems. However, studies of E. coli OGDC, which also has an
octahedral 24meric E2 core, report a chain ratio E1:E2:E3 of 0.5:1.0:0.5 (Reed
1974). This suggests that the E l and E3 may be present in equimolar ratio with
6 homodimers of each component assoeiated with the E2 core of mammalian
OGDC. Gel permeation analysis of the E1/E3 fraction, under low salt
associative conditions, was successful in isolating a higher molecular mass
complex (Mr 303 000) corresponding to a El:E3 complex exhibiting 1:1
stoichiometry. The presence of an apparent excess of E3 may reflect loss of
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some of the El component during the course of the protocol. Analysis of the rat 
and human succinyltranferase (E2) genes indicate that the domain typically 
involved in E3 binding is absent from the sequences.(Nakano et a l, (1991) and 
(1993). In human B CO ADC E2, the enzyme with which the OGDC E2 genes 
exhibit a very high degree of similarity, the domain responsible for E3 binding 
is coded within a single exon (Lau et al, 1992). It is likely that the loss of this 
exon, along with the surrounding introns occurred during the evolution of 
mammalian OGDC E2. However, the evidence that E l can physically interact 
with E3 is indicative that this E3 binding role now rests within the 2- 
oxoglutarate component in mammals.
Subsequent immunological analysis confirmed that antisera, specific for the 
E l component of mammalian OGDC, also recognises antigenic epitope(s) on 
mammalian E2 of PDC. Protein X antisera was also able to specifically detect 
OGDC E l. Digestion of OGDC, with the protease trypsin, has been shown to 
produce a veiy specific cleavage of the E l component into an enzymatically 
active C-terminal E l’ fragment (Mj- 100, 000) and a stable peptide (Mr 10,000). 
Interestingly, the peptide was responsible for the major proportion of the 
immunogenic response elicited; owing to its lipoyl-like structure (it is not 
however lipoylated) (Rice et al, 1992). Indeed, high immunogenicity is a 
characteristic of lipoyl domains which are implicated in the auto-immune 
disease, primary billiary chirrosis (for a review, see O’Donohue & Williams
1996). Thus, the cross-reactivity observed, between the El OGDC antisera and 
the E2 of PDC, is indicative of some sequence similarity. Since the E3 
(dihydrolipoamide dehydrogenase) component is common to all mammalian 
multienzyme complexes, it is not surprising that similar sequence motifs/domain 
stmctures appear to be present on the subunits involved in its binding.
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In mammalian OGDC the binding of E3 to the complex is not mediated by 
the E2 component, as in other 2-oxoacid dehydrogenase complexes, since the 
protein lacks the domain involved in E3 binding. In contrast to PDC from 
higher eukaryotes, the E3 binding role in OGDC has not been transferred to a 
separate gene product (protein X). Instead, it would appear that the E l of 
mammalian OGDC is a multifunctional enzyme; responsible for binding the E3 
component to the complex and carrying out the oxidative decrboxylation of 2- 
oxoglutarate. Recent identification of the odhA gene from Corynebacterium 
glutamicum , coding for the E l component of OGDC, revealed an N-terminal 
extension with sequence homology to E2s from PDC and OGDC, albeit to their 
C-termini (Usuda et al, 1996). The authors intimate that this may represent a 
degree of bifunctionality in this El protein. Thus, the catalytic role of 
mammalian OGDC El in the oxidative decai’boxylation of 2-oxoglutarate is 
supplemented by a second functional one of binding the E3 eomponent to the 
multienzyme complex.
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Chapter 6
1
Identification and cloning of bovine SP-22, a putative thiol specific antioxidant protein associated with mammalian PDC
•Ï
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6.1 Introduction
Since most organisms exist in an aerobic environment, there has been a 
need to develop mechanisms to prevent or limit damage to cellular components 
resulting from reactive oxygen species. To combat this, a variety of enzymatic 
and non enzymatic antioxidant systems have been developed. The list of 
molecules with antioxidant properties include glutathione (GSH), superoxide- 
dismutase, catalase, glutathione peroxidase. These and others, depending on 
their specific function and localisation, are involved in protection, prevention, 
interception and repair. Reactive oxygen species aie generated naturally within 
the cell during respiration. However, conditions in which the levels of oxidants 
strain the capacity of the antioxidants to deal with them has been tenned 
oxidative stress (Sies, 1997).
Although all the cellular compartments have to defend themselves against 
the deleterious effects of reactive oxygen, it is the mitochondrion more than any 
other organelle which is particularly vulnerable. This susceptibility primarily 
results from its central role in respiration. Indeed over 90% of the molecular 
oxygen utilised by the organelle is reduced to water (Stacpoole, 1997). During 
these reactions a number of potentially damaging molecular species are formed. 
The species formed as a result of the incomplete reduction of oxygen include; 
hydrogen peroxide (H2O2); the superoxide anion radical (0 2 *“); the hydroxyl 
radical (HO-) and hydroxyl anion (HO"). There are also other ways to produce 
reactive oxygen including, light, UV radiation, redox-cycling drugs and the 
stimulation of host phagocytes (Chae et al, 1994). Of further consideration is
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that cellular processes also generate reactive sulphur species (RS, RSSR",
RSOO) from thiol containing compounds capable of damaging cells.
The reactive oxygen and sulphur species damage all the major classes of 
biological molecules. Periods of oxidative stress can lead to DNA damage, both 
in terms of base modifications and strand breaks. Mitochondrial DNA has been 
shown to be particularly vulnerable, probably as it lacks the protection 
potentially afforded by histone proteins to the nuclear genome (Wallace, 1992).
It is also possible to cause membrane disraption, lipid peroxidation, and protein 
oxidation. Of particular interest, are conditions which lead to the oxidation of 
proteins which have been implicated in a number of disease states, including 
Alzheimer's disease, Parkinson’s syndrome, cancer and athrosclerosis (see 
Stacpoole, 1997 for review). What remains unclear is whether the protein 
oxidation observed in these pathological states represents a causative effect, or 
merely symptomatic. It is also not understood if such disease states arise from 
an inerease in the levels of reactive species or by lesion(s) in the cellular defence 
mechanisms.
Another medically important condition, in which reactive oxygen species 
play a pathological role, involves tissue injuries which lead to deprivation of 
oxygen and other nutrients. This condition is termed ischaemia. Perversely, 
reperfusion of such tissues, notably brain and cardiac muscle, generates reactive "
oxygen species which contribute to the cycle of mitochondrial membrane/protein 
damage, leading to further free radical generation and more component damage 
(Halliwell & Gutteridge 1990; Bolli, 1988). In particular, PDC activity has been 
shown to be severly compromised following reperfusion, and sulphydryl 
oxidation has been implicated as the major cause of inactivation (Tabatabaie et 
a l, 1996).
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The pyruvate dehydrogenase complex catalyses a key step in oxidative 
glucose metabolism. The product, acetyl CoA, can be utilised to drive a 
complete circuit of the tricarboxylic acid cycle, or used in other metabolic 
processes, notably fatty acid synthesis and, in neurological tissues, 
acetylcholine synthesis. PDC and PDC kinase have both previously been shown 
to have their thiodisulphide status altered by free radical agents (Crane et al, 
1983; Paetzke-Brunner & Wieland, 1980 and Petit et al, 1982). General free 
radical scavengers do exist within mitochondria and indeed, roles have been 
demonstrated for glutathione (Reed, 1986) and superoxide-dismutase (Sies & 
Moss, 1978). However, potential requirement of additional thiol specific 
antioxidant systems within this compartment can be easily reconciled with the 
known sulphydryl group sensitivity af many mitochondrial enzymes, including 
the family of 2-oxoacid dehydrogenase multienzyme complexes.
In this chapter we identify SP-22, a recently discovered mitochondrial 
protein (Watabe et ai, 1994), and detail preliminary evidence for its association 
with component(s) of bovine PDC. The protein has been shown to protect free 
radical sensitive enzymes such as glutamine synthase and tryptophan 
hydroxylase in vitro (Watabe et ai, 1995). Recently the protein was proposed 
to be a thioredoxin-dependent peroxide reductase (Watabe et ai, 1997). 
However, to date limited evidence exists for any specific interaction. Also 
reported is the cloning of the protein from full length bovine brain cDNA, 
employing a PCR protocol and primers specific to the database sequence which 
has recently been published (Hiroi et al, 1996). The possibility that this protein 
may be involved in the specific protection of components of PDC from 
adventitious oxidation is discussed.
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6.2 Results
6.2.1 Identification of a 22kDa protein associated with 
mammalian PDC
Purification of PDC from the mitochondrial matrix is performed under 
associative conditions to ensure that the noncovalent assembly of individual 
enzymes remains intact (See Materials and Methods section 2.2.8). SDS-PAGE 
analysis of the purified complex, after high speed centrifugation and subsequent 
resuspension of the pelleted PDC, revealed the presence of a polypeptide (Mr 22 
000) still associated with the multienzyme complex. This was somewhat 
surprising, given that the ultracentifugation step should only pellet large Mr 
complexes. Furthermore, preparative dissociation of PDC into its E2/X and 
E1/E3 fractions saw the partitioning of the polypeptide (Mr 22 000) with the 
E1/E3 fraction (for evidence of this and the association with PDC, see chapter 3 
Figure 3.3b).
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As a result of this, N-terminal amino acid sequence analysis was performed
on the polypeptide (as detailed in Material and Methods section 2.2.6) in an
.attempt to identify it. N-terminal sequence analysis identified the first 24 
residues of the polypeptide and an alignment was found to the N-terminus of the af
mature form of a protein previously sequenced at the amino acid level, bovine 
SP-22 (Watabe et al, 1994). The sequence obtained for the unknown 
polypeptide exhibited a 86% identity in a 24 amino acid overlap (see Figure 
6.1). The discrepancies between the two sequences occur among the
penultimate residues in the N-terminal sequence for the unknown protein. This
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probably results from difficulties in ascribing residues, either as a result of 
sample quantity, or build up of contaminants. However, the level of identity 
between the polypeptide (Mr 22 000) and bovine SP-22 was felt sufficient to 
make a positive identification.
SP-22 had been initially identified as a substrate for an ATP dependant 
protease (Watabe et al, 1994). The study used the strategy of proteolytic 
digestion and amino acid analysis to produce a polypeptide sequence. However, 
a novel cysteine derivative, cysteine sulphonic acid (S-O2H), was identified by 
FAB (fast atom bombardment) mass spectrometry. This led to speculation that 
the protein may perform a redox role.
Further details of the potential interaction between the polypeptide, now 
identified as SP-22, with components of the PDC complex came from the anion 
exchange protocol developed to separate the E l and E3 enzymes (see Materials 
and Methods section 2.2.10). It has already been stated that SP-22 co-elutes 
with the E1/E3 fraction during high salt gel peimeation chromatography. 
Subsequent anion exchange chromatography and SDS PAGE analysis of the 
fractions/pools demonstrate that the polypeptide remains associated with a 
fraction of the E3 eluted from the Mono Q column (See chapter 3, Figure 3.6b). 
The presence of SP-22, still associated with E3 of PDC, suggests that the two 
components interact. It may also indicate a possible thiol protection role for SP- 
2 2 .
Sequence alignment of the amino acid sequence of SP-22 with proteins 
present in the data base enabled the definition of key conserved regions around 
the active cysteines, and indicated that SP-22 belonged to a family of antioxidant 
proteins already diseovered and related to the mouse MER5 gene (Chae et al, 
1994 and Tsuji et al, 1995). Figure 6.2 details the levels of identity exhibited
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by the family/superfamily members with the MER5 gene product. It is clear that 
SP-22 has one of the highest levels of identity (86%) which extends over the 
entire polypeptide. Interestingly, SP-22 and MER5 are mitochondrially located 
proteins; in contrast to the majority of other family members. Recent alignment 
data (Hiroi et ai, 1996) shows that both the MER5 and SP-22 presequences 
have the propensity to form amphiphilic a  helical structures of the sort readily 
associated with mitochondrial import and signal peptide cleavage (von Heijne et 
al, 1989, and Rusch & Kendall, 1995). Another mitochondrial protein, Aopl, 
as well as showing a high degree of similarity to MER5, displays 88% identity 
to SP-22. This would indicate that the Aopl protein represents the human 
homologue of SP-22. Expression of the Aopl protein in a mutant E. coli strain, 
deficient in the alkylhydroperoxide reductase (ahpC), was sufficient to rescue 
resistance to alkylhydroperoxide (Tsuji et al, 1995).
Figure 6.2 also demonstrates the conserved nature of the region 
surrounding the two potentially catalytically important cysteines. Region 1, 
consisting of seven amino acids around cys 47 in the mature form of SP-22, 
appears to be absolutely conserved, except for a single amino acid variation in 
the Arch protein in M. thermoautotrophicum. This residue has been shown to be 
a sulphonic acid derivative (Cys-S-O^H) in SP-22 by fast atom bombardment 
and mass spectrometery of the appropriate peptide fragment (Watabe et al, 
1994). Recent speculation (Watabe et al, 1995) is that this represents an active 
Cys-S-OH two electron redox centre in vivo . Although the level of amino acid 
conservation around region 2 is lower, it remains nonetheless significant and 
may indicate a second active thiol centre within the polypeptide.
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6.2.2 The cloning of bovine SP-22: PCR amplification  
and product purification
:
■
In order to further study the SP-22 protein it was felt necessary to obtain a 
clone. The protein had been previously purified from bovine adrenal cortex 
(Watabe et al, 1994), although the same study had detected its expression in 
other tissues, including liver and heart, by radioimmunoassay. Since the protein 
was expressed at high levels in bovine brain, full length bovine brain cDNA 
was chosen as a suitable substrate for the specific amplification of the SP-22 
coding sequence. This was commercially available (Clonetech) and removed the 
need to prepare cDNA by mRNA isolation and cDNA synthesis. A search of 
nucleotide sequence databases was successful in locating the cDNA sequence 
coding for the protein, despite the absence of any such sequence in the 
published literature. This enabled the design of specific primers. Figure 6.3 
details the primers which were designed to the 5' region upstream of the ATG 
start site and to the 3' region of the coding sequence including the translation 
stop codon of SP-22. The primers were designed to have similar dissociation 
temperatures and GC contents in the recommended 40-60% region. The primer 
sequences were also checked for both inter and intra primer complementarity 
using Gene Jockey software. In particular the 3’ regions were compared to 
reduce the possibility of primer-dimers. In order to minimise the tolerance of
,mismatch neither primer had a T at its 3' terminus.
The PCR reactions were performed with the Expand High Fidelity PCR
system (Boehringer Mannheim) in an attempt to minimise base
misincorporation. The system contains, as well as Taq polymerase, Pwo DNA
polymerase which exhibits 3'-5' exonuclease proof-reading activity. Mixtures : i
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SP-22 primer 1
5'aTAACG AAG m g  (pCG GCC AC^'
3't AT TGC TTC TAG CGC CGG TGC CGC CCT TCC^' 
SP-22 cDNA
SP-22 primer 2
5'g AC GGT CTA CTG ATT TAG CTT CTC^'
3'CTG CCA (SAT|GAC TAAATG GAA GAG TTT TAT G A 5 
SP-22 cDNA
Primer length (bp) %GC Tm (°C)
Primer 1 20 55 60
Primer 2 24 46 60
Figure 6.3 Specific primers designed to amplify the coding region of SP-22 (820bp) 
from bovine cDNA.
Primeis were designed using Genejockey software to amplify the entire SP-22 coding 
region by PCR. Included in the primer pair are translation start and stop codons (indicated 
as boxed regions in the sense cDNA).
of the two thermostable enzymes have been shown to reduce the error rate at 
least three fold; while maintaining high yields of PCR product. PCR 
amplification was performed using the bovine brain cDNA and the primer pair 
detailed in Figure 6.3 (details of the PCR protocol are given in Materials and 
Methods section 2.4.5). Figure 6.4 illustrates the product obtained by PCR 
(Lane 3) migrating on a 2%(w/v) agarose gel. The absence of reaction 
component contamination was confirmed by the lack of amplified product in the 
control reaction without any template DNA (Lane 2). However, the PCR 
reaction components were functional; i.e. capable of generating the expected 
200bp fragment, using specific primers, from the pBluescript plasmid (Lane 1). 
The PCR reaction with bovine cDNA template resulted in the production of a 
number of DNA products of varying sizes (apparent sizes 270, 800 and 820bp. 
Lane 3). No primer-dimers were detected. The major product had an apparent 
size of 820bp, identical to that predicted from the database cDNA sequence for 
SP-22 (Figure 6.4). The presence of smaller amplified fragments may result 
from mispriming events during early cycles. Alternatively, amplification may 
reflect the presence within the template DNA of other sites, possibly coding for 
homologues of SP-22, for which the primers have the ability to anneal under the 
conditions of the PCR.
The large 820bp fragment was excised from an agarose gel, under UV, 
using a sterile scalpel. The DNA was then purified by means of a GenElute 
agarose spin column (Supelco) and subsequent ethanol/sodium acetate 
precipitation (for full details refer to Materials and Methods seetions 2.4.3 and 
2.4.6). An aliquot of the resuspended DNA was subjected to electrophoresis on 
a 1.5% (w/v) agarose gel to determine the quantity and quality of PCR product 
recovered. Figure 6.5 shows that the PCR product appears as a single band, 
running slightly bigger than the 800bp marker and that no contamination with 
other DNA fragments is apparent. A low M  ^ ladder (Gibco) was used to
124
bp
800
400
200
1 2  3 M
Figure 6.4 PCR amplification of the nucleotide sequence encoding 
SP-22 from bovine brain cDNA
Bovine brain cDNA (Clonetech) served as a template for amplification using the 
Expand PCR System (Boehringer Mannheim). The PCR reaction contained;
Ing of cDNA, 0.2pM of each primer 1 and primer 2; 200pM dNTPs; 1.5mM 
MgCl2: 2.6U of expand high fidelity PCR system enzyme mix. The PCR 
cycling conditions were as follows; 1 x 5min at 95°C; 30 x [55°C for 3min; 
65°C for 3min; 95°C for 30sec]; 1 x 65°C for 2min; 1 x 72°C for 5min. The 
products were analysed on a 2% (w/v) agarose gel.
1; Positive DNA control (pBluescript + M13 forward and reverse primers), 2; 
Negative DNA control (template DNA omitted), 3; Bovine brain cDNA 
template, M; 50 base pair ladder.
200 -
I I
1 2
Figure 6.5 Quantification of recovery and size determination of 
amplified DNA fragment
The major product of two PCR amplification reactions with bovine cDNA (as 
detailed in Figure 6.4) were excised from an agarose gel using sterile 
conditions. The DNA was eluted from the agarose plug using Gen Elute 
columns (Supelco) and precipitated using sodium acetate/ethanol. For 
quantitative recovery of DNA, the DNA pellets were resuspended overnight in 
20pl of TE buffer at 4°C. Samples (5pl) of each purification were analysed on a 
1.5%(w/v) agarose gel.
M: Mass ladder 200, 400, 800, 1200, 2000 base pairs (corresponding to 
20,40, 80, 120 and 200ng of DNA, lanes 1+ 2 Duplicate samples of DNA 
(5pl) recovered and prepared as detailed above.
6.2.3 The cloning of bovine SP-22: product ligation, 
bacterial transformation and transformant identification
DNA fragments amplified using Taq polymerase typically exhibit single 
deoxyadenosine (A) overhangs at their 3' termini. While this facilitates cloning 
of PCR fragments into plasmid vectors which can be cleaved to generate 3' T 
overhangs (TA cloning kit Invitrogen), the cloning of such fragments in a blunt 
ended fashion requires a prior polishing step. To this end, the pCR-Script 
Cloning Kit (Stratagene) was chosen as a suitable vector system to ligate in the 
purified PCR fragment containing the coding region of SP-22 (Figure 6.6). 
Clones which contained the vector could be selected for by plating out on agar 
plates which contained the antibiotic ampicillin. Detection of positive clones 
which contained an insert was afforded by blue/white screening on an IPTG/X- 
Gal background. The vector also contained transcription initiation sites (T7 and 
T3). These would allow the detection of clones which were capable of 
producing a protein product in an in vitro transcription/translation system (see 
later).
estimate that an approximate yield of 40ng of DNA in the 5p,l of resuspended 
DNA loaded from two purification procedures. Thus the total recovery of DNA 
in 40p.l was 320ng.
Due to the inefficient nature of blunt end ligation reactions it is important 
that the insert:vector ratio is high (typically between 40:1 and 100:1). 
Unfortunately, in this instance the insert DNA was too dilute to deliver such 
ratios in the ligation reaction; to permit adherance to the volume limits of the 
polishing step. Therefore, the ligation reactions were performed with
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insert:vector ratios of 5:1 and 10:1. This represented the only change with the 
manufacturer's protocol (see Materials and Methods, section 2.4.7).
Following fragment polishing, ligation into pCR-Script and transformation 
into Epicurian Coli XL 1-Blue MRF' Kan supercompetent cells was performed. 
Subsequently, bacteria were plated out on LB/agar plates containing ampicillin 
(50|Lig/ml), X-gal (20p.l of 10% (w/v) stock) and IPTG (20pl of 0.2M stock). 
The plates were left overnight at 37°C to allow for colony development. 
Examination of the plates revealed the presence of bacterial colonies, with >90% 
of the colonies appearing white (transformed) under the conditions of the 
IPTG/X-Gal detection system . Twelve clones (C l-C l2) were picked from a 
suitable plate and grown in 5ml LB/ampicillin (25p.g/ml) suspension cultures 
overnight. Following this, plasmid DNA from the twelve overnight cultures 
was prepared using the Wizard Mini plasmid prep system (Promega).
Analysis of yield and plasmid purity is detailed in Figure 6.6. Typically, 
values of 1.8 to 2.0 for 260/280nm ratios represent relatively pure preparations 
of DNA/RNA. The plasmid samples prepared using the Wizard mini preps give 
variable values ranging between 1.2-3.0. This probably represents 
contamination of the plasmid preparations with protein as a result of the alkaline 
lysis based protocol. Phenol, which also absorbs at 280nm, is not used in the 
protocol so possible sample contamination with this can be eliminated.
However, the yields of plasmid DNA are generally very high (15-20|ig) Indeed, 
this may be part of the problem with the purity levels observed. The yields of 
plasmid DNA are known to depend on the plasmid copy number and the host 
strain. The high copy number of pCR-script (which contains the colEI origin of 
replication) probably contributes to the high yields, but compromised purity, of 
the plasmid DNA samples.
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It was also observed that two of the overnight cultures (C9 and C6) did not 
grow to the same density as the other cultures. This may explain the relatively 
low plasmid yields obtained from these two cultures. Glycerol stocks were 
prepared from all the overnight cultures and stored at -80°C. The plasmid 
preparations were also stored at this temperature.
6.2.4 Identification of clones containing the correct 
insert: plasmid single digest.
Having purified plasmid from potential SP-22 transformants, as determined 
by blue/white selection on IPTG/X-gal containig media, a strategy was
Ideveloped which would identify those clones which contained an insert. Since 
the control plasmid (pBluescript Stratagene) exhibits a size (2960bp) almost 
identical to the vector into which the purified PCR product was ligated pCR- 
script (2961bp), the presence of larger linearised plasmids should indicate that 
these clones contain inserts. A suitable restriction enzyme for this would: be 
efficient at cleaving supercoiled plasmids; have a unique restriction site within 
the plasmid; would lack a restriction site within the cloned insert. The restriction
I
enzyme Bam HI was identified by restriction analysis of the plasmid and insert 
sequences, using the programme Genejockey, as fulfilling the criteria outlined 
above. It was used to digest samples of control plasmid and the purified plasmid 
from clones 1-12 (C l-C l2). The products of the digestion and samples of uncut 
plasmid were analysed by electrophoresis on a 0.8% (w/v) agarose gel (Figure
6.7 panels 1-3).
The assay utilises the fact that a supercoiled plasmid usually migrates more
rapidly through the agarose gel matrix than its linearised counteipart. In Figure
6.7 (panel 1) all the plasmids appear to be cleaved by Bam HI ; the majority of
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the linear versions (lanes 6, 7, 10, and 11) exhibit the same size as the cut 
control pBluescript (lane C). However, it is evident that the supercoiled version 
of the C3 clone (lane 4) migrates to the same position as the lineaiised control 
plasmid and that cleavage of C3 produces a linearised product much larger than 
the control (lane 9). The presence of salt in the digest samples probably results 
in the poor resolution of the DNA markers, thus preventing a more quantitative 
determination of the plasmid sizes. In addition the cleaved plasmid product from 
the C4 clone produces two products (lane 8), one of which is larger than the 
linearised control vector. It may be that, in this clone, there are two populations 
of plasmid, one of which contains an insert.
■d
The restriction digest used to examine clones 1-6 (C1-C6) was also 
employed to analyse the remaining clones 7-12 (C7-C12). Figure 6.7 (panel 2) 
details the electrophoretic analysis of the assay. Of the plasmids analysed in Gel 
2 only the C7 (lanes 5 and 6) clone contains a linearised plasmid which is bigger 
than the control. There is also some evidence that the digestion of the plasmid 
purified from clone C8 (lanes 3 and 4) did not go to completion. There also 
appears to be very little plasmid present in the preparation from clone C9 (lanes 
1 and 2). This concurs with the data for a low plasmid yield (0.26pg/pl) from 
the clone presented in Figure 6.6. Analysis of plasmid digests in Figure 6.7 
(panel 3) reveals the presence of another clone CIO (lanes 5 and 6) which may 
contain an insert. However it does not appear to be as large as the other insets 
detected.
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Figure 6.7 Bam Hl restriction analysis of the pCR-Script 
plasmids, potentially containg the coding region of SP-22, 
purified from clones C1-C12
4|U.l plasmid DNA (1. l-2.1pg) was digested in each reaction with 12U BamHl 
(Boehringer Mannheim) in the appropriate buffer (lOmM Tris/HCl, pH 8.0, 
100 mM NaCl, 5mM MgCl2, ImM 2-mercaptoethanol) at a final volume of 
20pl for 2h at 31°C. Incubations of control (uncut) plasmid took place in the 
same buffers and under the same conditions in the absence of BamHl. After 
2h, 5pl sample loading buffer (40% (w/v) sucrose, 0.25% (w/v) bromophenol 
blue) was added to each reaction and samples subjected to analysis by 0.8% 
(w/v) agarose gel electrophoreisis.
Panel 1
1: C6 undigested, 2: C5 undigested, 3: C4 undigested, 4; C3 undigested, 5: C2 
undigested C: control (pBluescript digested), 6: C6 digested, 7: C5 digested, 8: 
C4 digested, 9: C3 digested, 10: C l digested, 11: C2 digested, 12: Cl 
undigested, M: Hind m  digest of phage X DNA
Panel 2
C: control (pBluescript digested), 1: C9 digested, 2: C9 undigested, 3; C8 
digested, 4: C8 undigested, 5: C7 digested, 6: C7 undigested, M: Hind HI 
digest of phage X DNA
Panel 3
C: control (pBluescript digested), 1: C12 digested, 2: C12 undigested, 3: C l 1 
digested, 4: C ll  undigested, 5: CIO digested, 6: CIO undigested, M: Hind III 
digest of phage X DNA
Panel
bp
2960 -
1 I I I2 3 4 5 I I I I I I I I 6 7 8 9101112M
Panel 2
bp
2960
C 1 2  3 4 5 6
Panel 3
b p
2 9 6 0 -
C  1 2 3 4  5 6
6.2.5 Identification of clones containing the correct 
insert: excision of insert by double digestion t
While the single plasmid digest assay had been successful in the possible 
identification of clones which contained an insert, the results remained 
inconclusive. In order to identify clones containing an insert of the expected size 
it is possible to reamplify the fragment inserted within pCR-Script using PCR 
and the original SP-22 primers. Two disadvantages of this method are (i) 
possible contamination of the template DNA with salts/ions which could inhibit 
the PCR (ii) the need to re-optimise the PCR conditions, A simpler and quicker 
approach employs excision of the insert using two restriction enzymes selected 
for unique clevage sites at the immediate 5' and 3' loci of the insert. These 
enzymes, if no cleavage sites are present within the insert DNA, should release 
the insert fragment and allow its size to be determined. The restriction enzymes 
Notl and Xhol were chosen as suitable partners for a double digest. They 
exhibit their endonuclease activity in similar ionic strength and are able to cut 
supercoiled plasmid DNA efficiently. Both enzymes cleave within the multiple
respect to insert DNA and Xhol cleavage is 3'. The nucleotide sequence for the
cloning site of pCR-script (Figure 6.6); specifically Not 1 cleavage is 5' with
coding region displays no suitable cleavage sites for either enzyme.
Double digest restriction analysis of purified plasmid from clones C1-C6 is 
presented in Figure 6.8a. The inclusion of a linearised pBluescript control (lane 
10) illustrates that all digests have been successful in producing linear versions 
of the plasmids purified from the six clones. The double digest released an 
insert from plasmids derived from the C3 and C4 clones. The size of this
product would appear to be approx. 840bp, as determined by its migration on a
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Figure 6.8a Restriction analysis, employing a Not 1/Xho 1 double 
digest, of plasmids derived from clones C l-6
3|il of plasmid DNA (0.8-1.5pg) was digested in each reaction with I OU Xho 
1 and 5U Not 1 (New England Biolabs) in 50mM Tris/HCl, pH 7.9, lOOmM 
NaCl, lOmM MgCl%, ImM DTT, supplemented with BSA to a final 
concentration of lOOpg/ml. Digestion was in a final volume of 50pl at 37°C for 
2h. Subsequently, lOpl agarose sample buffer was added to each reaction tube 
and the samples subjected to analysis on a 2% (w/v) agarose gel.
M l: 50 base pair ladder, C: Control (pBluescript digested), 1: C6, 2: C5, 3: C4 
, 4: C3, 5: C2, 6 C l, M2: DNA 111 molecular mass markers (Boehringer 
Mannheim).
bp
______________________________ 947800
400 
200
C 1 2 3 4 5 6 M2
Figure 6.8b Restriction analysis, employing a Not 1/Xho 1 
double digest, of plasmids derived from clones C7-12
3pl of plasmid DNA (0.8-1.5pg) was digested in each reaction with lOU Xho 
1 and 5U of Not 1 (New England Biolabs) in 50mM Tris/HCl, pH 7.9, 
lOOmM NaCl, lOmM MgCl%, ImM DTT, supplemented with BSA to a final 
concentration of lOOpg/ml. Digestion was in a final volume of 50pl at 37°C for 
2h. Subsequently, lOpl agarose sample buffer was added to each reaction tube 
and the samples subjected to analysis on a 2% (w/v) agarose gel.
Ml; 50 base pair ladder, C: Control (pBluescript digested), 1; C l2, 2: Cl 1, 3; 
C I O, 4: C9, 5: C8, 6 C7, M2; DNA 111 molecular mass markers (Boehringer 
Mannheim).
Identical double restriction digest analysis was performed on plasmids 
purified away from the remaining six clones (C7-C12) (Figure 6.8b) . In this 
instance, a further single clone, CIO (lane 3) was identified as containing an
2% (w/v) agarose gel. The inclusion of some of the plasmid linker region DNA 
on the fragment excised provides an explanation for the apparent increase in 
insert size over the expected 820bp product. It is noticeable that considerably 
less of the fragment is produced in the C4 digest (lane 3) in comparison to the 
C3 one (lane 4). The low quantity of plasmid DNA derived from C6 derives 
from its poor growth in overnight culture and subsequent low plasmid yield 
(Figure 6.6)
'
insert of between 831 and 947bp. These results taken together with the single
plasmid digests performed earlier strongly indicate that Clones C3, C4, and CIO 
all contain the desired insert, coding for the entire amino acid sequence of the 
antioxidant protein SP-22.
6.2.6 In Vitro expression of cloned SP-22:Insert 
orientation analysis
s
The results from the restriction analysis of the clones C3, C4 and CIO has 
identified these clones as containing the appropriate insert. However, as the 
cloning of the PCR product into the pCR-script vector was achieved by blunt 
end ligation, the orientation of the clones within the plasmid remains uncertain.
One method to define the orientation involves a series of restriction enzyme 
double digests, using at least one enzyme which cuts within the SP-22 
nucleotide sequence. The analysis of the results of the various enzyme 
permutations would allow determination of the insert orientation.
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A more elegant and clear-cut alternative to insert orientation is the use of a 
transcription/translation reaction system, specific for one of the two 
transcription initiation sequences which flank the insert site. An additional 
advantage is this would also allow the identification of clones which contain the 
correct translation start and stop codons and are capable of producing a protein 
product. To this end the single tube protein system (Novagen) was employed. 
The system can be used for the direct synthesis in vitro of protein products 
from supercoiled plasmids. Transcription is dependent upon the presence of a 
bacteriophage T7 RNA promoter. The pCR-Script vector contains this promoter 
3' relative to the insert site.
The in vitro transcription/translation reaction was earned out (see Materials 
and Methods section 2.4.12) on four of the clones C2, C3, C4, CIO. The first 
control reaction was an in vitro transcription/translation reaction carried out in 
the absence of any DNA template. Also included, was the control reaction 
supplied by the manufacturers; STP2 T7 control DNA which produces a 119 
000 Mr product. The products of the reactions were labelled by the 
incoi'poration of methionine into the protein product. Detection of the 
radiolabelled products was achieved, following resolution by SDS PAGE, by 
fluorography.
Figure 6.9 illustrates the production of a protein band, slightly less than 30 
000 M r, in the reaction which included plasmid DNA from C3 clone as a 
template (Lane 2). It has already been stated that the mature form of the SP-22 
protein, appears as a 22 000 Mr band on a 10% (w/v) SDS-PAGE gel. However, 
the sequence cloned includes the nucleotide sequence which codes for the 
mitochondrial import pre-sequence. This adds a further 60 amino acids to the 
protein product, giving an expected mass of 28 000 M,-. This is consistent with
the protein product formed from C3 plasmid DNA (lane 2). No other protein
a
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6.9 SDS-PAGE separation and fluorographic detection of the 
[^^S]-methionine labelled products derived from in vitro 
transcription/translation reactions, employing plasmids purified 
from clones C2, C3, C4 and CIO as template DNA.
In vitro transcription/translation using plasmids from the clones detailed above 
was carried out using the single tube protein system (Novagen) according to 
manufacturer's instructions (see Materials and Methods section 2.4.12). Protein 
products were labelled by the inclusion of [-^^SJ-methionine in the translation 
reaction. Reactions (5jll each + 20|Lil Laemmli sample buffer) were subjected to 
SDS PAGE on a 10% (w/v) gel. The gel was fixed in 25% (v/v) isopropanol: 
65% (v/v) distilled water: 10% (v/v) acetic acid for 30 min and rinsed with 
distilled water. The gel was immersed and agitated slowly for 30 min in 
Amplify (Amersham Life science) to aid fluorographic detection before being 
dried under vacuum. Products were detected on Hyperfilm ECL (Amersham).
1: C2, 2: C3, 3: C4, 4: CIO, C l: Control reaction 1 (no template DNA), C2: 
Control reaction 2 (STP2 T7 control DNA )
f:':
products were detected in the reactions derived from plasmid DNA purified from 
the putative clones. While clone C2 (lane 1) was included only as a negative 
control (previous analysis had indicated that it did not contain any insert), the 
absence of any product corresponding to clones C4 (lane 3) and CIO (lane 4) may 
provide evidence that the inserts present in these clones do not function from the 
TV promoter. Instead, it is probable that they are inserted in the reverse fashion.
' - IThe control reaction in the absence of template DNA (lane 5) did not 
produce any protein product of the correct size. This demonstrates that there are 
no DNA substrates endogenous to the reaction system capable of producing the 
product produced from the C3 clone. Thus, only the insert cloned into the 
plasmid derived from the C3 clone has been shown to produce produce mRNA 
possessing the necessary start and stop codons to generate the desired protein 
product of the correct mass, as determined by SDS-PAGE
Subsequent work in the laboratory has introduced the SP-22 sequence into 
the pGEX-5X-l expression vector (Pharmacia).The system allows for the 
expression of the SP-22 protein as a GST fusion and facilitates a single step 
purification on a Glutatione Sepharose 4B column. Following purification, it is 
possible to cleave SP-22 from its GST fusion partner using factor Xa, a site 
specific protease. Gel peimeation analysis of the SP-22/GST fusion in a crude
;extract of E. coli JM109 expressing the reveals a shift in GST activity to an 
apparent higher Mr (U Sattler, personal communication). This is probably a 
reflection of the higher Mr of the SP-22/GST fusion when compared to GST 
alone. Further work aims to examine the assembly state of SP-22 and determine 
the nature and specificity of its interactions with the component enzymes of the 
mammalian 2-oxoacid dehydrogenase multienzyme complexes.
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6,3 Discussion
thioredoxin and Nbs2 reductase, had the ability to protect oxyhaemoglobin
against ascorbate-induced damage. It is believed that the cysteine-sulphonic acid
residue may act as a redox centre in such reactions.The E3 (dihydrolipoamide
dehydrogenase) component is a flavoprotein belonging to the disulphide
oxidoreductase family, which also includes glutathione reductase. These
enzymes employ an active site chemistry which involves reactive disulphide
bridge catalysis (for a review see Perham et al, 1995). This may leave the E3
component vulnerable to thiol oxidation. It is interesting to speculate that SP-22
has a more specific role in protecting this and/or other components of
mammalian PDC from adventitious oxidation.
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The presence of a 22 000 Mr polypeptide associated with preparations of 
mammalian PDC has been observed by other investigators (V. Bunick personal 
communication). Until recently, it may have been considered a contaminant, 
despite the fact that the protein remains associated with the large multienzyme 
complex during the final step in PDC purification, involving ultracentrifugation 
of the PDC/PEG supernatant at 200, OOOg for 2.5h. In addition, evidence for a 
more specific PDC component interaction with the 22 000 Mr polypeptide came 
from its ability to remain associated with the constituent E3 enzyme during 
anion exchange chromatography (chapter 3, Figure 3.6b).
IThe significance of the association is underlined by the subsequent identification of the polypeptide as SP-22. This protein has, like PDC, been 
located in the mitochondrial matrix (Watabe et al, 1994) and a putative general 
antioxidant role ascribed (Watabe et al, 1995). A recent report that the protein is 
a thioredoxin-dependent peroxide reductase (Watabe et al, 1997) provided 
evidence that SP-22, along two other protein components, mitochondrial
PDC is responsible for the production of acetyl-CoA, thus priming the 
tricarboxylic acid cycle with substrate and providing reducing equivalents which 
can be used by the respiratory chain to synthesise ATP. It represents a 
vulnerable site for free radical attack and thiol oxidation has been observed in 
other studies (Crane et al, (1983); Paetzke-Brunner & Wieland (1980);Petit et 
al, 1982). In addition, other possible metabolic fates for the acetyl-CoA 
generated, notably the synthesis of the neurotransmitter acetylcholine in 
neuronal cells and fatty acid synthesis in chloroplasts can increase its 
importance. The central role of PDC in carbon metabolism could be used to 
argue for a specific free-radical quenching mechanism. This is a role which in 
future may be definitively ascribed to SP-22.
The presence of the nucleotide sequence of the full length cDNA of SP-22 
in nucleotide data banks facilitated design of specific primers. This sequence 
was subsequently published (Hiroi et al, 1996). Using these primers, it was 
possible to amplify an 820bp fragment, consistent with the size of the known 
nucleotide sequence, by PCR, utilising full length double stranded bovine brain 
cDNA as a template. Other amplified bands may reflect mispriming events in the 
first few PCR cycles and subsequent propagation of these products. 
Alternatively, sequences in cDNA template upon which the SP-22 specific 
primers were capable of annealing may be indicative of the presence of SP-22 
homologues within that cDNA population.
The 820bp fragment was subsequently purified away from other amplified
products, contaminating primers, salts, nucleotides and polymerases. The
isolated product was polished, to remove any 3' deoxyadenosine overhangs,
and ligated, in a blunt end fashion, into the vector pCR-script. Recombinant
clones were identified using blue/white IPTG/X-Gal screening. Plasmids were
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purified from overnight cultures of 12 such clones and subject to restriction 
enzyme analysis. This restriction analysis, utilising both single and double 
digest strategies, was successful in identifying only three clones C3, C4 and 
CIO which appeared to contain the correct 820bp fragment. This is probably a 
result of the low insert: vector ratio used compared to that recommended by the 
manufacturers. Alternatively, the high levels of false positive clones may reflect 
the inability of the restriction endonuclease Srf 1, used to prevent pCR~Script 
from re-circularising. This however does not explain the failure of the X- 
gal/IPTG screen to discriminate between re-circularised plasmid and those 
which contain inserts. It is possible that very small inserts are not sufficient to 
disrupt the lacZ gene but no such inserts were detected in the clones by 
restriction analysis.
The orientation of the three inserts was investigated using an in vitro 
transcription/translation system. The plasmid derived from clone C3 was shown 
to contain an insert capable of producing a 28 000 Mr protein product. This size 
of protein product corresponds to that expected of the preprotein form of SP-22 
which includes a 62 amino acid mitochondrial import sequence.
Further work will require the sequencing of the insert, to confirm its 
identity. The overexpression of the polypeptide as GST fusion protein will 
permit the study of potential protein-protein interactions. These GST pull-down 
experiments and subsequent SDS PAGE analysis could be carried out with cell 
homogenates, or purified candidate proteins such as the individual components 
of mammalian PDC. Furthermore, the purified SP-22 could be used to raise 
specific antisera which may provide a tool to determine the levels of expression 
of this antioxidant protein in mammalian cell lines in response to a number of 
stimuli (heat shock, oxidative/heavy metal stress etc.).
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Chapter 7
General Discussion
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7 General Discussion
7.1 The E2/X core of mammalian PDC
The incubation of mammalian PDC with 2M NaCl and subsequent gel 
peimeation chromatography on a Superose 6 column, equilibrated in IM NaCl, 
produced lai'ge quantities of both E2/X and E1/E3 fractions (5-lOmg of each). 
SDS-PAGE and activity assays confirmed that the levels of cross contamination 
were minimal, with less than 5% of the E l component still associated with the 
E2/X core. The ability of the components to reconstitute PDC activity to high 
levels, typically > 70% compared to native PDC, indicated that the dissociation 
protocol had not caused high levels of component dénaturation.
The production of an E2/X core, containing minimal levels of 
contamination from other PDC components, allowed for further study of the 
folding and assembly of this subcomplex. Initial studies, utilising GdnHCl 
treatment, in conjunction with GPC, was successful in probing the dissociation 
states of this large oligomeric core. Evidence for the co-operative dissociation of 
the E2/X core into two smaller oligomeric states, at discrete concentrations of 
chaotrope, was produced. By calibrating the Superose 12 column with standard 
proteins, the My of the oligomeric species observed could be estimated. These 
corresponded to trimeric and monomeric forms of the E2 component (Wynn et 
al, 1994; Behai et al, 1994).
Further studies with GdnHCl on the E2/X core employed both (i) an 
assay for E2 transacetylase activity and (ii) a PDC reconstitution assay. These
I
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revealed key differences in the ability of a GdnHCl treated E2/X core to recover 
these activities; at higher levels of dénaturant, while transacetylase activity could 
be recovered, PDC activity could not be reconstituted. Subsequent work 
optimised refolding conditions to produce two distinct refolded E2 core types (i) 
produced by rapid dilution (as above), which contained no protein X and (ii) 
produced by a slow dialysis protocol, in which approximately 30% of protein X 
could be re-integrated into the refolded core. The refolded E2 core which 
contained no protein X, as judged by immunological analysis and reconstitution 
studies, was used to investigate the potential latent ability of the E2 component 
to bind E3; the possibility of which had been suggested by previous work in the 
laboratory (Sanderson et al, 1996b).
Reconstitution studies, which used an excess of native E3, purified by a 
protocol developed and detailed in chapter 3, in addition to stoichiometric levels 
of PDC E l, demonstrated the ability of E2 cores, devoid of protein X, to 
reconstitute PDC activity under these conditions. Further experiments, with E3 
components from a range of sources, clearly indicated that the E2 interaction 
with native E3 observed was a specific one.These data offered a biochemical 
explanation for the findings of clinical studies which had identified patients 
suffering from congenital lactic acidosis, resulting from a PDC deficiency, 
specifically an absence of protein X, but who, despite this, displayed significant 
(20%) levels of PDC activity (Geoffroy e ta l, 1996).
The development of an in vitro system of E2/X reassembly should 
permit further elucidation, of what may prove to be, a complex folding and 
association pathway(s). Recent reports which have discussed the ability of each 
E2 component to bind protein X (Maeng et al, 1996) and the apparent cavities
in each face of the E2 core structure which permit protein X binding (Stoops et
al, 1997). However, the mechanism and timing of protein X insertion into E2
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core structures remains to be studied, particularly in view of the oligomeric 
stoichiometery of 5:1 in the E2/X core assembly (Maeng e ta l, 1994; Sanderson 
et al., 1996a). Given that an homology between E2 and CAT has been reported 
(Guest et al, 1987), the isolation of a species with the M^ - equivalent to that of a 
trimeric E2 is significant. It serves to underline the similarities between the two 
proteins and suggests a possible role for the trimeric unit as a functional entity 
within the E2 core. Indeed, crystal structure determination of E2 cores from a 
variety of sources has already disclosed the structural importance of strong 
intra-trimeric interactions (Berg and de Kok, 1997).
Further work on these refolded E2 cores intended to focus on the 
potential catalytic role of protein X within the complex. The recent cloning of 
the protein X gene (Harris et al, 1997), while confirming the M^ obtained for 
the protein by ES/MS in Chapter 3, appeared to eliminate any catalytic function 
for the protein. Protein X sequence analysis indicated that the protein lacked a 
crucial serine residue normally required for acyltransferase activity. However, it 
may be that protein X may have another, as yet undisclosed, catalytic function. 
Future work could concentrate on the proposed role of protein X in the 
association and function of tissue specific PDC phosphatase and PDC kinase 
isoforms (Popov et al, 1994)
7.2 Reconstitution and association studies of mammalian 
OGDC
Previous protocols had not been successful in dissociating appreciable
quantities of the El and E3 components of mammalian OGDC from the B2 core
while maintaining their native (active) states. The combination of MgCl2 and
alkaline pH conditions did promote such a dissociation, the components being
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Iseparated by GPC. Reconstitution studies, with the E1/E3 fraction and the E2 
core, were successful in recovering significant levels of OGDC activity; albeit at 
lower levels than had been routinely obtained for mammalian PDC 
reconstitution. This is probably a reflection of the harsher conditions required to 
dissociate OGDC and their effect on component activity. The dissociation 
protocol did produce sufficient quantities of E l and E3 components to carry out
association state analysis on these two components on a Superose 12 column
(Watabe et al, 1994). Oligonucleotide primers, specific to 5’ and 3’ regions of
the published SP-22 sequence (Hiroi et al, 1996), were designed and the
polymerase chain reaction (PCR) was used to amplify the product (820bp) from
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previously calibrated with standard marker proteins to allow Mr estimation. The 
elution profile obtained, activity assays and SDS-PAGE analysis of the fractions
.obtained confirmed that the E l and E3 components did interact and form a stable 
complex with an apparent Mr corresponding to single copies of the two 
homodimeric enzymes. This provides evidence to confirm the inference drawn 
from previous proteolysis studies (Rice et al, 1992) that the E l of OGDC, in 
the absence of an E3 binding capacity on the E2 core assambly (Nakano et al,
1991), is responsible for the binding of this component to the multienzyme 
complex.
f
i:
7.3 Identification and cloning of the SP-22 protein
N-terminal sequence analysis was used to identify a small protein, 
which appeared to associate with mammalian PDC, specifically the E3 
component, as SP-22. This protein has been characterised as a thiol specific 
antioxidant protein present in mammalian mitochondria (Watabe et al, 1995).
.
Preliminary work centred on cloning the sequence coding for the protein from a 
bovine brain cDNA, a tissue where it is known to be expressed at high levels
bovine brain cDNA. The PCR product was purified and cloned into pCR-Script 
vector. Following identification of possible recombinant colonies, in vitro 
transcription/translation analysis of the clones obtained was used to identify one 
which was capable of producing a protein product with an apparent (28, 
000). consistent with that expected for the SP-22 preprotein (Hiroi et a l, 1996; 
Watabe et al., 1997).
The significance and detail of the putative interaction of SP-22 with 
mammalian PDC remains to be studied. Clearly, oxidation /inactivation of 
significant levels of PDC and other 2-oxo acid dehydrogenase complexes would 
have deleterious effect on energy metabolism within the cell. It is interesting to 
speculate that, given the E3 component is common to all three multienzyme 
complexes, protection of this component, against oxidative damage, may 
provide the most effective use of cellular resources. It is also worth noting that 
lipoate, which serves as a substrate for the E3 component, has thiol species 
which may be susceptible to oxidative attack. However, an alternative 
hypothesis, the association of SP-22 can be seen in the context of E3 
membership of the family of mitochondrial pyridine disulphide oxido- 
reductases. Thus, the interaction may represent a more general one, between 
SP-22 and the members of this family.
Subsequent work in the laboratory as been successful in expressing SP-
22 as a GST-fusion protein in E. coli and further plans involve the production
of knockout mice to investigate what effect, if any, this has on the phenotype
displayed. To complement this approach, in vitro functional analysis of the
ability of the protein to protect against the agents of oxidative damage can be
performed. Furthermore, it should be possible to study the interaction of SP-22
with 2 - 0 X 0  acid multienzyme components by signal plasmon resonance (SPR).
Such studies could provide quantitative data on the affinity of the individual
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component enzymes for the SP-22 protein and the kinetics of any such 
interactions.
Within in the field of medical research the field of oxidative damage has 
become an area of increased focus. Antioxidant defence mechanisms are 
required to maintain a wide range of cellular functions essential for cell integrity 
and viability. For mammalian PDC. the identification and putative association 
with this multienzyme complex of mitochondrial antioxidant protein SP-22 
represents a novel observation. The ability to overexpress and purify the protein 
will facilitate the investigation of multimeric nature and its 
biochemical/biophysical properties. It may be that levels of SP-22 expressed 
within a cell are effected by adverse environmental conditions. With the aid of 
polyclonal antiserum raised to the purified polypeptide and mammalian cell 
culture, it will be possible to investigate the precise nature of the stimuli (heat 
shock/oxidative stress) that are capable of inducing such a response.
The nature, specificity and stoichiometery of the interaction between SP- 
22 and the components of 2-oxoacid multienzyme complexes requires detailed 
investigation. The suggested thiol protective effect of SP-22 on the E2 and/or 
E3 components, in the presence of organic peroxides, or within oxidative 
systems capable of generating reactive oxygen or sulphur intermediates, remains
intervention may identify a number of additional candidate proteins and thus 
argue for the inclusion of SP-22, and its homologues, in the list of general 
cellular antioxidant responses.
143
to be investigated. Indeed, the search for other in vivo targets for SP-22
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Reconstitution of mammaiian pyruvate dehydrogenase and 2-oxogiutarate 
dehydrogenase compiexes: anaiysis of protein X invoivement and 
interaction of homoiogous and heteroiogous dihydroiipoamide 
dehydrogenases
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Optimal conditions for rapid and efficient reconstitution of 
pyruvate dehydrogenase complex (PDC) activity are dem on­
strated by using an improved method for the dissociation of the 
multienzyme complex into its constituent E l (substrate-specific 
2-oxoacid decarboxylase) and E3 (dihydroiipoamide dehydro­
genase) com ponents and isolated E 2/X  (where E2 is dihydroiipo­
amide acyltransferase) core assembly. Selective cleavage of the 
protein X com ponent o f the purified E 2 /X  core with the 
proteinase arg C decreases the activity of the reconstituted 
complex to residual levels (i.e. 8 -1 2 % ); however, significant 
recovery o f reconstitution is achieved on addition o f a large 
excess (i.e. 50-fold) o f  parent E3. N-terminal sequence analysis of 
the truncated 35000-M^ protein X fragment locates the site o f 
cleavage by arg C at the extreme N-terminal boundary o f a 
putative E3-binding dom ain and corresponds to the release o f a
15000-Mj. N-terminal fragment comprising both  the lipoyl and 
linker sequences. In native PD C this region o f  protein X  is shown 
to be partly protected from proteolytic attack  by the presence o f 
E3. Recovery of complex activity in the presence of excess E3 
after arg C treatm ent is thought to result from  low-affinity 
interactions with the partly disrupted subunit-binding dom ain 
on X  an d /o r  the intact analogous subunit binding dom ain on 
E2. Contrasting recoveries for arg C-modified E 2 /X /E 1  core, 
and untreated E2/E1 core o f the 2-oxoglutarate dehydrogenase 
complex, reconstituted with excess bovine heart E3, pig heart E3 
or yeast E3 point to subtle differences in subunit interactions 
with heterologous E3s and offer an explanation for the inability 
o f previous investigators to achieve restoration of PD C  function 
after selective proteolysis o f the protein X com ponent.
INTRODUCTION
The pyruvate dehydrogenase complex (PDC), the 2-oxoglutarate 
dehydrogenase complex (OGDC) and the branched-chain 2- 
oxoacid dehydrogenase complex are members o f the thiamin 
diphosphate (ThDP)-requiring 2-oxoacid dehydrogenase com­
plex family. Located in the mitochondrial matrix, each complex 
is responsible for the oxidative decarboxylation of 2-oxoacid 
substrates to CO^ and acyl-CoA derivatives. This is a multistep 
process involving co-ordinated and sequential catalysis by the 
individual enzyme eomponents. In PDC, E l (substrate-specific 
2-oxoacid decarboxylase) catalyses tlie rate-limiting and irre­
versible decarboxylation of pyruvate to an a-hydroxyethylidene- 
ThD P intermediate with further oxidation to an acetyl group 
and transfer to a covalently linked lipoic acid cofactor on E2 
(dihydroiipoamide acyltransferase). Acétylation of CoA  is pro­
moted by E2 and the reaction product released for further 
oxidation by the citric acid cycle or utilization in fatty acid 
synthesis. The reduced lipoamide prosthetic group on E2 is then 
reoxidized by cofactors FA D  and NAD+ linked to E3 (di­
hydroiipoamide dehydrogenase).
All 2-oxoacid dehydrogenase complexes comprise multiple 
copies o f E l and E3 arranged along the edges and faces 
respectively of an octahedral (24 subunits) or icosahedral (60 
subunits) E2 core [1,2]. In bovine heart PDC, 30 tetramers 
of E l (a, 42000; p, 36000) and 6 homodimers of E3 (Af^ .
55000) surround a 60meric E2 core. In addition, a fourth 
com ponent, protein X  (Af  ^42000-50000) has been identified in 
PD C from  Saccharomyces cereuisiae and various mammalian 
sources [3-5], and 12 copies exist per complex in yeast [6] and 
bovine heart [7].
Extensive characterization of protein X has revealed close 
structural, functional and organizational similarities to  E2 
[3,4,8-14]. Both components possess segmented dom ain struc­
tures joined by flexible alanine/proline-rich linker regions. These 
comprise, from the N-terminus: one to three functional lipoyl 
domains (one lipoyl on protein X) ; a peripheral subunit-binding 
dom ain; and an inner core dom ain that in E2 houses the catalytic 
site and E2 core self-assembly sequences. Owing to the tight 
association of protein X with the E2 core and their resulting co- 
purification, the function of this latter dom ain in  protein X 
remains unclear [15]. Evidence also suggests that protein X  might 
be arranged like E2 with the extended lipoic acid bearing regions 
interdigitating between E l and E3.
In general, for complexes with icosahedral (60mer) E2 core 
symmetry, the highly conserved subunit-binding domain on E2 
(approx. 50 amino acids) is responsible for E l and E3 binding, 
whereas in complexes w ith octahedral (24mer) core symmetry 
(e.g. PDC and O G D C from  Escherichia coli; PD C  from A zoto-  
bacter vinelandii) additional E l binding sites are provided by the 
N -term inus of the inner catalytic dom ain on E2 [16]. However, 
confirmation of an E3-binding role for protein X in yeast PDC
A b b r e v ia t io n s  u s e d ;  O G D C , 2 - o x o g lu ta r a te  d e h y d r o g e n a s e  c o m p le x :  E l ,  s u b s tr a te -s p e c if ic  2 -o x o a c id  d e c a r b o x y la s e ;  E 2 , d ih y d r o iip o a m id e  
a c y lt r a n s fe r a s e ;  E 3 , d ih y d r o iip o a m id e  d e h y d r o g e n a s e :  P D C , p y ru v a te  d e h y d r o g e n a s e  c o m p le x ;  T h D P , th ia m in  d ip h o s p h a te .
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[10,11] suggested the differentiation of peripheral subunit binding 
in some 60meric core-containing complexes with the subunit- 
binding domain of E2 apparently involved only in E l binding. 
Furthermore, sequence analysis of a cDNA clone of the rat 
OGDC E2 gene revealed the absence of a subunit-binding 
domain motif [17], a finding made more interesting by the 
discovery of E3-binding properties associated with the N-ter­
minus of El from bovine heart OGDC [18].
Previous extensive investigations into the E3-binding function 
of protein X from bovine kidney PDC employed the proteolytic 
cleavage of protein X by arg C from isolated E2/X /kinase core 
preparations and the analysis of E3-binding capacity by various 
methods. These included the measurement of overall PDC 
activity on réintroduction of E l and E3 [13,14,19,20]. Loss of 
activity was seen to parallel closely the cleavage of protein X and 
the release of its lipoyl domain. Recovery of complex activity 
after treatment with arg C was not achieved and it was initially 
concluded that the lipoyl domain might be involved in the co­
ordination of E3 binding to the E2/X  core. In addition, little 
information was provided on the conditions for and extent of 
recovery of original PDC activity after reconstitution. Moreover, 
the procedure employed in the production of E2/X  core and 
dissociated E l/E 3  fractions [21] when used in this laboratory led 
to component dénaturation and extremely low level (less than 
20%) reconstitution. Because subsequent gene-deletion studies 
in S. cereuisiae suggested no involvement of the lipoyl domain of 
protein X in E3 binding [10], and in the absence of similar 
research with mammalian PDC, a careful investigation of the 
role of the lipoyl and subunit-binding domains of protein X was 
performed here.
Presented in this paper are the optimal conditions for suc­
cessful, reproducibly high-level, reconstitution of bovine heart 
PDC activity after dissociation under non-denaturing conditions. 
Treatment with arg C is shown to remove both lipoyl domain 
and linker sequences of protein X with a decrease in E3 binding 
thought to arise from disruption to the neighbouring subunit- 
binding domain. Significant reconstitution of PDC activity is 
obtained in the presence of El and molar excesses of parent 
bovine heart E3 and is contrasted with the low levels of 
reconstitution achieved with pig heart E3 (used by previous 
investigators) and yeast E3. Similar results are presented for the 
restoration of OGDC function when intact E2/E1 core is 
incubated with E3 enzymes from various sources.
EXPERIMENTAL
PDC and OGDC were purified from bovine heart as described 
previously [7]. Dissociation of the purified complexes (15-30 mg) 
was as previously described [7], except that OGDC dissociation 
was modified to a 20 min incubation at a lower salt concentration 
(1 M NaCl) and column separation (on Superose 6; Pharmacia 
Biotech) included the additional presence of 2 mM MgClg and 
0.2 niM ThDP to maintain the stability of the E l component. 
Inclusion of 50% (v/v) glycerol in the dialysis buffer greatly 
improved the stability o f fractions stored at 4 or —20 °C over 2 
weeks and high levels of reconstituted complex activity were 
maintained. No variation in stability was noted with the different 
temperatures of storage.
Unless otherwise stated, reconstitution was facilitated under 
the following conditions. Complex activity was reconstituted for 
10-12 min at 30 °C in the assay cuvette in the presence of 
standard assay solutions (but without substrate). The extent of 
reconstitution was calculated as a percentage of the original 
specific activity determined before salt treatment and was of the 
order of 70-100%.
Native E3 was isolated from either complex by a 20 min 
incubation at 4 °C in 20 mM potassium phosphate, pH 7.6, 
containing 1 M  NaCl, then at 65 °C for 20 min to remove heat- 
labile proteins (pelleted at 10000^ at 4 °C  for 15 min). The 
supernatant, containing heat-stable E3, was dialysed overnight 
into 20 mM potassium phosphate buffer, pH 7.6, containing
2 mM MgClg, 0.2 mM ThDP, 1 mM benzamidine/HCl and 
1 mM PMSF. Commercial preparations of E3 (type III, pig heart 
and type IV, Candida utilis yeast; Sigma) were also extensively 
dialysed against this buffer, and all E3 samples were concentrated 
on Centricon 30 concentrators (Amicon) before use. The overall 
activities of PDC, OGDC and the E3 component were assayed 
spectrophotometrically at 340 nra, as the rate of formation of 
NADH, at 30 "C [22], for E3 resulting from the conversion of 
dihydroiipoamide to lipoamide [23]. Dihydroiipoamide was pre­
pared from the oxidized form of D,L-6,8-thioctic acid amide [24].
Detailed methods for standard SDS/PAGE, antisera prep­
aration, Western blotting and protein concentration determi­
nation were as previously described [3,7]. ^^®I-labelled Protein A 
(more than 30 mCi/mg) was supplied by N EN  Research 
Products. Arg C was of analytical grade from mouse submaxillary 
gland (Boehringer Mannheim).
Preparation of the 35000-M, protein X peptide for N-terminal 
amino acid sequence analysis used Fluka-grade 5%  (w/v) 
stacking/15 % (w/v) resolving acrylamide gels pre-run at 3 mA 
for 2 h in a discontinuous Tris/glycine-buffered system [25], with 
5 jjM  glutathione in the upper reservoir. E2/X  core treated with
3 % (w/v) arg C at 30 °C over 60 min was boiled in 60 mM 
Tris/H Cl, pH 6.8, containing 10 % (v/v) glycerol, 0.5 % (v/v) 2- 
mercaptoethanol, 0.4%  (w/v) SDS and 0.005% (w/v) Bromo- 
phenol Blue, and run with fresh buffer containing 14 fiM  sodium 
thioglycollate in the upper reservoir. Proteins were transferred to 
poly(vinylidene difluoride) protein-sequencing membrane (Bio- 
Rad) by the method of M atsudaira [26]. The stained 35000-M, 
band was excised from the membrane and sequenced at the 
BBSRC-funded protein-sequencing facility at Aberdeen with an 
Applied Biosystems model 477A gas-phase sequencer with a 
120 A on-line phenylthiohydantoin amino acid derivative an­
alyser and a modified version of the manufacturer’s BLOTT 4 
program.
RESULTS 
Establishing optimum conditions for reconstitution
A modified method for the dissociation of PDC into active E2/X  
and E l/B 3  fractions was adopted that involved treatment at 4 °C 
for 1 h in the presence of 2 M NaCl at pH 7.0 and separation of 
the E2/X  core and E1/E3 fractions on a Superose 6 gel- 
permeation matrix (see the Experimental section). The extent of 
release of the E l and E3 components from the core assembly 
(Figure lA) was an improvement on that achieved previously 
with more extreme conditions originally adapted for the pro­
duction of El-free E2/X  core [14,20,21,27,28], and on re- 
introduction, high levels of reconstitution in the range 65-85 % 
were routinely achieved (see below). In contrast, attempts by this 
laboratory to reconstitute PDC activity by the dissociation 
protocol of Linn et al. [21] employed by previous investigators, 
which uses 0.1 M glycine, pH 9.0, containing 1 M NaCl and 
0.01 M dithiothreitol for 1 h at room temperature resulted in low 
levels (20 %) of reconstitution. A study of recovery of overall 
PDC activity at room temperature after dissociation for various 
times in the presence of 1 M NaCl over a narrow range of 
buffered pH values (7.4-9.0) revealed a marked instability at 
pH 9.0 (Figure IB), which can probably be attributed to the 
sensitivity of the E l a  component to exposure to alkaline pH [29].
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Figure 1 Optimal con d ition s for obtaining highly purified, recon stltu tlvely  
activ e  E2/X  and E 1/E 3 su b traction s from  bovine heart PDC
(A) E2/X and  El p lu s E3 su b trac tion s  w ere sep ara ted  from in tact PDC by gei perm eation  on 
S u pe ro se  6 a s  d esc rib ed  in the  Experim ental sec tion . S am p les  w ere an a ly sed  for purity  by 
SD S/PA G E [10%  (w /v) gei] and  s ta in ing  with C oom assie  Blue, Lane fvt, 1 0 //g  iow-M, m arker 
p ro te in s ; lane 1, 2 0  /#g of in tact bovine heart PDC; lane 2 .1 5  / / g  of E2/X co re ; lane 3 ,1 5  / / g  
of E 1/E3. (B) S am p le s  of PDC (1 m g /m i) w ere incubated  in co lum n d issso c ia tio n  buffer 
[50  mfvl T ris/H C i, 1 fi/i NaCi, 1 mfvl dithiothreitol, 0 .0 2 5 %  (v/v) Triton X -100], a t d ifterent pH 
values over 30  min a t room  tem peratu re . At the  in tervals show n, a liquo ts w ere rem oved to a s sa y  
for in tact PDC activity and  e x p re ssed  a s  a pe rcen tage  of the  original activity. S ym bo ls ; O .  
pH 7 .4 , # ,  pH 8 ; □ ,  pH 8 .5 , ■ .  pH 9.
Thus greater recovery of complex activity was achieved if salt- 
induced dissociation was performed at pH 7.0-7.5, with further 
improvement if this incubation was perform ed at 4 °C (see 
below).
Increasing the length o f preincubation, during which E 2/X  
and E1/E3 were incubated in the presence o f assay solutions A 
(50 mM potassium phosphate, pH 7.6, 0.2 mM ThD P, 2 mM 
MgClg, 3 mM N A D  ) and B (3 mM L-cysteine, 0.14 mM CoA) 
in the absence o f substrate, seemed to have little effect on the 
extent o f reconstitution, suggestive o f instantaneous reassembly 
(Figure 2A). Before use, samples of E 2/X  and E 1/E 3 were 
diluted 1:10 in the above solutions and kept at 30 °C. In 
contrast, a gradual increase in activity was observed over
10-12 min from an initial 50 ”o to 7 0 when solution B was 
omitted from the sample dilution buffer. As a similar activation 
o f native PDC activity is often observed under these conditions 
this result suggests a lag period during which E 2/X  an d /o r
E1/E3 undergo a degree o f reactivation due to the reducing 
influence o f thiol agents rather than further reassembly. Thus, to 
ensure optim al conditions for reconstitution, before use both 
fractions were prepared in solutions A and B as described above 
and preincubated for 10 min at 30 °C.
Reconstitution was examined over a range o f ratios of 
E 2 /X :E 1 /E 3  spanning the native PD C stoichiom etry o f 1:1.45 
based on subunit com position and M^. Net activity increased 
until saturating levels o f E 1/E 3 were reached (Figure 2B), 
whereas reconstitution expressed as a percentage o f recovery of 
original specific activity was found to be maximal from a 
stoichiom etry o f I ; 0.7 to 1:1.45; this might be attributed to the 
ability o f PDC to function maximally with sub-stoichiometric 
levels o f E1/E3. Reconstitution was also studied at high 
(50-600 //g /m l) and low (0.7-9 //g /m l) com ponent concen­
trations over a range o f stoichiom etric ratios o f E 2 /X :E 1 /E 3  
(1:0.3-3.0). No variation in the degree o f  reconstitution was 
observed, indicating that the extent o f PDC recovery is in­
dependent o f the relative intimacy o f the dissociated com ponents 
on this time scale (results not shown).
In vestigation  of the E3-binding p otentia i of protein X em p loyin g  
p r o te a se  arg C
Having established optim al conditions for reconstitution, the 
E3-binding potential o f protein X was examined in reconstituted 
PDC. Isolated E 2/X  core was treated with 3%  (w /v) arg C at 
30 °C over 90 min and aliquots were removed at intervals for 
reconstitution with E1/E3 (Figure 3, upper panel). Digestion 
with arg C was performed in the presence o f cofactors T hD P  and 
Mg^^ to provide protection for residual E la  co-purifying with 
the core (less than 5 % of total E l), as this com ponent is known 
to be susceptible to proteolysis by arg C [30]. F rom  Figure 3 
(lower panels) it is clear that arg C cleaves protein X into a highly 
immunogenic 15000-M^ fragment, known from previous N- 
term inal am ino acid sequencing to contain the lipoyl dom ain 
[13], and a truncated core-bound 3 5 0 0 0 - fragment .  The 
imm ediate removal of the lipoyl dom ain fragment is accom panied 
by a decrease in the ability to reconstitute overall complex 
activity. However, as revealed below, this loss in complex function 
is not due to the absence o f lipoyl dom ains but results from the 
disruption of a putative E3-binding dom ain situated at the N- 
term inus o f the 3 5 0 0 0 - fragment .  After 60 min, a residual 
8 -12%  activity corresponds to the apparent removal o f all 
protein X-derived lipoyl dom ains (Figure 3, lower panels). 
A lthough limitations in the sensitivity o f immunological analysis 
do not entirely preclude the possibility o f incomplete protein X 
degradation, additional fluorographic analysis o f the arg C- 
treated core further modified with [2,3-‘^C]/V-ethylmaleimide, 
which labels thiol groups on the lipoic acid cofactor covalently 
attached to the lipoyl dom ains, also indicated the absence o f any 
intact protein X (results not shown). Immunological analysis o f 
the E la  and E2 com ponents (Figure 3, lower panels) showed no 
detectable degradation by arg C, suggesting that the loss in 
complex activity results solely from the specific cleavage o f 
protein X. Subsequent resolution o f the arg C-treated complex 
by gel filtration on Superose 6 revealed that approx. 90%  o f E3 
activity was released or failed to rebind to the E 2 /X  core, 
indicative o f a substantial decrease in E3-binding affinity. In 
contrast, for a sample o f intact PDC, less than 5 % o f total E3 
activity was eluted as unbound enzyme. For both samples, El 
binding was determined by direct enzyme assay after gel filtration 
and by W estern blot analysis after centrifugal sedim entation and 
found to be unaffected (results not shown).
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Figure 2  Time dependence end stoichiom etry of PDC reconstitution from purified E2/X and E1/E3 subtractions
(A) Equal volum es ol E2/X and E1/E3 dlluled 1 :1Q In assay  solutions A ( O )  or A plus B ( # )  to 0 .1 -  0.2 m g/m l were prelncubated together a t 30 °C In the cuvette containing solutions A 
and B without substrate lor the tim es indicated, before initiation of catalysis by the addition of pyruvate. The dissociated fractions exhibited negligible complex activity. Specific activity reconstituted 
was determ ined from duplicate assay s  and expressed  a s  a percentage of the specific activity of the intact complex before dissociation. (B) increasing volum es of E2/X core and a  constant volume 
of E1/E3 [diluted a s  in (A}] were preincubated for 10 min a t 30 °C in the assay  cuvette in the p resence  of assay  solutions A and B, and catalysis was initiated by addition of pyruvate. Reconstitution 
of PDC activity from duplicate assay s  is expressed in a fine graph as  overall activity and in a  bar chart a s  the percentage recovery of original Intact specific activity (% reconstitution).
Comparison of reconstitution In arg C-treated PDC and intact OGDC with different E3 preparations
After cleavage with arg C, 65-85%  recovery of the original 
reconstituted activity was facilitated in the presence of a 50-fold 
excess of parent bovine heart E3 (prepared from PDC; see the 
Experimental section). Illustrated in Figure 4(A) is a comparison 
of the extent of reconstitution achieved for arg C-treated E2/X  
core incubated with E1/E3 in the presence of 0-50-fold excess 
(with respect to parent E3 stoichiometry) of parent bovine heart 
E3, pig heart or yeast E3. Clearly, whereas substantial recovery 
of activity is gained with parent bovine heart E3, yeast E3 is 
unable to promote any recovery and seems to suppress the basal 
activity of arg C-modified PDC (see below). Reconstitution with 
pig heart E3 was limited to 5-7%  under these conditions; 
however, a maximum of 20%  reconstitution was obtained in 
several other experiments with a 200-fold excess with respect to 
parent E3. This was true for both fully and partly degraded E2/X  
core (i.e. where treatment with arg C proceeded until either 90 % 
or 50“'o of original activity was lost) and indicated that full 
recovery of reconstitution was not possible with up to a 200-foId 
excess of pig heart E3 after the complete or partial removal of the 
lipoyl domain of protein X (results not shown). In contrast, 
increasing excesses of parent bovine heart E3 beyond 50-fold led 
to further slight improvements in the recovery of PDC activity 
(i.e. 80-90%).
Similar control reconstitution experiments were performed on 
native bovine heart OGDC where E3 had been removed by salt 
treatment. Intact E2/E1 core was incubated in the presence of 
increasing amounts of bovine heart E3, yeast E3 and pig heart E3 
to levels several-fold higher than that of the parent complex 
stoichiometry. From Figure 4(B) it is clear that contrasting levels 
of reconstitution were achieved with E3 from different species. 
Yeast E3 gave no reconstitution of intact OGDC activity, pig 
heart E3 yielded intermediate levels of 20 % and bovine heart E3 
gave highest recoveries of 70-80% . As expected, maximal 
reconstitution was reached with stoichiometric levels of parent 
bovine heart E3 and also with pig heart E3, and increasing either 
E3 species to an 8-fold excess led to no further stimulation,
indicative of similar binding capacities. Identical recovery of 
reconstitution was seen for bovine heart OGDC E2/E1 core with 
E3 isolated from either bovine heart PDC or OGDC (Figure 4B). 
Similar results were also obtained for bovine heart PDC-derived 
E 2 /X /E I subcomplex (results not shown), indicating that E3 
from either complex is interchangeable.
As yeast E3 failed to stimulate reconstitution in both PDC and 
OGDC, its binding capacity for bovine heart OGDC core was 
investigated by two separate methods. In the first instance, 
increasing amounts of yeast E3 were incubated with a fixed 
amount of E2/E1 core and 5/tg of parent bovine heart E3 
(shown in Figure 4(B) to yield maximum levels of reconstitution). 
From Figure 4B, an immediate decrease in reconstitution from 
70 % to 50 % was seen in the presence of 2 jig of yeast E3 ; at 
equimolar amounts of both E3 species, less than 40 % of original 
reconstituted activity remained, suggestive of specific competition 
between yeast and bovine E3 for the E3-binding sites on the 
E2/E1 core. With 20 jig  of yeast E3 (a 4-fold excess with respect 
to bovine E3) complete inhibition of reconstitution occurred, at 
which point all E3 binding sites were presumably filled by yeast 
E3. It should be noted that all E3 samples exhibited a very high 
degree of purity when analysed on SDS/PAGE and Mono Q 
ion-exchange resin, and displayed similar specific activities.
To confirm a direct interaction between the E3-depleted 
mammalian OGDC core assembly and yeast E3, samples of the 
E2/E1 core reconstituted with either yeast E3 or parent bovine 
heart E3 were centrifuged at 100000 ^  at 4 °C for 16 h through 
a 30 % (w/v) sucrose cushion, and the pellet and supernatant 
fractions were recovered. For both samples, more than 90 % of 
total E3 activity was detected in the pellet, co-sedimenting with 
the E2/E1 core. SDS/PAGE analysis of the pellets revealed the 
presence of E l, E2 and E3, indicative of E3/core binding 
interactions, whereas only residual amounts o f E3 were detected 
in the supernatant fractions (results not shown).
Location of the site  of arg C cleavag e  in bovine heart protein X
Gene-deletion experiments on S. cerevisiae PDC have located the 
E3-binding function to a specific domain on protein X adjacent
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Figure 3 Profile of reconstitution during the p rogressive  c le a v a g e  of protein X within the purified E/X core a ssem b ly  by p rotein ase arg C
Upper panel, E2/X core  (diluted 1 :1 0  in a ssa y  so lu tions A and  B) w as incubated  in tiie p resen ce  ( # )  or a b sen ce  (O) of 3%  (w /v) arg C for 90  min at 30  °C  and tim ed aliquo ts w ere rem oved 
to 5 mM benzam idine/H C i to a rres t proteolysis. Duplicate a s sa y s  w ere perform ed after a 10 min p re incubation  a t 30  °C witti E1/E3 (diluted 1 :1 0  in a s sa y  so lu tions A and B and  p resen t in 
sto ichiom etric am ounts) in the  a s sa y  cuvette containing the sam e solutions. PDC activity w as initiated by the  addition of pyruvate to the cuvette ; the resu ltan t specific activity is ex p re ssed  a s  
percentage  reconstitution. Lower panel, arg  C-treated core, rem oved from the pro te inase  d igestion  perform ed in the  upper panel, w as resolved by SDS/PAGE [10%  (w /v) gel] for screen ing  with 
anti-protein X (I) and anti-E2 p lus E l a  se ra  (It), im m unoiogicaiiy reactive fragm ents w ere detec ted  with ’^^l-iabelied Protein A. Lane tvi, 10 / / g  iow-W, m arker p ro te in s; lanes 0 - 9 0 , arg  C-treated 
E2/X incubated  for 0 -9 0 m in  (4 /rg  per track). The released  iipoyi and linker regions (M, 1 5 0 0 0 ) and  truncated  core-bound fragm ent {M, 3 5 0 0 0 )  a re  indicated.
to the N-terminal lipoyl and linker regions [10,11], However, the 
results presented here and elsewhere [14] show a loss in E3- 
binding potential with the removal of the lipoyl domain on X. 
This discrepancy could be explained if arg C were found to 
remove more than simply the lipoyl domain of protein X; hence 
N-terminal amino acid sequencing of the truncated protein X 
was performed to determine the precise site o f cleavage. Isolated 
E2/X  core was treated with arg C, and the 35000-A/  ^ fragment 
was sequenced. The sequence obtained was 23 residues in length 
and when matched with 15 known acyltransferase sequences 
from various sources a region of similarity was identified within 
the E3-binding domain (Figure 5), placing the point o f cleavage 
by arg C close to the N-terminus of this domain. Hence 
proteolysis would result in the release of the lipoyl domain, with 
the attached linker region exposing the truncated E3-binding 
domain. Disruption to domain folding would seem highly 
probable under such conditions and would explain more sat­
isfactorily the lowered E3-binding potential o f protein X observed 
after treatment with arg C. Previous N-terminal amino acid 
sequencing of the 3 5 0 0 0 - fragment [13] generated an almost 
identical sequence of 18 residues; however, because of a misplaced 
assumption that arg C cuts within the linker region joining the
lipoyl and E3 binding domains the authors failed to locate any 
region of identity.
Additional support for the close proximity of the site of 
cleavage by arg C to the subunit-binding domain of protein X is 
provided by the observed protection offered by E3 in intact PDC. 
Selective proteolysis o f protein X by arg C in native PDC 
compared with PDC in the presence of high salt concentration 
(i.e. 1 M NaCl or 0.25 M MgCl^) showed a marked increase in 
the rate of degradation of protein X and an accompanying loss 
o f complex activity in the presence of salt (Figure 6). At neutral 
pH, high ionic strength causes the reversible dissociation of El 
and E3 from the E2/X  core. On dilution out of high salt. PDC 
reassembles and complex activity is maintained at high levels 
(Figures 1B and 6). These conditions favour greater access for 
arg C to the subunit-binding domain on protein X but no 
additional proteolysis of the other core com ponents (results not 
shown). Substantial recovery (70-80 "o) o f original PDC activity 
is once again apparent on the addition of excess parent E3, 
dem onstrating that the com bination of high salt concentration 
and arg C does not promote additional instability or inactivation 
o f the complex when compared with arg C treatment in the 
absence of salt (results not shown).
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F i g u r e  4  C o m p a r i s o n  o f  r e c o n s t i t u t i o n s  o f  a r g  C  m o d i f i e d  P D C  a n d  n a t i v e  O G D C  b y  u s i n g  p a r e n t  a n d  h e t e r o i o g o u s  E 3  s p e c i e s
(A) Arg C treated  E2/X co re  and  E 1/E3 w ere reconstitu ted  Initially a t 30  °C  in a final volum e of 5 0 - 1 0 0 /<l a s  d esc rib ed  in Figure 3  and  a lso  in the  p re sen ce  of increasing  am ounfs of bovine 
heart E3 ( ■ ) ,  pig heart E3 ( A )  and  y east E3 ( # ) .  All E3 p repara tions had sim ilar specific  activifies. Before arg  C treafm ent, m axim um  reconstitution  w as 6 5 ± 3  (S.E.fVl.)%. After incubation 
with 3%  (w /v) arg  C over 9 0  min a t 30  °C , reconstitu ted  activity w as 5  ± 0 . 4  (S.E,M .)%. D uplicate aliquo ts (5 //.I) w ere rem oved to a s sa y  cuve ttes contain ing the  com plete  a s sa y  mix m inus su b stra te  
for a  10 min p rem cubation before a s sa y  of th e  extent of reconstitution  a s  d esc ribed  previously, (B) Purified E2/E1 subcom plex  of OGDC (see  the  Experim ental sec tion) w as incubated  with increasing  
am o u nts  of E3 from bovine heart OGDC ( x  ). bovine heart PDC ( ■ ) ,  pig heart E3 ( A )  and  yeasf E3 ( # ) .  S am p les  w ere w ere incubated  for 12 min a t 30  °C  with a  fixed am ount (14  /^g) of 
bovine heart OGDC E2/E1 core. All sam p le s  w ere p resen t in so lu tion  A (except NAD"^). Intact OGDC activity (5 //.g) w as a ssay ed  in duplica te  ; reconstitu ted  activity is e x p re ssed  a s  a  percen tage  
of original com plex activity. A com petitive binding a s sa y  w as perform ed with E2/E1 core  (14 fiq) and  an  e x c es s  of paren t bovine heart OGDC E3 (5  fiq) in th e  p re se n ce  of increasing  am ounts 
of yeast E3 a s  indicated  ( O )  and  incubated  for 12 min af 30  °C  before a ssay ing . R econstitu ted  OGDC activity is  ex p re ssed  a s  a  percen tage  of original activity.
E-O: SP *IRRLLA*HNLDASAIKOTOVGORLTR*B-0: 8P SAMUJÜIXKOIOLS0VPTG DPLORVRKQA-0: SP AARKIAEINAIAADSITOTOKGORVTK*
E-P: TP LIRRLARmFOVNLAKVKOTORKGRILR:B-P: MP SVRKYARRKOVDIRKVTOSONNORWK*S-P: MP SVRXYARRKOVDIRLVQOTOKNORVLRC
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P-B: SP AVRRRALDAOIELRYVHOSOPAORILHEB-B: TP AVRRIAMBNNXKLSEVIOSOKDORILKE
H-B: TP AVRRLAMXNNXKLSEWOSaKDORXLKR
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35X: LSP AARNIL-BKQ - AI.DAN0OTA?G
F i g u r e  5  A l ig n m e n t  o f  t h e  N - t e r m i n a l  s e q u e n c e  o f  t h e  3 5  0 0 0 - W , f r a g m e n t  
o f  p r o t e i n  X f r o m  b o v i n e  h e a r t  w i th  v a r i o u s  E 3 - b i n d i n g  d o m a i n  s e q u e n c e s
A reas of identify betw een the  dihydrolipoam ide acy ltran sfe rases  from OGDC (0), PDC (P), 
b ranched  chain  2-oxoacid d ehy d ro g en ase  com plex  (8 ) and  profein X from PDC (X). isolated 
from E coli (E), Bacillus sublilis (8 ), A vinelandii (A), B. stearothermophilus (S), S. cerevisiae 
(Y). Neurospora crassa M RP3 (N), rat (R), hum an  (H), Pseudomonas putida (P). P ositions of 
Identity with the  equivalent region from the  350(X)-W , fragm ent of protein X (35X), are 
rep resen ted  by aste risk s . Two g a p s  w ere in se rted  on either side  of the  EKG motif fo perm it 
optim al seq u en ce  a lignm ent
D I S C U S S I O N
Previous investigations have provided conflicting evidence for 
the involvement of the lipoyl dom ain o f protein X in E3 binding. 
Whereas gene-deletion studies in S. cerevisiae definitively located 
E3 binding solely to the peripheral subunit-binding dom ain on
protein X [10] and the E l-binding function to the same dom ain 
on E2 [11], proteolysis by arg C o f protein X from bovine kidney 
suggested that the lipoyl dom ain of protein X was essential for 
maximal binding o f E3 [13,14,19,20]. After removal o f the lipoyl 
dom ain o f protein X by arg C, the authors were unable to recover 
PD C activity from the truncated E 2 /X  core and dissociated 
E1/E3 fractions, and noted a marked reduction in E3-binding 
capacity. The method for dissociation o f PD C used by those 
authors [21] has been shown in this laboratory to yield extremely 
poor levels o f reconstitution (approx. 20% ), owing to a high 
degree o f com ponent dénaturation. An improved dissociation 
protocol is described here that routinely yields high levels o f 
PD C reconstitution. In addition, after treatm ent with arg C, 
substantial recovery of PD C activity is dem onstrated in the 
presence o f excess parent E3. Im portantly, these results are now 
in agreement with those in yeast [10,11], which suggest no 
involvement o f the lipoyl dom ains in E3 binding. Alignment o f 
a 23 am ino acid sequence from the N-terminus o f the truncated 
35 0 0 0 - protein X core fragment with known E3-binding 
dom ain sequences o f various E2 species revealed that loss in 
protein X -E3-binding affinity probably results from the close 
proximity of the site o f cleavage by arg C to the subunit-binding 
domain, and the recognition that the released N-term inal frag­
m ent contains the entire lipoyl and linker regions. This result is 
supported by the observed partial protection o f protein X offered 
by E3 in native PDC. Clearly, if the site o f cleavage by arg C were 
situated within the peripherally extended lipoyl-linker regions of 
protein X, as previously proposed [13], E3 would not be expected 
to provide protection from proteolysis by arg C.
Recent two-dimensional N M R  resolutions of the subunit- 
binding dom ain o f E2 from Bacillus stearothermophilus PDC [31] 
and o f a 51-residue synthetic peptide comprising the E3-binding 
dom ain o f E2 from E. coli O G D C [32] have revealed similar
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Figure 6  Effect of high ionic strength on the rate of se ie c tiv e  arg C- m ediated p roteoiysis of protein X in intact PDC.
(A) Intact PDC (1 m g/m l) w as inactivated by selective proteolysis of its protein X com ponent 
with 3%  (w /v) arg 0  in a s sa y  solution A in the p resence  (O) or ab sence  ( # )  of 1 M NaCI. 
Arg C-treated and control sam p les, incubated  with ( □ )  or without ( ■ )  1 M NaCI in the 
ab sence  of p roteinase, w ere rem oved at intervals a s  indicated and assay ed  in duplicate for intact 
PDC activity a s  described  in Figure 1. (B) Arg C-treated and control sam p les  w ere a lso  
sub jected  to analysis by SDS/PAGE [10%  (w/v) gel] and the rate of degradation  of protein X 
w as m onitored by im m unoblotting with anti-X-specific serum  a s  described  in Figure 3. Lanes 
C are  control lanes incubated  in the ab sence  of p ro tease  and NaCI; lanes 1 - 3  show  incubations 
with arg  C without NaCI, w hereas lanes 4 - 6  are  incubations conducted  in the p resen ce  of 
p ro tease  and NaCI. The su b sc rip ts  on individual lanes represen t the  tim e of incubation in min. 
The m ajor 3 5 0 0 0 -W, and 15000-44, proteolytic fragm ents of protein X are  a lso  highlighted.
secondary structures comprising a disordered N-terminus fol­
lowed by two parallel a-helices separated by a short extended 
strand and an irregular loop (OGDC) or by a 3jo-helix and 
overlapping ji turns (PDC). Alignment of subunit-binding do­
main sequences with strict identity at the N- and C-termini of 
both a-helices suggests four regions of absolute or highly 
conserved residues [32]. At positions corresponding to the E. coli 
synthetic domain, this includes: (1) a core o f hydrophobic 
residues, lie-16, Leu-20, Leu-25, Ala-27, Ile-30, Leu-39 and Val- 
44, with interhelical contacts providing stability; (2) a glycine or 
asparagine residue at positions of tight turns (i.e. 37 and 24); (3) 
a structurally restrictive proline (Pro-14) at the N-terminal 
boundary of helix 1 ; and (4) positively and negatively charged 
residues, A rg-17, A rg-18, Arg-8, Arg-41, Glu-22 and Asp-43, 
thought to be involved at the E2/E3 interface. In addition, the 
solvent-exposed Thr-33 and Asp-43 of E2 from E. coli O G DC 
are buried and are therefore thought to be crucial for stability
[32]. Alignment o f the amino acid sequence obtained from the 
truncated 35000-A/,. fragment of protein X (Figure 5) revealed 
the presence of conserved residues P ro -14, A rg-17, A rg-18, Leu- 
20, Glu-22, Gly-24 and Thr-33. Assuming that the subunit- 
binding domain of protein X in bovine heart PDC is similarly 
positioned, these results place the site o f cleavage by arg C at the 
extreme N-terminus of the E3 binding domain specifically, at 
the proline boundary. This close proximity might cause minor 
disruption to domain folding with corresponding impairment of 
protein X-E3-binding function.
Clearly, recovery of arg C-treated E2/X  core activity with El 
and excess parent E3 could arise from low-affinity binding to the 
disrupted subunit-binding domain on protein X. However, 
evidence of a residual (i.e. 15 % ) PDC activity [33,34] in cell lines 
isolated from patients suffering from severe lactic acidaemia, 
corresponding to the absence of immunoiogicaiiy detectable 
levels o f protein X, strongly indicates the ability of E2 to bind the 
E3 component with low affinity, which appears at apparently 
normal stoichiometric levels in the defective PDC. The E2- 
binding potential o f these cell lines is currently under investigation 
in collaboration with this laboratory. Thus it remains a possibility 
that recovery of reconstituted PDC activity results from low- 
affinity binding to putative E3-binding domains on the E2 core 
after gross disruption and complete loss of protein X-E3-binding 
potential through treatment with arg C.
Sequence analysis has shown that E3 is a highly conserved 
enzyme with approx. 96 sequence identity between human 
liver and pig heart E3, yet reconstitution with pig heart and 
yeast E3 was shown here to produce poor levels o f recovery 
com pared with that achieved with parent E3. As similar patterns 
of reconstitution were also seen for untreated E2/E1 core from 
O G DC incubated with different sources of E3, this is evidently 
not an effect o f protein X proteolysis in PDC, where large 
excesses of the enzymes are necessary to effect maximal re­
constitution. Comparison of bovine heart and yeast E3 binding 
in E3-depleted OG DC core revealed high-affinity binding of 
yeast E3. Progressive loss in bovine heart E3-induced O G DC 
activity accompanied the addition of increasing am ounts o f yeast 
E3, resulting in complete inhibition once the levels of yeast E3 
were in 2-fold excess with respect to parent E3. This inhibition 
might point to subtle differences in catalytic an d /o r binding 
orientations between E3 from different species whereby once 
bound, the lipoyl domains of bovine heart E2 are unable to 
service the active site o f heterologous E3, preventing effective 
reconstitution of overall PDC or O G D C activity.
It has been proposed that the pig heart E3 preparations 
isolated from total heart tissue [35,36] comprise two immuno­
iogicaiiy distinct E3 isoforms relating to the E3 component o f the 
glycine decarboxylase complex and o f the 2-oxoacid dehydro­
genase complexes [37]. However, electron-spray mass spectro­
scopy of pig heart E3 before and after purification by F P L C - 
M ono Q ion-exchange chrom atography has confirmed the pres­
ence of only one major E3 species (results not shown). As 
dem onstrated here, E3 from bovine heart PDC and O G D C is 
interchangeable, suggesting no differences in E3 binding and 
catalytic efficiencies between 2-oxoacid dehydrogenase complexes 
from the same species and tissue (Figure 4B). It seems that 
heterologous E3s should be avoided for reconstitution studies in 
future. Indeed, the inability o f previous investigations to achieve 
recovery with arg C-treated core and dissociated E1/E3 com­
ponents o f the bovine kidney complex [13,20] can probably be 
attributed to the use of pig heart E3.
In bacterial PDC and OGDCs, E3 association is mediated by 
subunit-binding domains located on the oligomeric E2 core 
enzymes. In contrast, eukaryotic PDCs have evolved a distinct,
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peripherally located, iipoyl-bearing polypeptide, protein X, to 
promote high-affinity E3 binding to the E2 core structure despite 
the coexistence of similar subunit-binding domains on E2 itself. 
Moreover, the domain organization of the mammalian dihydro­
lipoamide succinyltransferase (E2-0G D C ) is notable for the 
complete absence of sequences corresponding to a putative E3- 
binding domain, which, in this complex, are uniquely located in 
the N-terminal region of the El component [17].
In some respects, protein X can be regarded as an isoenzyme 
of E2 that has evolved a specialized stiictural role in E3 binding, 
although its catalytically active lipoyl domain has retained a 
limited ability to promote overall complex activity. Whereas E2 
of PDC has a primary role in the acétylation reactions of the 
complex, it might have also retained a residual capacity to 
interact with E3, as suggested by the results presented here and 
the observation that patients lacking the protein X component 
still have 10-20% of normal PDC activity. The existence of 
dilTcring modes of association of E3 in this family of multienzyme 
complexes could simply reflect the stochastic nature of the 
evolutionary process.
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a bstra ct : Reconstitution studies have been conducted on the dihydrolipoamide acetyltransferase—protein 
X core subcomplex of the mammalian pyruvate dehydrogenase complex. GdnHCl-induced dissociation 
of this core is an ordered cooperative event involving formation of specific lower-Mr intermediates 
corresponding to dihydrolipoamide acetyltransferase trimers and monomers. Recovery profiles of the 
dihydrolipoamide acetyltransferase—protein X core, unfolded in 6 M GdnHCl prior to the removal of 
dénaturant by either (a) slow dialysis or (b) rapid dilution, demonstrated rapid initial reappearance of 
substantial levels of dihydrolipoamide acetyltransferase activity with complete recovery occurring in 4—6 
h. Immunological analysis of reconstituted cores revealed reduced levels of protein X (approximately 
30—35%) after slow dialysis and the total absence of this component following rapid dilution. The 
dihydrolipoamide æetyltransfer^e core, devoid of protein X, was unable to sustain overall complex activity 
when reconstituted with stoichiometric amounts of its companion pyruvate decarboxylase and dihydro­
lipoamide deydrogenase components, whereas the protein X-depleted core could sustain 30—35% of control 
activity. Further reconstitution analyses of overall complex function with these two types of reassembled 
core structures in the presence of excess dihydrolipoamide dehydrogenase (100-fold) demonstrated 
significant additional stimulation of pyruvate dehydrogenase complex activity (25—30%) which was 
dependent on the source of exogenous dihydrolipoamide dehydrogenase. Thus, this constituent enzyme 
can interact directly with the dihydrolipoamide acetyltransferase oligomer with low affinity in addition to 
its normal high-affinily binding to the protein X subunit. These results provide definitive in vitro evidence 
in support of recent clinical observations reporting residual pyruvate dehydrogenase activity (10—20%) 
in cell Unes derived from patients lacking protein X.
Located in the mitochondrial matrix, in close association 
with the inner membrane, the pyruvate dehydrogenase 
complex (PDC)^  is one of the largest multienzyme complexes 
detected to date with an apparent molecular weight of 9—10 
X 10®. This macromoiecular E^ sembly is responsible for the 
oxidative decarboxylation of pyruvate, yielding acetyl-CoA, 
CO2, and NADH. It thus occupies a key site in flux 
regulation of two carbon units into the TCA cycle. Central 
to the catalysis is the consecutive action of its constituent 
enzymes: a pyruvate decarboxylase, El; a dihydrolipoamide 
acetyltransferase, E2; and a dihydrolipoamide dehydrogenase, 
E3. PDC from mammalian sources is organized around a 
60-mer E2 core with icosahedral (532) symmetry to which
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 ^Abbreviations: PDC, pyruvate dehydrogenase complex; OGDC, 
2-oxoglutarate dehydrogenase complex; BCOADC, branched-chain 
2-oxoacid dehydrogenase complex; El, pyruvate decarboxylase; E2, 
dihydrolipoamide acetyltransferase; E3, dihydrolipoamide dehydroge­
nase; GdnHCl, guanidine hydrochloride; ThDP, thiamine diphosphate.
are attached a maximum of 30 a2^2 El tetraraers and 6—12 
B3 homodimers [for recent reviews, see Behai et al. (1993) 
and Patel and Harris (1995)].
Mammalian PDC contains an additional subunit, protein 
X, 12 copies of which are very tightly associated witii the 
B2 core assembly. Its major role appears to be that of 
binding and positioning the B3 component at the correct sites 
on the surface of the E2 core (Maeng et al., 1994; Sanderson 
et al., 1996a). In addition, several copies of ti^tly associated 
kinase and loosely associated phosphatase are responsible 
for the regulation of PDC activity by a phosphorylation/ 
dephosphorylation mechanism involving covalent modifica­
tion of the Ela subunit (Yeaman, 1989).
PDC deficiency is one of the most common causes of 
congenital lactic acidosis (Patel et al., 1992). The cases of 
human pymvate dehydrogenase deficiency studied to date 
implicate defects in the E la  component as the major cause, 
with considerably fewer lesions specifically associated with 
other enzymes of the complex. However, recent studies 
(Marsac et al., 1993; Geoffroy et al., 1996) have identified 
patients, suffering from chronic lactic acidosis, with reduced 
levels (15—20%) of PDC activity and an apparent absence 
of protein X. In these cases, while the levels of E3 appeared 
to be normal, no inununologically detectable protein X was
80006-2960(96)03001-2 CGC: $14.00 © 1997 American Chemical Society
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present in cultured fibroblast cells from the patients.
Association of the individual enzymes of the complex is 
achieved solely by noncovalent forces, with the E2 compo­
nent providing the structural lattice to which the constitueht 
enzymes are attached. Evidence from genetic studies of PDC 
from Saccharomyces cerevisiae (Niu et al, 1990; Lawson 
et al, 1991a,b) indicate that this core must be in a native or 
near native state for whole complex assembly to occur. More 
recent reports (Behai et al, 1994; De Marcucci et al, 1995) 
using dénaturation and sedimentation velocity analysis 
provide compelling evidence that assembly of the E2/X 
subcomplex proceeds in an ordered fashion, involving a 
lower-molecular weight (8S) intermediate, as opposed to 
other possible random or sequential assembly mechanisms. 
However, the dissociation method employed by these authors 
has been shown to be suboptimal as the harshness of the 
dissociation conditions promoted a significant degree of 
component dénaturation and resulted in poor levels of 
reconstitution (i.e., <20%) of original overall complex 
activity (Sanderson et al, 1996b).
Recently, our laboratory has developed a gentle but 
effective method of separating the E2/X subcomplex from 
E1/E3 which has facilitated reconstitution studies. It has 
been possible to utilize the improved separation protocol to 
produce a more detailed picture of the processes involved 
in PDC folding and assembly (Sanderson et al, 1996b).
In this paper, we demonstrate that dissociation of the E2/X 
subcomplex, and by implication its assembly, is an ordered, 
cooperative event. Complete unfolding of mammalian E2/X 
in guanidine hydrochloride and subsequent removal of the 
dénaturant by either (i) slow dialysis or (ii) rapid dilution 
result in both instances in complete restoration of E2 catalytic 
activity and reassembly of the multimeric structure. How­
ever, compared to the native B2/X core, the reassembled E2 
cores exhibit, respectively, (i) a reduced level of bound 
protein X or (ii) no immunoiogicaiiy detectable protein X. 
Further, both core preparations can still mediate E3 binding, 
through proposed low-affinity, specific sites on E2, and thus 
support PDC activity, a property not previously observed. 
This ability provides in vitro evidence in support of previ­
ously reported clinical data (Geoffroy et al, 1996) and 
clarifies data from a previous study (Sanderson et al, 1996b), 
where low-affinity binding to proteolytically cleaved protein 
X remained a possible explanation.
MATERIALS AND METHODS
Materials. Ultrapure grade GdnHCl was purchased from 
Gibco-BRL (Paisley, Scotland). Concentrations of stock 
solutions and samples were determined by refractive index 
measurements (Nozaki, 1972). Commercial preparations of 
E3 (type HI, porcine heart, and type IV, Candida utilis) and 
gel filtration molecular weight markers were obtained from 
Sigma Chemical (Poole U.K.). All other reagents were of 
the highest grade commercially available.
PDC Dissociation and Individual Enzyme Purification. 
PDC was purified as detailed in Sanderson et al (1996a) 
with the following modifications. Preparative dissociation 
of PDC into active E2/X and E1/E3 fractions was performed 
on an FPLC system (Pharmacia) using a lOOmL bed volume 
prep grade Superose 6 column (1.6 x 50 cm) equilibrated 
with 50 mM imidazole/HCl (pH 7.0), 1M NaCI, and 0.01% 
(v/v) Triton X-100. PDC (15 mg/mL) in 100 mM MOPS/
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NaOH (pH 6.8), 5 mM EDTA, and 1% (v/v) Triton X-100 
was spun at lOOOOg in a bench top centrifuge for 15 min to 
remove any particulate material, before incubation at a 1:1 
(v/v) ratio with 50 mM imidazole/HCl (pH 7.0) and 4 M 
NaCI on ice for 1 h. A preinjection of the 4 M NaCI buffer 
(2 mL) was performed prior to PDC loading (2 mL) and 
subsequent column elution at a flow rate of 1 mL/min. The 
initial peak of absorbance corresponding to the high-Mr E2/X 
subcomplex eluted at or near the void volume of the column 
(Ve =  30—33 mL), whereas tire second peak containing the 
El and E3 enzymes exhibited a Ve of 60—66 mL, Peak 
fractions were diaiyzed extensively, at 4 °C, against multiple 
changes of buffer, into 50 mM imidazole/HCl (pH 7.4), 1 
mM EDTA, and 50% (v/v) glycerol and stored at 4 ®C. Both 
pools exhibited no significant cross-contamination as judged 
by enzymatic assay or SDS—PAGE analysis and were stable 
under these conditions for over 2 weeks as reported previ­
ously (Sanderson et al, 1996b).
Purification of the E3 component of mammalian PDC, 
used in reconstitution studies, was achieved by anion 
exchange chromatography. Following the preparative dis­
sociation of PDC, the E1/E3 fraction was exchanged into 
20 mM triethanolamine/HCl buffer (pH 7.4), 10 mM NaCI, 
and 1 mM CHAPS, either by extensive dialysis or by 
Centricon 30 ultrafiltration (Amicon). After a clarification 
spin at lOOOOg in a benchtop centrifuge, the sample (<4 mg 
of protein) was loaded onto an 8 mL Pharmacia Resource Q 
column ( 1 x 1 0  cm) pre-equilibrated with 20 mM trietha­
nolamine/HCl buffer (pH 7.4), 10 mM NaCI, and 1 mM 
CHAPS (buffer A). The column was washed with 2 column 
volumes of buffer A, to remove any unretained material, 
before being developed with a linear gradient of 20 mM 
triethanolamine (pH 7.4), 500 mM NaCI, and 1 mM CHAPS 
(buffer B) over 200 mL. In addition to the continuous 
monitoring of the eluent at 280 nm, individual fractions were 
assayed for El or E3 activity. Peak fractions which 
contained significant levels of noncontaniinated activity were 
pooled and subsequently desalted using Centricon 30 ultra­
filtration (Amicon) into storage buffer [50 mM MOPS (pH 
6.8), 10 rnM NaCI, and 3 mM EDTA] before use. Bacterial 
E3 was purified from Escherichia coli as detailed previously 
(Russell et al, 1992).
Gel Permeation Analysis of E2/X Quaternary Structure. 
Association state analysis of the purified E2/X subcomplex 
was performed on a 24 mL bed volume Superose 12 column 
(1 X 30 cm) attached to an FPLC system Pharmacia). The 
column was calibrated with gel filtration molecular weight 
markers (Sigma). This allowed the construction of a 
calibration curve of Vp/Vo versus log Mr, from which it was 
possible to estimate the Mr of the E2/X species observed by 
interpolation. The column was equilibrated, at 0.2 mL/min, 
with increasing concentrations of GdnHCl in 50 mM MOPS 
(pH 7.4) and 200 mM NaCI. The B2/X subcomplex was 
preincubated at room temperature for 15 min in the ap­
propriate concentration of GdnHCl, clarified for 15 min at 
lOOOOg, and loaded onto the column. The elution profiles 
obtained were from on-line detection at 280 nm.
Unfolding and Refolding Conditions. Dénaturation/ 
reactivation profiles obtained with GdnHCl were based on 
protocols detailed in Pace (1990) and West and Price (1988). 
Routinely, incubations were for 15 min at 20 °C. Rapid 
dilution and slow dialysis protocols were adapted from those 
detailed in Behai et a l (1994) and De Marcucci et al (1995),
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F ig u r e  1 : Gel permeation analysis of E2/X association. Association 
state analysis of the E2/X subcomplex was performed on a 
Pharmacia Superose 12 FPLC column (24 mL) equilibrated, at 0.2 
mL/min, with increasing concentrations of GdnHCl in 50 mM 
imidazole/HCl (pH 7.4) and 200 mM NaCI. E2/X subcomplex (100 
/fg), in column equilibration buffer, was preincubated at room 
temperature for 15 min in the appropriate concentration of GdnHCl 
and then subjected to analysis on the Superose 12 column. Protein 
elution was detected at 280 nm. Elution profiles in the absence of 
GdnHCl (□), 2 M GdnHCl (A ), and 4 M GdnHCl (O) are shown.
respectively. Additional experimental details are presented 
in the appropriate figure legends.
Determination of Enzyme Activity. All enzyme assays 
were performed on a Shimadzu UV-2101 PC UV-VIS 
scanning spectrophotometer. Reconstitution of PDC activity 
was performed as detailed in Sanderson et al. (1996b). The 
individual enzymes were assayed by the following methods. 
Pyruvate decarboxylase (El) was assayed by the reduction 
of dichloroindophenol (DPIP) at 600 nm (Khailova et al, 
1976). Dihydrolipoamide acetyltransferase (E2) was assayed 
in a coupled assay system following the acétylation of free 
dihydrolipoamide (Reed & Willms, 1966). Dihydrolipoa­
mide dehydrogenase (E3) was monitored following NADH 
formation at 340 nm from free dihydrolipoamide substrate 
(Jackman et al, 1990).
Immunological Analysis. Denaturing gel electrophoresis 
and subsequent Western blot analysis were performed as 
detailed previously (Sanderson et al, 1996a), except that 
immunocomplexes were detected with Amersham BCL 
detection reagents as per the manufacturer’s instructions.
RESULTS
Association State Analysis of the E2/X Subcomplex. 
Analysis of the quaternary structure of the purified E2/X 
subcomplex involved pretreatment with 0,2, or 4 M GdnHCl 
prior to gel permeation analysis on a Superose 12 column 
equilibrated at the same concentration of dénaturant (Figure 
1). The results provide evidence for an ordered, cooperative 
decline in the apparent Mr value of the E2/X core produced 
at discrete increments in the concentration of chaotrope. No 
initial dissociation of the native core was observed in the 
presence of 0—1.5 M GdnHCl; thereafter, there was a rapid 
transition to an approximately 200 000 Mr species which was 
stable in the range of 1.8—2.8 M GdnHCl. At higher 
GdnHCl levels, there was a fiirther rapid conversion to a
partially or fully unfolded monomeric form with an apparent 
Mr value of 82 000.
Previous attempts (West et al, 1995) to produce GdnHCl- 
induced dissociation of the E2/X core resulted in the 
production of nonspecific aggregates. In this study, inclusion 
of 200 mM NaCI in the gel permeation buffer appears to 
stabilize structure and minimize aggregation of E2/X dis­
sociation products. Moreover, the appearance of an inter­
mediate species, stable in 2 M GdnHCl, between that of the 
native core and the monomeric form present at 4M GdnHCl, 
is consistent with the reversible perturbations in tertiary and/ 
or quaternary structure observed by intrinsic tryptophan 
fluorescence (West et al, 1995), whereas little or no 
corresponding disruption of secondary structure (as judged 
by circular dichroism measurements) was detected under 
these conditions. This result suggests that assembly of the 
E2 structural lattice may occur through a lower-order 
intermediate, as opposed to possible random or sequential 
mechanisms (Behd et al, 1994). Molecular weight estima­
tions produce an apparent Mr of 200 000 db 24 000 (« =  4) 
for the species in 2 M GdnHCl and an Mr of 82 000 ±  12 000 
(n  — 4) for that formed in 4 M GdnHCl. These Mr values 
are consistent with formation of E2 trimers at 2 M GdnHCl 
and further dissociation to fully or partially unfolded 
monomers when the chaotrope concentration is increased to 
4 M. Available crystallographic data on the truncated 
transacetylase core from Azotohacter vinelandii support 
strong intratrimeric interactions between transacetylase mono­
mers as the basic unit for core association (Mattevi et al, 
1992). In addition, the structural and functional similarity 
of E2 to chloramphenicol acetyltransferase, CAT (Guest, 
1987), active as a trimer, led to the suggestion that the 60- 
mer mammalian E2 core represents an association of 20 
trimeric units, an idea which has received experimental 
support from recent publications (Behai et al, 1994; De 
Marcucci et al, 1995) and current evidence.
Kinetics of E2 Refolding/Reassembly. We have reported 
previously that overall PDC activity is rapidly inhibited at 
low levels of GdnHCl (0—0.2 M) under conditions which 
have only a limited effect on the catalytic functions of its 
three constituent enzymes. The susceptibility of the intact 
complex to GdnHCl results from its ease of dissociation into 
the individual El, E2/X, and E3 components. All three 
constituent enzymes display similar susceptibilities to the 
presence of GdnHCl with approximately 50% inhibition 
occurring by 0.3 M and complete inhibition in the range of 
0.7—1.0 M with the E2 component proving slightly more 
refractory to dénaturant treatment. However, in all cases, 
inhibition occurs at levels of dénaturant which are signifi­
cantly lower than those which produce any major structural 
impact (West et al, 1995). Since, in multidomain proteins, 
individual domains can be viewed as separate folding entities, 
it is probable that each domain displays a particular sensitiv­
ity to dénaturant. Thus, initial loss of component activity 
usually reflects minor architectural changes in the most 
sensitive domain which are readily reversible. It has been 
proposed that in a number of proteins the active site is 
particularly sensitive to dénaturant perturbation (Tsou, 1986).
Figure 2 illustrates the profiles of irreversible loss of 
overall complex activity and that of its individual component 
enzymes with increasing GdnHCl concentrations as judged 
by their inability to recover spontaneously following rapid 
dilution directly into assay buffer. In each case, the
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F ig u re  2: Reactivation/renaturation profiles of PDC, E2/X, E l/ 
E3, and E2 (transacetylase) activity following pretreatment with 
GdnHCl. I\irified PDC, E2/X, or E1/E3 preparations were incubated 
in 50 mM MOPS/KOH (pH 7.4) containing the stated concentration 
of GdnHCl for 15 min at 20 °C. Renaturation/reactivation was 
initiated by a rapid dilution into the appropriate assay buffer. The 
final protein concentration in the renaturation mixture was 10-30 
/rg/raL, and the residual GdnHCl concentration was less than 30 
mM. After a 15 min period at 20 °C, reconstitution/activity assays 
were performed (see Materials and Methods) for PDC activity on 
intact PDC (O), pretreated E2/X (□), and pretreated E1/E3 (a ) .  
E2 transacetylase activity was also determined for pretreated E2/X 
(■), All activities arc expressed relative to control samples incubated 
in the absence of GdnHCl.
concentration of GdnHCl was reduced to below 30 mM, 
given the acute sensitivity to GdnHCl demonstrated previ­
ously (West et al, 1995). Irreversible loss of constituent 
enzyme activities correlates closely with the onset of major 
structural perturbations as judged by circular dichroism and 
intrinsic tryptophan fluorescence measurements (West et al, 
1995). Recovery of intact complex activity is intrinsically 
coupled to the sensitivity of the El and B3 enzymes which 
are most susceptible to GdnHCl-induced dénaturation. In­
terestingly, however, major differences were observed in the 
ability of the E2/X subcomplex to support PDC reconstitution 
compared to the return of its intrinsic transacetylase activity. 
Whereas irreversible loss of E2-linked transacetylase activity 
occurs in the range of 3.8-5 M GdnHCl (Figure 2), the 
ability of the GdnHCl-treated E2/X core to pramote overall 
complex reconstitution declines rapidly at lower levels of 
GdnHCl (2.8—4 M). Extension of the renaturation/recon­
stitution period prior to assay had no effect (results not 
shown). This discrepancy between the ability of the 
reactivated core assembly to support PDC reconstitution and 
the return of its transacetylase activity raised the possibility 
of a renaturation/refolding process dependent on tiie correct 
reintegration of protein X into the refolded core (see later).
Refolding by rapid dilution was optimized to maximize 
the recovery of transacetylase activity from fully unfolded 
monomers and found to exhibit a marked temperature and 
protein concentration dependence, The kinetics of refolding/ 
reassociation of the E2 core at 4 ®C (the optimal temperature) 
were monitored by activity assays (Figure 3A), There is a 
rapid and efficient reconstitution of E2 activity (at 50 /ig/ 
mL) with 60—80% of the original transcetylase activity 
appearing within 30—45 min and complete recovery occur­
ring in 4 -6  h.
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F ig u r e  3: (A) Renaturation of the E2/X subcomplex initiated by 
rapid dilution. Renaturation of E2/X, after complete dénaturation 
in 6 M GdnHCl for 2 h at 20 °C, was initiated by a rapid dilution 
into renaturation buffer [50 mM potassium phosphate (pH 7.0) and 
5 mM cysteine/HCI] at 4 “C, The protein concentration in the 
renaturation buffer was 50 or 200 /ng/wL. Aliquots were removed 
at the time points indicated and assayed for transacetylase, (■) 50 
(Mg/mL and (□) 200 ^g/mL, and reconstituted PDC activity, (A) 
50 and 200 fig/mL . Activities are expressed relative to control 
samples which underwent the entire protocol in the absence of 
GdnHCl, (B) Renaturation of the E2/X subcomplex by dialysis. 
Following complete dénaturation of the E2/X subcomplex in 6 M 
GdnHCl for 2 h at 20 °C, reactivation and reassociation were 
initiated by dialysis against 4 L of 50 mM potassium phosphate 
buffer (pH 7.5), 250 mM NaCI, 1 mM MgCL, 0.1 mM EDTA, 
and 5 mM /5-mercaptoethanol at 4 °C. At the time points indicated, 
aliquots were removed and assayed for transacetylase activity, (■) 
0.5 mg/mL and (□) 1 mg/mL, and the abiUty to reconstitute PDC 
activity, (A) 0.5 mg/mL and (A ) 1 mg/mL, upon the addition of 
the correct stoichiometric quantity of E1/E3. The GdnHCl concen­
tration (^), at the time points indicated, was determined by 
refractive index measurements. Activities are expressed relative to 
control protocols carried out without GdnHCl.
The biphasic nature of the kinetic profiles is consistent 
with two populations of folding intermediates. Fast folders 
are thought to collapse rapidly to the native state, whereas 
slow folders undergo incorrect nucléation and are thus 
trapped in non-native/misfolded states. These molecules 
must unfold to some degree before proceeding further along 
the correct folding/assembly pathway (Todd et al, 1996). 
Similar biphasic kinetics for E2 recovery, although over a 
prolonged time scale (25 h), have been reported, previously
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(Behai et al., 1994; De Marcucci et al., 1995). The improved 
rates of E2 core assembly reported here may reflect the 
milder conditions employed in the initial purification of the 
E2/X core (Sanderson et al., 1996b) in comparison to the 
original protocol of Linn et al. (1972) routinely used by other 
investigators which results in significant component déna­
turation and poor levels (<20%) of overall complex recon­
stitution (Sanderson et al., 1996b). Attempts to refold at 
elevated temperatures and protein concentrations resulted in 
dramatic declines in the yield of active E2, presumably 
resulting from promotion of competing nonspecific aggrega­
tion reactions.
Despite the rapid and complete reconstitution of E2-linked 
catalytic function on dilution from 6 M GdnHCl, these 
reassembled E2 cores were unable to sustain PDC activity 
on addition of the correct stoichiometric levels of E1/E3. 
As a result, a slow dialysis protocol was developed which 
permitted the return of approximately 35% of PDC activity 
(Figure 3B) upon addition of the appropriate amounts of 
native bovine E1/E3. Slower removal of the chaotrope 
z^ pears to minimize incorrect hydrophobic interactions 
within the E2/X core during folding and to allow a more 
controlled passage through the critical, aggregation-sensitive, 
midpoint of folding. This observation represents the first 
report of the recovery of PDC complex activity following 
complete unfolding of the E2/X core. In addition, renatur­
ation by slow dialysis still allows the complete return of E2 
activity within 6 h and is effective at protein concentrations 
20—50-fold higher than those of the rapid dilution method 
with no marked concentration/aggregation effects. From 
direct measurement of GdnHCl concentrations during the 
dialysis step (Figure 3B), it is clear that a rapid decrease in 
dénaturant concentration occurs in the initial stages. A 
slower stepped dialysis was developed which allowed the 
removal of GdnHCl at a much reduced rate. However, this 
did not produce any improvement in the levels of reconsti­
tuted PDC activity (results not shown).
Immunological Analysis o f  Refolded/Assembled E2/X Sub­
complexes. It was anticipated that the differing efficiencies 
of the two types of reassembled E2 cores in promoting 
overall PDC function could be correlated with the extent of 
reincorporation of the peripherally located protein X subunit 
during in vitro assembly. Immunological analysis of the 
purified, reconstituted cores (Figure 4) confirmed a reduction 
in bound protein X (to 30—40% of normal levels) from the 
subcomplex reassembled by slow dialysis (lane 2) and an 
elimination of protein X firom the reassembled core produced 
by rapid dilution (lane 3) when compared to untreated E2/X 
core (lane 1). In contrast, identical loadings showed no 
detectable differences in the levels of the E2 component 
(lanes 4—6). Thus, loss of protein X does not affect E2 core 
assembly, as previously demonstrated using a genetic ap­
proach in 5. cerevisiae (Niu et al., 1990). The extent of 
depletion of protein X (lane 2) correlates closely with the 
reduced ability (approximately 35%) of this reassembled core 
to promote PDC reconstitution (Figure 3B), while the absence 
of immunoiogicaiiy detectable protein X (lane 3) provides 
an explanation for the ineffectiveness of this core in 
sustaining PDC activity in view of the known participation 
of protein X in high-affinity E3 binding (Figure 3A).
Reconstitution Studies with E2(X) Refolded Cores. As 
indicated in Figure 3, levels of PDC reconstitution, obtained 
after incubating either reassembled E2 core, devoid of protein
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Figure 4; Immunological analysis of refolded/reassembled E2/X 
cores. Samples (500 pL) containing renatured transacetylase and 
native untreated core were pelleted by ultracentrifugation using an 
optima TL ultracentrifuge (Beckman) for 25 min at lOCXXXlg 
through a 2(X) pL 30% (w/v) sucrose cushion. Following resus­
pension and protein assay, identical quantities of each sample (5 
^g) were subjected to SDS—PAGE and subsequent immunological 
analysis with anti-protein X (lanes 1 —3, panel A) or anti-E2 (lanes 
4—6, panel B) serum; lanes 1 and 4, untreated E2/X core (control); 
lanes 2 and 5, refolded E2/X core (slow dialysis); and lanes 3 and 
6, refolded E2/X core (rapid dilution).
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F ig u r e  5: Reconstitution of PDC activity of refolded E2/X cores 
in the presence of excess parent E3. Renatured/reassembled E2/X 
cores (5 pg) were reconstituted with the correct stoichiometric 
quantity of E1/E3 in an assay mixture without substrate. Additional 
E3 was added at the amounts shown and allowed to associate prior 
to addition of pyruvate and assay of PDC activity: native E2/X 
core (□); refolded E2(X) core, slow dialysis (O); refolded E2(X) 
core, rapid dilution (O). Values are expressed as ±  SEM.
X, or X-deficient E2 core with stoichiometric amounts of 
E1/E3, yielded values of 0 and 30—35%, respectively, 
compared to recoveries with native E2/X. Both types of 
reconstituted E2 subcomplex were then tested for their ability 
to promote PDC activity in the presence of an increasing 
excess of bovine heart E3 (Figure 5). In both cases, this 
resulted in the restoration of appreciable levels of PDC 
activity in the reassembled complexes. Thus, E2/X sub-
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complex deficient in protein X could support 60—65% of 
control PDC activity, virtually double its basal activity, in 
the presence of a 100-fold molar excess of E3. Importantly, 
reassembled E2 core lacking protein X can now be induced 
to reconstitute significant levels of PDC activity (25—30%) 
by a similar molar excess of native bovine E3. Thus, it 
appears that mammalian E2 oligomer can interact physically 
and functionally with E3, albeit with low affinity. No similar 
stimulation of PDC activity on addition of excess E3 is 
evident with native E2/X core which can sustain maximal 
yields of PDC activity with minimal (stoichiometric) amounts 
of El and E3. In support of these findings, patients with 
genetic disorders in PDC function which are characterized 
by the total absence of the protein X subunit have been 
described recently. Interestingly, these patients stül have 
measurable, although much reduced (<20%), PDC activity 
(Geoffroy et al., 1996). Such evidence is also consistent 
with a limited ability of the E2 core to interact physically 
and functionally with E3 in the absence of its protein X 
subunit.
Reconstitution analysis with these refolded E2/X core 
preparations employing a number of heteroiogous E3s in vast 
excess (Figure 6) confirms the specificity of the E3-induced 
stimulation of PDC activity, indicating that it is not the result 
of nonspecific interaction or random collision of E3s with 
the reconstituted E1/E2 subcomplex. As a control. Figure 
6A illustrates that bovine, bacterial, and porcine E3, when 
added in excess over and above stoichiometric amounts of 
parent E1/E3, have no additional stimulatory effect on 
reconstituted PDC employing native (untreated) E2/X core; 
however, addition of yeast E3 produces a marked inhibition 
of PDC activity. This phenomenon has been observed 
previously with protease arg C-treated E2/X core and native 
E1/E2 core from OGDC. It apparently reflects tight and 
specific binding of yeast E3 to Üiese cores in an orientation 
which is unable to support complex catalysis (Sanderson et 
al, 1996b). This marked inhibition is also observed when 
yeast E3 is added to the E2/X core produced by slow dialysis 
(Figure 6B). In this instance, while bacterial E3 has no 
detectable effect, presumably because it is unable to bind, 
porcine E3 does produce a small stimulation. However, it 
is much less pronounced, representing only 25% of that 
observed with native bovine E3.
The specificity of the E3 response is also observed with 
B2 core totally lacking protein X (Figure 6C). A small but 
significant level of stimulation is obtained with porcine E3 
(again around 25% of that of bovine heart E3), whereas 
bacterial and yeast E3s are completely ineffective. This 
ability of porcine B3 to promote the final step in PDC 
catalysis reflects the high degree of conservation between 
bovine and porcine E3s. However, usage of porcine E3 is 
clearly suboptimal in reconstitution studies and may explain 
why previous investigators were unsuccessful in detecting 
any PDC reconstitution after refolding of the denatured E2/X 
core (De Marcucci et al, 1995).
DISCUSSION
Dissociation and Unfolding ofE2/X Core. Gel permeation 
analysis of mammalian E2/X core indicates that it can be 
dissociated into discrete intermediates corresponding to 
trimers and subsequently fully unfolded monomers as judged 
by Mt analysis in specific ranges of GdnHCl concentrations.
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F ig u r e  6: Reconstitution of PDC activity of refolded E2/X cores 
with excess heterologous B3. Renatured/reassembled E2/X cores 
(5 /tg) were reconstituted with the correct stoichiometric quantity 
of E1/E3 in an assay mixture without substrate. Additional E3 was 
added at the amounts shown and allowed to associate prior to 
addition of pyruvate and assay of PDC activity. (A) Native 
(untreated) E2/X core, (B) refolded E2/X core produced by slow 
dialysis, and (C) refolded E2/X core produced by rapid dUution. 
Parent E3 (A ), yeast E3 (□), bacterial E3 (O), and porcine E3 (O). 
No results are presented for bacterial E3 in panel C as it also gave 
zero reconstitution. Values are expressed as ±SEM.
Thus, the 200 000 ±  24 000 Mr is close to the expected value 
for a trimeric species since bovine monomeric E2 has an Mr 
value of 59 963 as determined by electrospray mass spec­
trometry (data not shown). Although the monomeric species 
has an apparent Mr value of 82 000 ±  12 000 on gel filtration, 
this is compatible with monomeric E2 existing in a loosely 
or fully unfolded state at high dénaturant concentrations 
which would result in its more rapid elution from the gel 
permeation matrix relative to a globular intermediate of 
equivalent size. Interestingly, a stable trimeric species of 
the bovine branched-chain 2-oxoacid dehydrogenase complex 
(BCOADC) E2 has been isolated after dissociation in 
GdnHCl (Wynn et al, 1994). Moreover, previous sedimen­
tation velocity analysis of chaotrope-treated E2/X subcom­
plexes of PDC from bovine kidney in sucrose gradients 
produced data consistent with an ordered assembly of this 
subcomplex (Behai et al, 1994). Notably, a range of
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subcomplex species were detected intermediate to the 
purported trimer mid native 60-mer, thus supporting a 
noncooperative transition. In contrast, no evidence of such 
species was detectable during our study.
In this context, the recent discovery that sucrose and other 
polyhydric compounds oppose the effect of dénaturants on 
water structure, thus increasing the concentration of dénatur­
ant required to unfold an enzyme, is of considerable interest 
(Taylor et al., 1995). In addition to influencing the state of 
aggregation of E2 dissociation products located at different 
levels in the sucrose gradient, this could explain discrepancies 
between the critical chaotrope concentrations required for 
trhner formation and complete unfolding of monomers stated 
in Behai et al. (1994) in relation to those determined in this 
publication and in other studies (West et al., 1995).
In Vitro Reconstitution ofE2(X) Core Assembly. The rapid 
and successful chaperone-independent refolding and func­
tional maturation of the mammalian E2(X) core in high yield 
in vitro is somewhat surprising, given its complex multido­
main organization and quaternary structure. Elevated ionic 
strength (200 mM) h^ been suggested as a key factor which 
enables kinetically trapped intermediates to return to produc­
tive folding by lowering the activation energy barrier between 
the trap and its normal folding pathway (Todd et ah, 1996). 
For example, ribulose bisphosphate carboxylase (RUBISCO) 
does not fold successfully at low ionic stmngth but behaves 
as a slow folder in elevated-ionic strength buffers (Schmidt 
et al, 1994), Previous successftil folding and assembly of 
a truncated 24-mer com of BCOADC could only be achieved 
with the inclusion of molecular chaperones (Wynn at at, 
1994). It is possible that the absence of the N-terminal region 
of this polypeptide prevents the establishment of critical 
transient associations which are essential for promoting 
ordered folding of the E2—BCOADC oligomer. In this 
study, although functional reassembly of the E2 oligomer 
in high yield could be achieved by rapid dilution or slow 
dialysis, partial reintegration of the protein X subunit w^  
critically dependent on both the controlled removal of 
dénaturant and the presence of 200 mM NaCI (Figure 3B). 
These findings on E2/X core formation of PDC, however, 
do highlight its high intrinsic capacity for self-assembly and 
provide further evidence in support of the hypotiiesis 
(currently under investigation in our laboratory) that the 
extended presequences on the cytosolic precursor forms of 
the various complex-specific E2s may be involved in 
preventing their premature association prior to mitochondrial 
import (Hunter & Lindsay, 1986; De Marcucci et al., 1988; 
Clarkson & Lindsay, 1991).
Reintegration of Protein X into the E2 Oligomeric Core. 
Whereas regeneration of active E2 cores displaying complete 
restoration of dihydrolipoamide acetyltransferase (B2) activ­
ity occurs rapidly in high yield on removal of GdnHCl by 
either slow dialysis or rapid dilution, these reassembled 
structures have distinctive properties, reflecting their differing 
protein X content which influences their ability to support 
overall complex reconstitution on addition of stoichiometric 
amounts of El and E3. Thus, recomtitution by rapid dilution 
is incompatible with reincorporation of the protein X subunit 
into the reassembled E2 cores, whereas 30—40% of expected 
protein X levels can be functionally reintegrated by controlled 
removal of dénaturant. As expected, no significant recon­
stitution of PDC can be obtained with the E2 oligomer 
lacking protein X, whereas corresponding levels of recon­
stitution (30—40%) are readily achieved with the X-depleted 
core in the presence of stoichiometric levels of El and E3. 
The possibility of achieving complete functional integration 
of wild-type levels of protein X into reassembled E2 
oligomers in the presence of molecular chaperones is 
currently under investigation.
Interestingly, maximal levels of PDC reconstitution (30— 
35%) are restored within 30—45 min using reassembled E2- 
(X) cores formed by slow dialysis, whereas only 50—60% 
of intrinsic acetyltransferase activity has reappeared at this 
stage with complete reactivation of E2 occurring over 4—6 
h. Such data suggest that initial formation of E2 oligomers 
and subsequent incorporation of protein X occur on a 
relatively rapid time scale, whereas further more subtle 
rearrangements of enzymatically inactive E2 polypeptides 
incorporated into the repolymerized core structures (slow 
folders) are necessary to effect the complete recovery of 
acetyltransferase activity. These observations are compatible 
with the observation teat E2 does not catalyze the rate- 
limiting step in the overall reaction; moreover, as tee lipoyl 
domains of individual E2 molecules form a complex 
interacting network within the core assembly, it has been 
shown previously teat removal of a substantial fraction of 
E2 lipoyl domains can be accommodated without significant 
effects on overall complex activity (Ambrose-Griffin et al., 
1980; Stanley et al., 1981).
E3 Interactions with Equivalent Subunit Binding Domains 
on E2 and Protein X. In yeast, sequence similarities between 
protein X and transacetylase E2 component have been 
documented previously (Behai et al., 1989). This extends 
over most of tee N-terminal region and also includes putative 
peripheral subunit (specifically E1/E3) binding domains. The 
major differences appear in the C-terminal regions which, 
in the E2 component, are known to be involved in catalysis 
and also self-^sociation. The presence of equivalent putative 
subunit binding domains in both mammalian and yeast E2 
and X components displaying significant homology may 
suggest that B2 oligomers have retained a residual affinity 
for E3 (Sanderson et al., 1996b; Maeng et al., 1996).
Evidence reported here demonstrates for the first time teat 
reconstituted PDC, deficient in or totally devoid of its protein 
X subunit, can, in the presence of a large excess of its E3 
component, still support overall complex activity via specific 
low-affinity B3 interactions with the putative peripheral 
subunit binding domains on the E2 component. Thus, E2 
cores containing 30—40% of tee normal levels of protein X 
are able to support an equivalent level of reconstitution with 
stoichiometric amounte of El and E3 in contrast to E2 core 
totally stripped of protein X which is totally ineffective under 
similar conditions. Thereafter, bote types of core can sustain 
an additional 25—30% of control PDC activity in the 
presence of a 100-fold excess of parent E3, consistent with 
the involvement of protein X in mediating high-affinity E3 
binding and a residual capacity of E2 to promote low-affinity 
E3 interactions.
In support of this hypothesis, a group of patients with 
genetic defects in PDC function who contain no im­
munoiogicaiiy detectable protein X subunit have been 
discovered (Geoffroy et al., 1996). These patients display 
residual levels of PDC activity (10—20% of controls) which 
can now be accounted for in terms of low-affinity B2- 
mediated interactions with tee E3 component. Current 
studies also represent a significant advance on previous
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analysis of the role of protein X in E3 binding employing 
selective proteolysis of this subunit with protease arg C 
(Sanderson et a l, 1996b). In this investigation, the single 
arg C cleavage site on protein X was located at the 
N-terminal boundary of its putative E3 binding domain and 
the truncated 35 000 Mr fragment remained tightly associated 
with the E2 core. Consequently, reconstitution of complex 
activity in the presence of excess E3 could have been 
mediated directly via the E2 component or reflect low-affinity 
interaction with a partially disrupted E3 binding domain on 
the truncated protein X component.
In summary, these results demonstrate unequivocally for 
the first time that the presence of the protein X subunit of 
mammalian PDC is not absolutely essential for maintaining 
partial complex function in vitro and probably also in vivo. 
Thus, significant levels of complex reconstitution can be 
attained in the presence of an excess of the E3 component 
using the purified constituent enzymes of PDC in dilute 
solution. Partial PDC activity also appears to be maintained 
in vivo where piotein concentrations are on the order of 200 
mg/mL in the mitochondrial compartment. These observa­
tions highlight the distinctive but overlapping roles of the 
E2 and protein X subunits of mammalian PDC. While the 
dihydrolipoamide acetyltransferase (E2) component has a 
prominent role in complex catalysis, specifically the acéty­
lation reactions, in the absence of E2 lipoyl domains, a degree 
of complex activity (approximately 20%) can be mediated 
exclusively via lipoyl groups on protein X (Sanderson et al, 
1996b). Similarly, as shown here, the primary involvement 
of protein X in mediating optimal high-affinity binding of 
dihydrolipoamide dehydrogenase (E3) homodhners can be 
replaced, at least partially, by direct E3 association with 
equivalent regions situated on the E2 oligomer. Access to 
a catalytically active form of PDC, lacking protein X, will 
permit more detailed investigation of the properti  ^ of the 
modified PDC and facilitate elucidation of possible additional 
catalytic functions of the protein X subunit.
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Summary
Selective tryptic proteolysis of the mammalian a-ketoglutarate dehydrogenase complex 
(OGDC) leads to its rapid inactivation as a result of a single cleavage within the N-terminal 
region of its a-ketoglutarate dehydrogenase (El) component which promotes the dissociation 
of the dihydrolipoamide dehydrogenase (E3) enzyme and also a fully-active E l' fragment. 
Similarities between the N-terminal region of the E l enzyme and the dihydrolipoamide 
acetyltransferase and protein X components of PDC aie highlighted by the specific cross- 
reactivities of subunit-specific antisera. Analysis of the pattern of release of El and El' 
polypeptides from the complex during tryptic inactivation suggests that both polypeptide chains 
of individual E l homodimers must be cleaved to permit the dissociation of the El and E3 
components.
A new protocol has been devised which promotes El dissociation from the 
oligomeric dihydrolipoamide succinyltransferase (E2) core in an active state. Significant 
levels of overall OGDC reconstitution could also be achieved by re-mixing the 
constituent enzymes in stoichiometric amounts. Moreover, a high-affinity interaction 
has been demonstrated between the homodimeric El and E3 components which form a 
stable subcomplex comprising single copies of these two enzymes.
Introduction
The a-ketoglutarate dehydrogenase complex (OGDC), along witli tiie pymvate 
dehydrogenase complex (PDC) and the branched-chain a-ketoacid dehydi'ogenase 
complex (BCOADC), constitute the family of a-ketoacid dehydi'ogenase multienzyme 
complexes important in controlling carbon flux from cai'bohydrate precursors and a 
group of five amino acids into and around the citiic acid cycle. Located in the 
mitochondrial matrix in mammals, these complexes catalyse the hreversible oxidative 
decarboxylation of their respective a-ketoacid substrates yielding the appropriate acyl 
CoA derivatives (succinyl CoA in the case of OGDC), NADH and CO2. Central to this 
catalysis is the consecutive action of three catalytic components, each present in 
multiple copies: a substrate-specific a-ketoacid dehydrogenase (El), a distinct 
dihydrolipoamide acylti’ansferase (E2) and a common dihydrolipoamide dehydi'ogenase 
(E3) (see 1 and 2 for recent reviews)
Alpha-ketoacid dehydi'ogenase complexes are assembled in a tight but non 
covalent fashion. Then' multi-component and multi-copy nature results in the for'mation 
of massive complexes with Mr values in the range 5-10 xlO^ which are organised 
around 24-meric or 60-meric E2 cores (dependent on the specific multienzyme complex 
and source organism), exhibiting octahedi'al and icosaliedial symmetry respectively. In 
prokaryotes, in combination with its catalytic role, the oligomeric E2 core is responsible 
for tethering and orientating both the El and E3 enzymes within the multienzyme 
complexes via compact, peripheral subunit binding domains (3-5). In higher eukaryotes 
the identification of an additional component of PDC, protein X, with similarities in 
domain structure to E2 suggested a possible devolution of subunit function (6,7). 
Subsequent studies of protein X (also lei'med E3 binding protein, E3BP) have shown 
that it is responsible for mediating tire high-affinity interaction of the E3 component to 
this multienzyme complex in eukaryotes (8-12).
Studies on mammalian OGDC in this laboratory, employing specific proteolysis 
and N-terminal sequence analysis, have identified a Tipoyl-like' region at the extreme
N-terminus of the El component with significant sequence similaiity to the protein X
and E2 components of mammalian PDC (13). These similarities suggested that the E l
component may perform some functions normally devolved to E2 in the case of
mammalian OGDC. Further indirect evidence, in support of putative additional roles for
E l of OGDC came also when the genes for rat and human E2-0GDC were cloned (14,
15). Analysis of their predicted primary sti'uctures failed to locate any apparent El or
E3 binding motifs although such sequences were readily located in E2-0GDC genes
from other organisms, notably Escherichia coli (16), Azotobacter vinelandii (17).
.Pi’evious studies of OGDC have successfully purified the intact multienzyme 
complex to homogeneity (18,19). However, no method for the dissociation of OGDC 
into functionally active E2 and E1/E3 fractions has been reported to date owing to the 
high affinity of the El enzyme for the core assembly in this complex, a property it 
shares with the protein X subunit of PDC (20).
In this paper, we report the development of a method for tiie successful 
dissociation of mammalian OGDC into its E2 and E1/E3 fractions. Subsequent 
reconstitution studies with the E2 core recovered appreciable levels (30%) of overall 
complex activity on addition of tiie isolated El and E3 components. Gel permeation 
analysis of the E1/E3 fraction of OGDC, under associative conditions, demonsuated 
tliat these two enzymes interact with high affinity to form a stable complex witli an 
apparent Mp consistent with a 1:1 stoichiometry. These studies provide the first direct 
biochemical evidence that uniquely, in the case of mammahan OGDC, its constituent E l 
enzyme is responsible for binding the E3 component to the multienzyme complex.
Experimental Procedures
%'
Gel permeation analysis o f tryptic digestion products o f mammalian OGDC Following 
purification of OGDC from bovine heart as detailed previously (19), samples of OGDC 
were digested with 0.01% (w/w) trypsin at 30°C in 50 mM potassium phosphate 
buffer, pH 7.6, 3mM NAD+, 2mM MgCh, 0.2 mM ThDP until the complex was 50% 
or 90% inactivated. A control OGDC sample was incubated similarly in the absence of 
trypsin. Digestion was stopped by tire addition of soya bean trypsin inhibitor and the 
OGDC immediately loaded onto a Sephacryl S 300 gel permeation column (bed 
volume-120ml) equilibrated in 50mM potassium phosphate buffer, pH 7.6, lOmM 
NaCI. The column was eluted at a flow rate of 25ml.h"l and the fractions assayed for 
OGDC activity (21), E3 activity (22) and El activity (23).
Preparative dissociation o f mammalian OGDC OGDC was dissociated into its E2 core 
and E1/E3 fractions by the following method: OGDC (30mg.ml“l) was incubated at a 
l:l(v/v) ratio with dissociation buffer (50mM MOPS/KOH, 7.6, 2M MgCli, 20mM 
DTT, 0.2%(v/v) Triton X-100) for 1.5 h on ice. The sample was spun at 10,000g in a 
bench top centrifuge for 15 min to remove any particulate material. The E2 core of 
OGDC was separated from the E1/E3 fraction on an FPLC system (Phaimacia) using a 
100ml bed volume prep grade Superose 6 column (1.6x50 cm) equilibrated with 50mM 
MOPS/KOH, pH 7.6, IM MgCl2, 0.1%(v/v) Triton X-100. A pre-injection of the 
dissociation buffer (2ml) was performed prior to OGDC sample loading (2ml) and 
subsequent column elution at a flow rate of Iml.mim^. The eluent was monitored on­
line at 280nm. Pooled fractions were dialysed extensively, at 4°C, against multiple 
changes of buffer, into 20mM MOPS/KOH, pH 7.0, lOmM KCl, 0.1% (v/v) Triton 
X-100.
Reconstitution o f OGDC activity from E2 core and E l IE3 fractions The method used to 
reconstitute OGDC activity was derived from the one optimised previously for PDC
(24). Reconstitution was staited by adding quantities of E1/E3 (0-30pg) to cuvettes 
containing E2 (lOfig) and the appropriate assay solutions. Following a 15 min 
incubation at 20°C, the production of NADH was initiated by the addition of 14pl 
lOOmM a-ketoglutarate. NADH production was monitored at 340nm and activities are 
expressed either as pmoLmin-^.ml’i or a percentage relative to the specific activity of 
undissociated OGDC.
Association state analysis o f E l and E3 Gel permeation analysis of E1/E3 quaternary 
structure was performed on a Superose 12 column (24ml; lx30cm) attached to an 
FPLC system (Pharmacia). The column was cahbrated with gel filtration molecular 
mass markers (Sigma) for the construction of a cahbration curve of Vq/V q versus log 
Mr after initial equilibration, at 0.3ml.min'^ in 25mM MOPS/KOH, pH 7.0, lOmM 
KCl, 0.1%(v/v) Triton X-100. E1/E3 samples were clarified for 15 min at 10,000g in a 
benchtop cenuifuge prior to loading onto tire column (500pl sample). Elution profiles 
obtained were from on-line protein detection at 280nm and from E3 activity assays on 
the eluted fractions.
Immunological analysis Denaturing gel electrophoresis and Western Blot analysis were 
performed as detailed previously (20), except that immunocomplexes were detected with 
Amersham ECL detection reagents according to the manufactiu'er’s instmctions.
Results
Immunological analysis of similarities between the E l component of 
OGDC and the E2 and protein X subunits of PDC
I
Previous biochemical studies on mammahan OGDC detected significant 
sequence similarities between the N-teiminus of its El component and that of the E2 
and protein X subunits of eukaryotic PDCs corresponding to the N-terminal regions of 
their peripherally-located, conformationally-mobile lipoyl domains (13). Similar 
investigation of the N-terminus of the E l' fragment indicated that these sequence 
relationships extended into the interior of the the El polypeptide and tiiat the tryptic 
cleavage site was situated at a putative subunit binding domain. In this respect it also 
resembles protein X of PDC which contains a highly susceptible arg C cleavage site on 
the N-teiminal boundary of its E3 binding domain (24).
These similarities are confumed in Fig. 1 which demonsti*ates significant 
immunological cross-reaction between these three components. Anti-El (OGDC) senim 
ehcits a clear cross-reaction with the E2 component of mammalian PDC as well as a 
strong and specific response to the E l component of OGDC (panel A). In addition, as 
depicted in panel B, anti-protein X (PDC) serum also recognises the E l component of 
mammalian OGDC. As indicated, sequence similarities between E l of OGDC and 
mammalian E2 and protein X subunits have been documented previously (13); this 
immunological evidence confirms that these three polypeptides possess shared antigenic 
detemiinants and are thus likely to contain equivalent domains with common or 
overlapping functions.
In Fig. 2 (insert) the specificity of tryptic digestion of intact OGDC is illustrated 
by SDS-PAGE analysis following treatment resulting in 0% (lane 1), 50% (lane 2) and 
90% (lane 3) loss of overall complex function. It is appaient that there is a close 
coiTclation between the extent of OGDC inactivation and the percentage conversion of 
the 110,000 Mr E l subunit to a stable 100,000 Mr E l' fragment with no detectable
degl'adation of the E2 and E3 components. Resolution of the paitially inactivated 
. "X . complex (50%) on a Sephacryl S 300 gel filtration column (Fig. 2) shows that the 
constituent E l and E3 activities are distributed approx. equally between two peaks 
corresponding to the complex-associated and free forms of these enzymes which elute 
at the void volume along with residual OGDC activity and as individual homodimeric 
enzymes with values of 200,000 and 110,000 respectively. Similar profile analysis 
of intact OGDC indicates that all the constituent enzymes elute at tlie void volume 
whereas, after 90% tryptic inactivation, the vast majority of the ET and E3 activities are 
no longer associated with tlie complex (not shown). Interestingly also, there is no 
evidence for any interaction between the El' and E3 species which ai*e partially 
separated by gel filtration as expected on the basis of their differing Mr values.
Fig. 3 (panel A) compares the percentage of OGDC inactivation induced by 
trypsin with time to the extent of E l conversion to E l' and the conesponding amount 
of E3 release fr'om the complex. It is appai'ent during the early stages of Uyptic 
degl'adation of OGDC that the rate of El proteolysis exceeds the rate of complex 
inactivation or the extent of E3 dissociation. A possible explanation for this 
phenomenon is that both subunits of the El polypeptide must be cleaved prior to 
complex dissociation and that the heterodimeric E l/E l' species which will be produced 
^  preferentially in the initial stages of the digestion (assuming a random cleavage
mechanism) is able to maintain the smictural integrity and full catalytic activity of the 
complex. This idea is supported by assessment of the distribution of E l and El' 
species in the complex-bound and fi*ee fornis of the enzyme (Fig. 3B) isolated by gel 
filtration after 50% inactivation of OGDC witli trypsin as shown in Fig. 2. It is clear 
from this SDS-PAGE analysis that the complex-associated El enzyme contains a 
mixture of E l and ET polypeptides whereas only ET fragments are located in the peak 
of free E l activity. In contrast, if only a single cleavage were required to effect El 
dissociation, it would be expected that the complex-bound E l should contain 
exclusively intact El polypeptide chains whereas the peak of free El activity should 
contain a mixtur'e of full-length El subunits and ET fragments.
Dissociation of bovine heart OGDC
The promotion of the complete dissociation of OGDC into its constituent E2 and 
E3 enzymes and an active, stable ET species by a single proteolytic cleavage event 
within the N-terminal region of tlie E l component underlines the importance of this 
region in maintaining subunit interactions which are critical to the structural integrity of 
the complex. Earlier sequence compaiisons have also suggested tliat the site of 
proteolytic cleavage may lie within a putative subunit binding domain (13), implying 
the potential for direct interaction between the El and E3 components in this complex.
J It has not been possible to test this hypothesis to date owing to the tight association of
E l component with the oligomeric E2 core in mammalian OGDC as no methods have 
been reported which permit release of the El component from the E1/E2 subcomplex in 
active form.
Preliminary studies in Moscow (Dr. Victoria Bunik, personal communication) 
indicated that high concentrations of divalent cations, in particular Mg2+ ions, were 
capable of disrupting the high affinity interaction between the El and E2 enzymes of 
OGDC whilst also promoting release of the E3 component under mildly alkaline 
conditions.
Fig. 4 demonsU'ates the ability of bovine heart OGDC to be reconstituted 
successfully after pre-ti'eatment with IM MgCl2 at a vaiiety of pH values. The data 
suggest that high Mg2+ concentrations have a minimal effect on overall complex activity 
' 4" at pH 6.5 and 7.0 (neutral/slightly acidic conditions). In contrast, treatment of OGDC 
in more alkaline conditions (pH 8.0 or above) caused rapid inactivation of the complex 
with a further decrease over the time course investigated leading to almost complete 
disappearance of OGDC activity after 5 h. Incubation with MgCl2 at pH 7.6 (mildly 
alkaline conditions) caused a slow inactivation of the complex although 50-80% of the 
original OGDC activity could be restored after a 1-2 h incubation period. Further 
control studies (not shown) indicated (a) that the intact complex was stable to pH 
treatment alone in the range 6.5- 9.0 indicating that the marked pH sensitivity was
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induced by the dissociating conditions provided by the presence of divalent cations and 
(b) that the increased stability to IM MgCl2 at acidic or neutral pH values partly 
reflected incomplete dissociation of the E l component under these conditions. 
Accordingly, it was considered that the optimal pH for OGDC disassembly, consistent 
with maintaining maximum stability of the El component, was 7.6.
Preparative dissociation of OGDC was performed by Superose 6 gel permeation 
chromatography (see Methods section). The elution profile suggested initially tliat 
dissociation of the high Mr OGDC had occuired with two peaks of UV absorbance 
eluting from the column (Fig. 5A). The initial peak, corresponding to the high Mr E2 
core, eluted at or near the void volume of the column (Ve, 30-32ml). The second peak, 
containing the E l and E3 enzymes, eluted in the later column fractions (Ve, 60-70 ml).
. S  The nature and extent of the dissociation achieved was evident from SDS-PAGE 
analysis of the column fractions (Fig. 5B). Clearly, MgCl2 treatment and column 
chromatography had been successful in removing El and E3 from the E2 core of 
OGDC. Lanes coiresponding to the E2 core (column fractions 15-17) show no 
significant contamination with associated El or E3 enzymes although a small amount of 
E l could be detected at the void volume (fractions, 13 and 14) which may have 
contained some aggregated material. The obseiwed elution profile is consistent with 
appearance of the individual enzymes of OGDC from the Superose 6 column on the 
basis of size; the 24-meric E2 core elutes first, close to the void volume of the column, 
followed by the homodimeric E l and E3 components. The El and E3 components 
appear as a single unresolved peak in the absorbance trace; however, SDS-PAGE 
analysis reveals that in IM MgCl2 elution buffer, E l (220,000 Mr) elutes before E3 
(110,000 Mr) although there is a degree of overlap as expected; however, under these 
conditions, the E l and E3 components are clearly not associated as a single complex.
R econstitu tion  studies with bovine OGDC
While the protocol detailed above was successful in promoting the dissociation 
of the E l and E3 components of OGDC from its E2 core, the effect of this dissociation
1 1
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on the three constituent enzyme activities remained unclear. For PDC, it is possible to
examine all three enzyme activities in conceit by mixing stoichiomeüic amounts of the 
E1/E3 pool with the E2 core, reconstituting overall complex activity in high yield (60- 
80%; 24). A similar approach was adopted for OGDC in which the levels of 
reconstitution are expressed as a percentage of the activity of undissociated OGDC, 
thus providing an index of the degree to which the dissociation protocol has maintained 
the structural integiity of the constituent enzymes. Fig. 6 (panel A) illustrates the ability 
of the E2 and E1/E3 components to reconstitute overall OGDC activity up to approx. 
30% of the levels compared to native untreated complex; hence the components have 
retained the capacity to re-assemble and produce a native or neai* native OGDC capable 
of significant rates of catalysis. Neither the purified E2 core or E1/E3 fractions were 
able to support OGDC activity by themselves, indicative of good fraction resolution 
during the dissociation (Fig. 6B), whilst also providing definitive proof that the 
recovery of OGDC activity resulted from genuine reconstitution of the complex. 
Maximal levels of reconstitution were obtained with E2:E1/E3 ratios above 1:2 on a 
weight for weight basis. No increase in the levels of OGDC activity were obtained by 
adding extra quantities of E1/E3. In the case of OGDC reconstitution, maximal levels of 
overall complex activity ai'C expected in tliis range as the ratio of E2:E1/E3 in the native 
complex is approx. 1:2 which is in the range for the expected stoichiometry of the 
native complex assuming tliere are 6 copies of the E l and E3 enzymes present per E2 
core.
Optimal levels of reconstitution of mammalian PDC were previously obtained 
also employing sub-stoichiometric levels of E1/E3 (24). While this may also be the case 
for OGDC, the reason for this remains unclear, but may reflect the situation in the 
native complex where maximal occupancy of all potential El and E3 binding sites is not 
essential for maximum rates of catalysis. Alternatively, it was noted that the relative
recoveries of the E l component in the isolated E1/E3 fraction were only 30-50% of 
those achieved for E3, presumably reflecting its inherent instability and/or a degree of 
preferential selection during the pooling procedure.
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peiformed after calibration of the column with standard marker proteins. Since E3 is a
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Association state analysis of the E l and E3 components of mammalian 
OGDC
The measured levels of reconstitution of OGDC activity were considered 
sufficient to permit detection of a direct interaction between the El and E3 components 
by gel permeation analysis. Following dissociation from the E2 core as detailed above, ^
the E1/E3 pool was rapidly dialysed, employing multiple changes of buffer, into a low 
salt buffer (20mM MOPS/KOH, pH 7.0, lOmM KCl, 0.1% (v/v) Triton X -100) and a
0.5 ml sample applied to a Superose 12 column (24ml) already equilibrated in the low 
salt buffer (see Methods section). The monitoring of the column eluate at 280nm 
revealed the presence of two peaks of absorbance, not fully resolved to baseline levels 
(Fig.TA). Assays of the collected fractions demonstrated that the two absorbance peaks 
coincided with two eluted peaks of E3 activity. The protein present in the two peak 
fractions was precipitated with TCA and subjected to SDS-PAGE analysis (Fig. 7B).
Both E l and E3 enzymes were present in the higher molecular mass peak (PI) whereas f
only fr‘ee E3 was detected in the lower molecular mass peak (P2).
Estimation of the Mr values of the two resolved peaks of E3 activity was
IShomodimer with a subunit Mr corresponding to 55,000, the average value of 
126,000+/-13,000 (n=3) is in close agreement with the expected value of 110,000.
For the larger molecular mass peak, its measured Mr value of 303,000+/- 8,000 (n=3) 
comelates well witli the expected Mr for an E1/E3 complex comprising one E3 
homodimer (110,000) bound specifically to one El homodimer (220,000). The I
presence of this distinctive subcomplex represents the first direct biochemical evidence
'#that the E l and E3 components of mammalian OGDC interact physically and 
functionally witli each other. The additional peak of free E3 activity representing 60- 
70% of total E3 is as expected from the reduced recoveries of tlie El enzyme relative to
its companion E3 component as described previously.
i
Discussion
Selective proteolysis of OGDC
Previous proteolytic studies and subsequent N-terminal sequencing have located 
a lipoyl-like' domain at the N-teiminus of the E l component of mammalian OGDC. 
Specific degiadation of E l with trypsin results in a single cleavage of its constituent 
polypeptide resulting in the production of an N-terminal peptide (subunit Mr 10 000), 
abolition of E3 binding and dissociation of an active E l' species (subunit Mr 100,000). 
Complete disassembly of the OGDC following this single cleavage event indicates that 
the subunit binding potential of mammalian OGDC is likely to reside in this segment of 
the El component where a putative peripheral subunit binding domain has been 
identified at the site of Uyptic attack (13). It is now appai*ent that this limited proteolysis 
also promotes release of the E l component implying that sequences critical for its high 
affinity interaction with the E2 core also reside in this N-teiminal region or that a 
conformational change occurs on generation of the E l' species which drastically 
reduces its affinity for the E2 core.
Interestingly, a single cleavage witliin an El homodimer generating an E l/E l' 
inteimediate appeal's insufficient to promote dissociation of the complex. This evidence 
suggests that a single intact E l polypeptide chain within a E l/E l' heterodimer is 
capable of supporting overall complex activity. The biphasic degradation of El by 
trypsin (Fig. 3A) may also indicate that one site on the El homodimer is more 
accessible than the equivalent site on its companion subunit. Such an observation is 
compatible with a recent, elegant X-ray structural deteimination of E3 interaction with 
its E2-derived subunit binding domain from Bacillus stearothermophilus PDC (5) 
which demonsti’ates that a single peripheral subunit binding domain mediates the 
binding an E3 homodimer via a site located near to its twofold axis of symmeuy, 
thereby preventing access to a second identical binding site on the adjacent E3 subunit. 
A degree of protection of the protein X subunit of PDC from cleavage by protease arg 
C in the presence of the bound E3 enzyme has been observed previously (24) and
14
similar data have been obtained for arg C-mediated proteolysis of El-OGDC (not 
shown).
Dissociation of mammalian OGDC
Initial protocol development to dissociate OGDC into E2 and E1/E3 fractions 
focused on the adaptation of the standard high salt (NaCl) dissociation procedure 
designed for the disassembly of PDC into its E2/X and E1/E3 fractions. Although NaCl 
(1-2M) could be employed successfully for releasing the E3 component from native 
OGDC, the E1/E2 subcomplex was stable to treatment with 4M NaCl (results not 
shown). Attempts to use low (non denaturing) levels of GdnHCl also proved fruitless. 
The successful disassembly of mammalian OGDC into active E2 and E1/E3 fractions, 
reported here for the first time, employs a combination of high levels of MgCla and 
slighdy alkaline pH to achieve optimal dissociation with minimal dénaturation of the 
individual constituent enzymes. Under the dissociative conditions employed in this 
separation (Fig. 5), it is cleai’ that the El and E3 components aie not interacting, as 
would be expected owing to the high level of divalent cations in die column running 
buffer.
An impoitant criterion, upon which the success of the OGDC dissociation was 
judged, was that it produced components which maintained their native structure and 
were thus functionally active. Reconstitution analysis provided a good indication if this 
had been obtained. The extent of reconstitution (30%) was appreciably lower dian that 
achieved with the E2/X and E1/E3 fractions of PDC of 60-80% (24). However, it was 
also noted that dissociated El was quite unstable and lost 50%-70% of its original 
activity within 12h at 4°C even when dialysed as rapidly as possible into buffers at pH 
6.5-7.0. As this represents the minimum time required to prépaie this enzyme for 
reconstitution and binding studies, fuither work is required to improve its stability 
during the isolation procedure although it can then be stored for up to 2-3 weeks in 
50% (v/v) glycerol at -20®C without funher loss of activity.
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Parallels with protein X function
It is of interest to note the physical and functional parallels between El of OGDC 
and protein X of PDC (25). Although it was not possible to obtain as high levels of 
reconstitution of OGDC (30%) compared to PDC (60-80%), the two dissociation and 
reconstitution protocols are not strictly equivalent, with harsher treatment requked to 
remove the E l from the E2 core of OGDC than is the case for PDC. Moreover, for 
PDC, no comparable method exists for removing protein X from the E2 core and 
maintaining its activity. In view of the possible functional overlap between the two 
proteins i.e. participation in E3 binding, it is also interesting that both E l of OGDC and 
protein X of mammalian PDC aie tightly, but peripherally, associated with theh 
respective E2 cores. Recent structural studies of the E2/X core of Saccharomyces 
cerevisiae PDC position the protein X binding sites at 12 lai'ge openings in the E2 core 
structure (26). Similar' studies on mammalian OGDC will be necessary to shed light on 
whether its E l homodimers are positioned in a similar fashion although mammalian 
OGDC is built upon a structui'al E2 lattice which foims a 24-meiic core exhibiting 
octahedral symmetry. If this proves to be the case, it would be predicted that the 
mammalian OGDC would be composed of 6 E l homodimers attached to the surfaces of 
its cubic (24-meiic) E2 core mediating the association of an equivalent number of E3 
dimers. The absolute number of E l and E3 homodimers associated with the E2-OGDC 
core has not been determined unequivocally in mammalian systems. However, studies 
of E, coli OGDC, which also has an octahedral 24-meric E2 core, in this case 
supporting the binding of both peripherally-associated enzymes, report a chain ratio 
E1:E2;E3 of 0.5:1.0:0.5 (27). These values suggest the presence of 6 El and E3 
dimers bound to the E2 core in E. coli OGDC.
Gel permeation analysis of the isolated E1/E3 fraction from bovine heart OGDC, 
under low salt associative conditions, was successful in detecting the formation of a 
higher molecular* mass complex (303,000 M J coiTesponding to an E1:E3 subcomplex 
exhibiting 1:1 stoichiometry. The presence of an apparent excess of E3 reflects the 
relatively greater losses of E l incuired during the isolation procedure. Tire direct
:l:
participation of the El component in E3 binding is borne out by analysis of cDNAs 
encoding tlie rat and human dihydrolipoamide succinyltranferase (E2) genes which 
indicates that the domain typically involved in E3 binding is absent from tliese 
sequences (14,15). In the human gene for E2 of BCOADC which exhibits a high 
degree of simüaiity to the corresponding OGDC gene, the domain responsible for 
E1/E3 binding is encoded within a single exon (28). It is likely that loss of this exon, 
has occurred during the evolution of mammalian E2-0GDC. Moreover, the evidence 
that E l can physically interact with E3 in this complex is indicative that this E3 binding 
role now resides within the a-ketoglutarate dehydrogenase component in mammals.
Subsequent immunological analysis confirmed that antisera, specific for the El 
component of mammalian OGDC, also recognises antigenic epitope(s) on mammalian 
E2 of PDC. Anti-protein X serum was also able to detect El-OGDC specifically, 
emphasising the close structural and functional relationship between segments of these 
polypeptides. Selective digestion of OGDC witli trypsin, has been shown to produce a 
very specific cleavage of the E l component into an enzymatically active El ’ fragment 
(subunit Mr 100, 000) and a stable peptide (subunit Mr 10, 000). Interestingly, the 
peptide was responsible for the major proportion of the immune response ehcited due to 
its lipoyl-like structure (13), Indeed, high immunogenicity is a characteristic of lipoyl 
domains which are implicated in the autoimmune disease, primary biliaiy curhosis 
(29). Thus, the observed antigenic cross-reactivity between these thi'ee polypeptides 
undoubtedly reflects the presence of sequences usually found in lipoyl domains and 
other common sequence elements. Since the E3 (dihydiolipoamide dehydi'ogenase) 
enzyme is common to all mammalian a-ketoacid dehydi’ogenase complexes, it is not 
surprising that similar sequence motifs/domain stmctures appear to be present on the 
enzymes involved in its binding and catalytic function.
In mammalian OGDC the binding of E3 to the complex is not mediated by the E2 
component, as in other a-ketoacid dehydi’ogenase complexes, since this protein lacks 
the domain involved in E3 interactions. In conti’ast to PDC from higher eukaryotes, the 
E3 binding role in OGDC has not been uansfen’ed to a separate gene product (protein
17
X). Instead, it would appear that the El of mammalian OGDC has acquired an 
additional structural role in this respect which is noimally peiformed by the E2 or 
protein X components in other prokaryotic and eukaryotic complexes. Recent 
identification of tlie odhA gene from Coiynebacterium glutamicum encoding the El 
component of OGDC, has revealed an N-terminal extension with sequence homology 
to E2s from PDC and OGDC, albeit to their C-termini (30). The authors intimate that 
this may represent a degi'ce of bifunctionality in this El protein also. In our case, the 
catalytic role of mammalian El-OGDC in the oxidative decarboxylation of 2- 
oxoglutai’ate is supplemented by a second suuctural one, namely mediating tlie 
integration of the E3 component into the multienzyme complex in optimal orientation to 
promote the required interaction with conformationally-mobile lipoyl domains located 
on the oligomeric E2 core.
CuiTent research involves overexpressing the native El enzyme of OGDC and 
various subfragments in E, coli with a view to mapping its domain organisation more 
precisely, in particular those regions involved in maintaining critical subunit contacts.
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F igu re  legends
Fig. 1 Immunological analysis of subunit cross-reactivity in mammalian OGDC and 
PDC
Purified samples of PDC and OGDC (5fxg) were subjected to 10% (w/v) SDS-PAGE 
and subsequent immunological analysis with anti (OGDC)-El (lanes 1-2, panel A) or anti­
protein X (lanes 3-4, panel B) serum. Lane 1 and 3, bovine heart PDC; lanes 2 and 4, bovine 
heart OGDC. Mr markers, PDC and OGDC samples were run in adjacent lanes and stained 
with Coomassie blue to aid subunit identification.
Fig. 2 Gel permeation analysis of OGDC partially inactivated by limited treatment 
with trypsin
OGDC (15 mg.ml'l) was digested with 0.01% (w/w) trypsin at 30°C in 50 
mM potassium phosphate buffer, pH 7.6, 3mM NAD+, 2mM MgCU, 0.2 mM ThDP 
until it retained 50% of its original activity. Following termination of digestion by 
addition of a 10-fold molar excess of soybean trypsin inhibitor, tlie OGDC was loaded 
onto a Sephacryl S 300 gel permeation column (bed volume-120ml) equilibrated in 
50mM potassium phosphate buffer, pH 7.6, lOmM NaCl at a flow rate of 25ml.h'l.
Fractions (1ml) were collected and assayed for OGDC ( # —# ), E l (Ch "O) and E3 
(âr-A . ) activity.
The insert depicts the specificity of tryptic digestion of OGDC illustrating the 
extent of E l degradation to E l' as detected by 10% (w/v) SDS-PAGE and Coomassie 
blue staining. Lane 1, control OGDC (no trypsin); lane 2, after 50% inactivation with 
trypsin; lane 3, after 90% inactivation; lane M, Mr marker proteins
a
Fig. 3 Analysis of rate of decline of OGDC activity as compared to E l' appearance and 
E3 release during trypsin-induced inactivation of intact OGDC.
1
OGDC was degraded with trypsin as described in Fig. 2 and, at the times 
indicated, samples were taken for assay of residual overall complex activity ), 
densitometiic determination of E l to E l' conversion (Q—O ) following 10% (w/v) 
SDS-PAGE (13) and for assay of E3 release (A— A )  after ultracenüifugation of the 
complex at 130,000g for 5h to pellet intact OGDC (Panel A). All results aie expressed 
as a percentage of initial activity (OGDC) remaining or percentage of E l' and E3 release 
into the supernatant fraction. Panel B shows a similar SDS-PAGE analysis of the 
distribution of E l and E l' species between the complex-bound (lane 3, 5p.g) and free 
states (lane 4, 5|U,g) harvested fr om partially-inactivated OGDC (50%) which had been 
separated by FPLC-based gel permeation chromatography as shown in Fig. 2; lane 1, 
intact OGDC (15|ig); lane 2, OGDC (15p.g) after 50% inactivation with uypsin
Fig. 4 Reactivation profiles for bovine heait OGDC following treatment with IM 
MgCl2 at a variety of pH values
OGDC (2.5mg.ml"^) was incubated on ice for vaiious times in 50mM 
MOPS/KOH buffer, 20mM DTT, 0.1%(v/v) Triton X-100 buffer at the stated pH 
values in the presence of IM MgCU. During tire time course, samples (10-30|ug) were 
removed and reactivation /renaturation was initiated by a rapid dilution into the 
appropriate assay buffer. The final protein concentration in the renaturation mixture was 
10“30|J-g/ml and residual MgCU reduced to below 30mM to prevent enzyme inhibition. 
Samples were assayed for OGDC activity after a 3 min pre-incubation. All activities are 
expressed relative to contr ol samples of enzyme incubated in the absence of MgCl2- pH 
6.5,o - o  ; pH 7.0, D-Q; pH 7.6, A-A; pH 8.2, Ar-A •
2 2
Fig. 5 Dissociation and separation of the constiuent enzymes of bovine heart OGDC
Preparative dissociation of OGDC into active E2 and E1/E3 fractions was 
peiformed on an FPLC system (Pharmacia) using a Superose 6 column (100ml) 
equilibrated with 50mM MOPS/KOH, pH 7.6, IM MgClz, 0.1% (v/v)Triton X-100 
(see Methods section). Fractions were pooled on the basis of A28O peaks (Panel A) and 
dialysed extensively, at 4^C, against multiple changes of tlie 20mM MOPS/KOH, pH 
7.0, lOmM KCl, 0.1% (v/v) Triton X-100.
Aliquots (1ml) of the eluent fractions were subjected to TCA precipitation (Panel B) 
and separated by 10% (w/v) SDS-PAGE prior to staining with Coomassie blue. Lane L, 
OGDC column load (15|J.g); lanes 14-34, TCA-precipitated samples from column fractions 
showing resolution of the constituent enzymes.
Fig. 6 Reconstitution of overall OGDC complex activity from purified E2 core and 
E1/E3 fractions: levels of reconstitution and component stoichiomeuy
Following the dissociation of OGDC as described in Fig. 5, the E2 and E1/E3 
fractions were dialysed into 50mM MOPS/KOH, pH 7.4, ImM EDTA, 50% (v/v) 
glycerol and stored at 4°C. E2 and E1/E3 fractions were pre-conditioned by a 1:1 
dilution in 50mM potassium phosphate buffer, pH 7.6, 3mM NAD+, 2.7 mM cysteine- 
HCl, 2mM MgCla, 0.2 mM ThDP, 0.02mM CoASH and incubated for 15min at 20°C.
To initiate reconstitution, increasing quantities of E1/E3 (0-40|ig) were added to 
cuvettes containing E2/X (lOp-g) under the appropriate assay solutions. The production 
of NADH was subsequently initiated by the addition of 14ql lOOmM 2-oxoglutarate. 
Activities ai'e expressed as percentage reconstitution relative to the activity of the native 
OGDC complex before dissociation (Panel A). The purity of the pooled fractions 
employed for this reconstitution study was determined by 10% (w/v) SDS-PAGE
23
%
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• • s i .3analysis and Coomassie blue staining. Lane M, Mr marker proteins; lane 1, intact 
OGDC (lOfrg; lane 2, E1/E3 fraction (15qg); lane 3, E2 core (5qg).
Fig. 7 Association state analysis of the purified El and E3 components
Detection of formation of a stable E1/E3 subcomplex was perfoimed by 
resolving the purified E1/E3 pool on a Superose 12 column under non dissociating 
conditions (see Methods section). Protein elution was detected at 280nm ( ) and
assays for E3 activity (o-~-o) peiformed on the column fractions (Panel A). Peak 
fractions from the column were subjected to TCA precipitation and subsequent 10% 
(w/v) SDS-PAGE analysis prior to staining with Coomassie blue (Panel B). Lane M, 
Mr markers; lane L, E1/E3 load fraction (3qg); lane PI, peak 1 fraction (2fig) ; lane P2, 
peak 2 fraction (2pg) from Panel A.
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